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PREFACE
vii
The National Agricultural Biotechnology Council’s eighteenth annual meeting (NABC 
18)—Agricultural Biotechnology: Economic Development through New Products, Partner-
ships, and Workforce Development—was the first to focus primarily on vehicles for transfer 
of knowledge generated mainly in the publicly-funded sector to benefits. Knowledge 
generation by universities, government laboratories and research institutions produces 
science, technology and intellectual property (IP). Historically, agriculture has used the 
extension service to deliver benefits from this knowledge to farmers and consumers. dur-
ing the past 25 years, the need to protect increasingly complex IP (such as biotechnology) 
has been recognized increasingly as a necessary first step for investment of risk capital to 
deliver benefits—economic growth, job creation, and value-added products, processes and 
services—resulting from generation of knowledge. A diversity of vehicles is being used to 
facilitate transfer, including research parks, partnerships, licensing, SBIRs, CRAdAs, and 
venture-capital investment. At NABC 18, a wealth of examples was presented from the 
United States and Canada as well as from Europe, China, India and Brazil. In one case, 
the University of Wisconsin, there is almost complete segregation of knowledge-genera-
tion from transfer and from benefit-delivery, whereas, at the other extreme, in China all 
occur within the university. In general, transfer facilitation is moving from a major focus 
on economic benefits to considering other benefits as well. As experience continues to 
accrue, it is suggested that commonality will evolve in transfer facilitation. It is hoped 
that the information in NABC Report 18 will prove useful in this evolution.
 Briefly, NABC 18 focused on the following themes and related areas:
• Past successes, future prospects and hurdles
• Function and role of university-based research parks in economic development
• An up-close look at one research park—the Cornell Agriculture & Food 
 technology Park (CAFtP)
• Bridging the gap: From laboratory to commercial product
 From presentations on past successes and future prospects, the impressive—but not 
well recognized—role of agricultural research in providing seminal advances in the life 
sciences is documented. For example, the initial research on RNA interference (RNAi), 
the basis of one of the 2006 Nobel Prizes, was a product of agriculture, although it was 
not recognized as such in the award. We need to better communicate the contributions 
of agriculture to broad knowledge generation.
viii
 Hosted by Cornell University June 12–14, 2006, NABC 18 had 110 attendees, 
with representation from eight countries. Activities on the Monday afternoon, early 
tuesday morning and Wednesday morning took place on Cornell’s Ithaca campus, and 
buses transported the delegates for tuesday lunch and afternoon activities at the Cornell 
Agriculture & Food technology Park (CAFtP) on the campus of the New York State 
Agriculture Experiment Station in Geneva, NY. The return to Ithaca included a stop to 
sample viniferous delights at the Chateau laFayette Reneau Winery.
 The speakers included scientists who have established spin-off companies, leaders of 
agricultural biotechnology parks in the United States and internationally, government 
and university administrators, and community and government leaders who have worked 
on economic development programs involving biotechnology. At the conclusion of the 
formal presentations, attendees convened in breakout sessions for further discussion of 
issues raised by the speakers and in Q&A sessions, and to make recommendations to 
policymakers.
 This volume contains an overview of the meeting, a summary of the breakout work-
shops and the recommendations, and the presentations including those made during the 
banquet and in a supplementary session. transcripts of the Q&A sessions and of a panel 
discussion are included. Video recordings of the presentations are available at http://www.
nysaes.cornell.edu/ent/nabc/schedule.html.
 NABC 19—Agricultural Biofuels: Technology, Sustainability, and Profitability—will 
be hosted by South dakota State University and will convene May 22–24, 2007, in 
Brookings, Sd. The activities will include tours of a large-scale ethanol plant and of a 
biodiesel-production facility. Further information may be accessed via http://nabc.cals.
cornell.edu.
Allan Eaglesham Ralph W.H Hardy
Executive Director President
NABC NABC
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NaBC’s eighteenth annual meeting, hosted by Cornell University, convened in Ithaca 
and Geneva, NY, June –4, 006. Delegates were welcomed to Cornell by Bill Fry 
(Senior associate Dean of the College of agriculture and Life Sciences), and by Steve 
Slack (NaBC Chair 005–006/Ohio State University), tony Shelton (NaBC-8 Host/
Cornell) and ralph Hardy (NaBC President). activities on the Monday afternoon, early 
tuesday morning and Wednesday morning took place on Cornell’s Ithaca campus, and 
buses transported the delegates for tuesday lunch and afternoon activities at the recently 
established Cornell agriculture & Food technology Park (CaFtP) on the campus of the 
New York State agriculture Experiment Station, Geneva. 
Presentations on past technology-transfer accomplishments and both national and 
foreign experiences in various structures that facilitate technology transfer provided a 
strong background for discussions on how public-sector research can produce economic 
growth through new products, partnerships and workforce development. agriculture’s 
track record for public good is impressive; technology transfer has been achieved through 
diverse methods. The presentations and discussions at NaBC 8 provided guidance for 
the future structure of technology transfer from public-sector research to public good 
and commercial products.
Session —Past Successes, Future Prospects and Hurdles—comprised plenary presentations 
by alan Wood (Boyce Thompson Institute, Agricultural Research: Beyond Food and Fiber), 
Peggy Lemaux (University of California and Berkeley, Ag Biotech Pipeline: What’s in the 
Lineup?), ralph Hardy (NaBC, Research to Market/Public Good: Economic Perspectives) 
and Deborah Delmer (rockefeller Foundation, Road Bumps and Pitfalls for Agricultural 
Biotechnology). and presentations covering technology transfer in Canada, India, Brazil, 
China and Germany were made, respectively, by Keith Downey (agriculture Canada, 
Rapeseed to Canola: Rags to Riches), K. Vijayaraghavan (Sathguru Management, India: 
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New Products and Opportunities), ana Claudia rasera da Silva (alellyx applied Genetics, 
New Perspectives for Ag Biotech in Brazil), Zhanglian Chen (China agricultural University, 
Chinese Agricultural Biotechnology in the Field) and Peter Welters (Phytowelt, Globaliza-
tion of European Biotechnology: Commercialization of Agbiotech Products Despite Political 
and Legal Restrictions).
alan Wood described a proposal for a National Institute for Food and agriculture to 
enable the United States to maintain competitiveness in this field. Having invited NaBC-
member institutions to submit information regarding recent agricultural research beyond 
food and fiber with significant societal impacts, Wood described outstanding contributions 
to society under the headings Energy, Food Safety/Diet, New Products, Animal, Health, 
Environment and Plant Biology. Seventeen Nobel Prizes have been awarded to scientists 
involved in aspects of agricultural research, most of whom are not known to the public 
at large. The value and significance of US agricultural production and research must 
be more effectively communicated to the public and to legislators in order to improve 
understanding of the national and global importance of US agriculture, its breadth of 
impact and an appreciation of its many contributions to society beyond food and fiber, 
including human health and biobased products.
Peggy Lemaux pointed out that new applications of genetic engineering in agriculture 
are not limited by the technology. Progress is clouded by factors outside the control of 
scientists, particularly of academic scientists, like high regulatory costs and limited access 
to key technologies because of intellectual-property protection. Consumer-acceptance 
will also be important. It is likely that modern biotechnology will play an increasingly 
important role in other countries—China for example—where these issues are not likely 
to be key factors.
ralph Hardy outlined methods for science/technology transfer to market to achieve 
public good. He provided public- and private-sector examples of venture capital for early 
commercialization of agricultural science and technology. Hardy emphasized that licens-
ing income is likely to be relatively small and that the objective of technology transfer 
should be to maximize public good not to maximize financial gain to the institutional 
“home” of the invention. Evaluations by and of technology-transfer offices should use 
the public-good metric, not the income metric.
according to Debbie Delmer, the problems for biotechnology vary according to 
who you are—a large company that deals with important crops and developed-country 
farmers, a small private company, a public sector entity, university, national agricultural 
system or a CGIar institution. It is difficult to judge the degree to which negative pub-
lic perception remains a significant issue. Strong research programs on development of 
genetically engineered (GE) crops are in progress in China, India and Brazil. Even in the 
European Union, GE crops are now planted in a few countries. Some 0% of people 
say that genetic engineering of crops is great stuff and another 0% hate it, while in the 
middle is a vast disengaged majority who really don’t care, including many farmers in 
the developing world. People are growing tired of the debate. “It’s time to get on with 
it.” Delmer also noted the importance of making IP available to developing countries 
and public-sector research.
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The development of canola from rape-seed oil, described by Keith Downey, diversified 
Canada’s agriculture base, eliminated dependence on imported vegetable oil and increased 
returns to producers while expanding markets at home and abroad. It resulted also in the 
establishment of a large rural-based, value-added oilseed-crushing and -refining industry. 
The story continues in that canola is a preferred biodiesel source for northern climates 
because of its low content of saturated fatty acids. Canola development continues, to 
better meet user needs. 
India’s economy is among the fastest growing in the world—6% to 8% annually over 
the past decade—according to “Vijay” Vijayaraghavan. On the other hand, growth in 
agriculture has been less than %. a national mission is in progress to revive the un-
der-performing agriculture sector by enhancing farm production and food quality while 
reducing waste. The strategy includes attracting investments that will trigger high growth 
in agriculture and in the processed-food industry and partnering in global research 
initiatives that will help India to acquire as well as provide technologies.
In Brazil, the production of ethanol from sugar cane has increased three-fold in the 
past 5 years. The current average yield is 6,000 L/ha. However, in line with the Kyoto 
Protocols, a production increase of at least 3-fold again will be needed by 00 to satisfy 
projected demand. This goal is achievable as a result of Brazil’s scientific expertise in 
breeding and genetic engineering, to increase productivity of sugar cane as a crop and 
improve efficiency of ethanol synthesis.
The public debate in China on the safety of GE crops was “imported” from Europe, 
stated Zhangliang Chen. It is germane in particular to the improvement of rice productivity 
in that country, where GM varieties are in final field-trial stages. On the other hand, Peter 
Welters reported that the scare-mongering of anti-GM-activists in Europe is increasingly 
recognized for what it is. Examples showing benefits of applying genetic engineering to 
plants are finding acceptance by the general public. “We have only to inform people cor-
rectly and constantly about the progress and the benefits of this new technology. Millions 
of farmers worldwide can’t be wrong.”
In session —Function and Role of University-Based Research Parks in Economic Develop-
ment—presentations were made by ashley O’Sullivan (ag-West Bio, Inc., Canada, From 
Tools to Products: The Evolution of Saskatchewan’s Agbiotech Cluster), allen Dines (University 
of Wisconsin, From Equines to Economic Development: The Story of University Research 
Park), Wim Jongen (Wageningen Business Generator, Netherlands, Food for Innovation: 
The Food Valley Experience) and Zhianglian Chen (agricultural University, China, The 
Chinese Experience in Innovation).
“What is the bio-economy?” asked ashley O’Sullivan. From the perspective of ag-West 
Bio, it simply involves creating and capturing value from biological systems. The chal-
lenge and the opportunity for each region are the ability to understand and to effectively 
exploit global comparative advantages. The strategy at ag-West Bio for Saskatchewan is 
twofold: (i) marketing their excellent bio-economic infrastructure, and (ii) identifying 
and targeting strategic opportunity sectors. ag-West is probably the earliest example of 
a technology park focused exclusively on agriculture.
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allen Dines’ story of the University research Park in Madison provided an instructive 
case study of how favorable outcomes can arise from university-established parks focused 
on fostering commercialization of university research. Wisconsin has a long-term record 
in technology transfer; the irradiation of milk to produce vitamin D in the 90s is a 
seasoned example. recently, several companies have expressed interest in relocating to the 
Madison area as a result of opportunities resulting from association with the university-
research environment. 
The concept that science-based economical development is crucial for general economi-
cal development and competitiveness, according to Wim Jongen, begs the question of 
how to organize the process. The objective of the Food Valley cluster, developed in the 
Netherlands, is the creation of a network for innovation and business involving companies, 
research institutes, experimental facilities, incubators and public-private-partnership based 
r&D programs with the foci being food, health and nutrition. The initiative—by three 
city councils—has grown into a regional economic force.
Zhianglian Chen reported that, since 99, the Chinese government has encouraged 
university professors to form companies. Even in public universities, a professor can run 
a business from her/his own laboratory, owning 00% of the company or shares thereof. 
Some professors have made large amounts of money. On the other hand, Chen expects 
that universities will continue to play a vital role in high-tech business development and 
innovation, making major contributions to a knowledge-based economy in China. This 
merging of universities and business was the most tightly coupled example described at 
the meeting.
Session 3—An Up-Close Look at One Research Park: the Cornell Agriculture & Food Tech-
nology Park (CAFTP)—took place at CaFtP as a “town hall” discussion moderated by 
Dan Fessenden (CaFtP). Brief comments from Michael Manikowski (Ontario County 
Development), Karen Springmeier (Finger Lakes Workforce Investment Board), James 
Hunter (Cornell University/New York State agriculture Experiment Station), Susan riha 
(Cornell) and roger Williams (Cornell) helped to focus the discussion.
Dan Fessenden sketched a brief history of the New York State agricultural Experiment 
Station in Geneva, NY, on the campus of which CaFtP is situated, and described the 
thinking that underpins the Park and the process whereby physical-plant infrastructure—a 
flexible technology facility—is now available for occupancy. It is envisaged that CaFtP 
will eventually occupy 70 acres of what was, until recently, apple orchards that had been 
“retired” from research use. Four start-ups, including agbiotech companies, occupy of-
fice space on campus and are expected to enter pilot production in the main facility in 
the near future. Ground-breaking is expected in 007 of a USDa-funded grape-genetics 
research center.
Session 4—Bridging the Gap: From Laboratory to Commercial Product—comprised pre-
sentations from William Goldner (USDa-SBIr, Vision, Opportunity, and Challenge: The 
USDA-Small Business Innovation Research Grants Program), richard Brenner (USDa-arS, 
Technology Transfer in the Agriculture Research Service), Michael adang (University of 
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Georgia, From the Bench to a Product: Academics and Entrepreneurship), Mary Pat Huxley 
(California Community Colleges, The “Central Dogma” of Economic and Workforce Develop-
ment), richard Broglie (DuPont, Translating Discovery Research into Commercial Products) 
and Paul Thompson (Michigan State University, Technological Ethics in University-Industry 
Partnerships: The Best of Both Worlds?).
Bill Goldner described the USDa’s Small Business Innovation research Program. This 
competitive funding program, authorized by Congress in 98, stimulates and facilitates 
r&D by US-owned and -operated for-profit small businesses (<500 employees). all ex-
ecutive branch departments with extramural research budgets exceeding $00 million are 
directed by legislation to provide a .5% set-aside to fund SBIr. rick Brenner reminded 
the audience that the USDa helps drive continuous innovation through science and 
technology by forming Cooperative research and Development agreements (CraDas) 
with research institutions and the private sector. The Office of technology transfer in 
the arS is key in facilitating these partnerships and in transferring research outcomes 
for broad beneficial use by the public and agricultural industries of the United States and 
other nations. Given recent concerns about rising petroleum prices, the United States will 
be increasing research emphasis on new, environmentally favorable crops for industrial 
uses representing new economic opportunities for farmers and reducing dependence on 
imported fossil fuels. There is renewed hope that the most prosperous era in american 
agricultural history is dawning to meet continuing and expanding national needs.
Mike adang described his experience in translating research discoveries to a product 
via a new company that he founded: Insectigen. He discussed ethical conflicts between 
the role of the entrepreneur—which can be time-consuming—and the role of the pro-
fessor with obligations to students, to postdocs, to research colleagues, and to others in 
the university milieu.
Mary Pat Huxley discussed development of the workforce in general and of the bio-
technology workforce in particular. She remarked that the United States is not outpacing 
its competitors with as wide a margin as it did 40 to 50 years ago. Many workers are 
unable to meet new technical needs in the workplace, and incoming workers often fail 
to realize that innovation is t he driver of the US economy. Such innovation increasingly 
relies on workers having scientific, mathematical and technical ability, alongside work-
place-competency skills.
rick Broglie provided concrete examples of bridging “the valley of death”—i.e. trans-
ferring science and technology into commercial products. He concentrated on the work 
that is going on at DuPont Crop Genetics research and Development, where they try 
to predict trends for agricultural production in the next 5–0 years. He sees growing de-
mands for biobased fuels and materials, which with other factors, will drive their farmer 
customers towards more-intensive production systems. They use two complementary 
paths for product development: the transgenic, gene-discovery approach that has been 
used for products currently on the market, and, for more complex traits—e.g. balanced 
amino acids, increased energy availability via increased oil and decreased fiber content—a 
“new technologies” approach that may or may not involve genetic engineering. New traits 
have to be commercialized in high-yielding germplasm, and several enabling technologies 
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are employed including molecular genetics; backcrossing can be made more efficient by 
using molecular markers to select lines with the background of the recurrent parent.
Paul Thompson suggested that technological ethics are today better served in the 
private sector than in the universities. If so, university-industry partnerships could have 
the result of improving the capacity for university-based science to address ethical issues, 
if they bring some of the norms and practices that are commonplace in the private sec-
tor into the university. Or they could have the result of transferring the relatively weak 
ethics performance of university science to the private sector. While we can hope for 
the better outcome, his suspicion is that university-industry partnerships are likely to 
produce the latter.
The banquet presentation was by Mark Crowell (University of North Carolina, Knowledge 
Transfer and Economic Development: The Role of the Engaged University in the Twenty-First 
Century) and a supplementary talk was given by rick Welsh (Clarkson University, Agricul-
tural Biotechnology and University-Industry Research Relationships: Perceptions of University 
Scientists and Administrators and Industry).
Mark Crowell discussed the function of the association of University technology 
Managers (aUtM), an international organization with about 3,500 members. Mirror-
ing the global economy, 5% of the membership is outside North america and growing 
at ½ times the rate of the US group. The aUtM’s Better World Project is an attempt 
to show the impact of public-sector research that is not necessarily reflected in terms of 
licenses, patents and revenue. twenty-five in-depth stories of university innovation have 
been collated demonstrating impact regardless of financial implications. a companion 
piece, Reports from the Field, contains a hundred similar stories in vignette form. These 
reports are being sent to all members of Congress and to agencies in Washington, DC, to 
promote understanding of the important roles academic research and technology transfer 
play in making our world a better place in which to live.
according to rick Welsh—based on a recently completed study—industry funding 
generally brings modestly less basic and more excludable (e.g. patentable) research than 
does NSF or NIH funding. Industry is wary of the decline in the level of basic research 
at universities, but contributes to it through its funding relationships. This points to 
the importance to a number of parties of continuing to publicly fund basic research at 
universities.
In addition to Q&a discussions with audience participation at the conclusion of each 
session, breakout workshops were held, during which delegates, in smaller groups, had 
the opportunity to discuss further issues raised in the presentations, to raise other related 
matters and to make recommendations to share with policymakers. The Q&a sessions 
are included in this volume as is a summary of the workshops.
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Part II
Breakout Sessions
Workshops Summary 
Sarah Nell Davidson, James Hunter, Z.B. Mayo,
Bruce McPheron, Anthony Shelton
9
0 agricultural Biotechnology: Economic Growth Through New Products, Partnerships and Workforce Development
Three workshop sessions were held, with nine questions posed to help focus the discus-
sions. Participants were encouraged to formulate recommendations on the basis of the 
presentations and discussions at the plenary sessions as well as at the workshops.
SESSION 1
Question : Should not-for-profit agencies, institutions and universities actively focus 
on economic and workforce development as part of their mission?
• Whether we believe that to be part of a university’s mission or not, people who 
are supporting public universities are increasingly expecting it in return for invest-
ing in universities. taxpayers support public universities and may expect a return 
in the form of economic development.
• Different parts of universities are affected in different ways. Certain colleges, cer-
tain departments, are on the firing line. Others see little impact on their faculty 
activities.
• The land-grant institution may be viewed as a three-legged stool with teaching, 
research and extension. Some see economic development as a logical fourth leg 
which should be encouraged via legislation.
• In California, specific economic workforce development occurred at the commu-
nity college level after it was mandated by law in the mid-990s.
Sarah Nell Davidson
Cornell University
Ithaca, NY
James Hunter & anthony Shelton
Cornell University/New York State Ag. Exp. Sta.
Ithaca/Geneva, NY  
Workshops Summary
Z.B. Mayo
University of Nebraska
Lincoln, NE 
Bruce McPheron
Pennsylvania State University
University Park, PA  

Question : Have not-for-profit agencies, institutions and universities made an economic 
impact in the international, national, state, and local economies by creating new tech-
nologies/products/information?
• although there is an inextricable link between new knowledge generated in 
universities and the harnessing of that knowledge to create economic growth and 
we should do everything we can to foster economic growth, the university’s fun-
damental mission should not change: to educate, to expand knowledge through 
research, and to provide service. Economic development is part of the service.
• Economic impact should be a “side-product” of universities; consideration should 
more commonly be given by faculty to formal relationships with specialists in 
economic development.
• The traditional land-grant procedure is to give away technologies and not protect 
intellectual property. It needs to be redefined. Disagreement continues over the 
new model, the degree to which new knowledge should be channeled carefully 
and deliberately via protecting intellectual property.
• Many faculty lack the skills to convert research discoveries into products for the 
common good. Years ago, it was seen to be the responsibility of extension, but 
this is far more than extension.
• This philosophy is changing promotion and tenure policies. Economic develop-
ment is written into the mission statements of many universities. Some high-level 
administrators have “economic development” in their titles.
• There are many other things in the public good besides economic development.
• The metric for economic development needs to be defined. Is it number of pat-
ents filed, how many technology transfers have occurred, other?
• Number of patents is a metric of something original that was granted but a poor 
indication of impact. Would a better measure of impact be number of technol-
ogy-transfer transactions?
• The best metric is positive impact on quality of life, but how is it measured?
• although it is essential for economic development to occur and to be a part of 
universities’ programs, striking the right balance can be difficult ethically in terms 
of who assigns research priorities for faculty scientists with interests in IP, involved 
in start-up companies.
Question 3: Does biotechnology represent a new paradigm, or just a continuation of 
what land-grant universities have done?
• It depends on how biotechnology is defined. If the focus is on genetically modi-
fied crops then it is a new paradigm because public-perception issues are integral.
• also, the time to develop a GM product is greatly increased because of regulatory 
strictures and the need to patent genes and new technologies.
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• an obvious change is that before the 980 Bayh-Dole act, modifications to 
organisms couldn’t be patented. There has been a huge proliferation of patents.
• If land-grant universities continue to focus on local problems for economic devel-
opment, it will deplete international outreach efforts. 
Question 4: How do we communicate the role agricultural biotechnology plays, not only in 
food, feed and fiber, but also in human health, energy, chemicals and the environment?
• In Europe they have tried to change the terminology.
• Demonstrating how important agriculture is in many areas of life beyond its 
traditional role may put it in a more positive light, with benefits for agricultural 
biotechnology.
• agbiotech should be as transparent as possible.
• There is need for recognition by administration of the possibility that discoveries 
may contribute to economic development upstream.
SESSION 2
Question : What has the Cornell agriculture and Food technology Park (CaFtP) done 
right and what needs improvement.
• CaFtP has a flexible structure amenable for many purposes.
• It is managed by a corporation, therefore funds are not being diverted from the 
research-station budget.
• There is positive involvement of the community, which was engaged early in plan-
ning.
• It is unclear: 
– how long businesses can stay at the park,
– what are the criteria for selecting tenants,
– whether the necessary expertise is available,
– whether the small faculty can keep ideas in the pipeline,
– in bringing expertise in from outside, whether it is possible to compete success-
fully with other university parks,
– whether transportation is adequate and if the distance to the Cornell main cam-
pus is problematical,
 – how capital will eventually be accumulated,
 – how many parks the area can support given the presence of other parks in the 
vicinity.
• Would it be easier to find resources within a larger area?
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Question : Can CaFtP be replicated/modified for use at other universities?
• Yes, in that this park is, at least to some degree, a replicate of others; those 
involved in the planning visited other parks and implemented what seemed to 
work.
Question 3: What are the benefits/liabilities to the university of the CaFtP?
• It will help attract faculty and students and provide jobs for graduates.
• a job-training program at the local community college system would be mutually 
beneficial.
• any financial losses will not directly affect the university; however, its reputation 
may be positively or negatively affected depending on the success of the park.
Question 4: What are the benefits/liabilities of having domestic/international collabora-
tions between agtech parks?
• This will depend on the site of manufacture. 
• NaBC could play a role in facilitating interactions between parks.
• Complications may result from sharing proprietary information.
• Geneva needs a nearby airport.
• Collaborative projects moved elsewhere would give the impression of lack of com-
mitment to the Geneva area.
It was recommended that CaFtP focus on community strengths: wine, value-added 
foods, and perhaps less on biofuels for example, which does not have a long-standing 
local base. Thus local investment may be encouraged through a Pr campaign. The park 
may be marketed within the Syracuse/rochester/Ithaca triangle. It is important to create 
a web of interactors; for example, advantage should be taken of the Johnson Business 
School on the Ithaca campus. 
SESSION 3
Question . What are the negatives of a land-grant university focusing on economic and 
workforce development?
• It is unclear how the economic development mission will be viewed along with 
teaching, research and extension in the tenure process. Will impact on economic 
development be given equal weight as number of publications, grants obtained 
and teaching contributions?
• Workforce development is a component of teaching, whereas economic develop-
ment is different.
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• There may be intra-departmental conflict if some faculty members are more 
entrepreneurial than others.
• Will university faculty suffer identity crises? Can a university faculty member be 
an academic and an entrepreneur simultaneously?
Question : What are the barriers to economic and workforce development that will be 
encountered and how can they be overcome?
• There are few such barriers in today’s climate.
• adding economic development obligations may overburden university faculty; 
that burden would be lessened by having a support system in place.
• There is a limit to the objectives that a university can address efficiently. a 
division of labor may be needed. If too much emphasis is given to economic 
development, then teaching, for example, may be compromised.
• Being involved with economic and workforce development might bring univer-
sity faculty more into contact with the private sector, with positive influence on 
the educational mission and preparation of students for workforce entry.
It was recommended that the people who need education be engaged to a greater extent 
in the process. although we are constrained by our history and environment, it is time 
to take a new look, to break through tradition-bound ways of educating and explore new 
technologies that will better capture the “Net” generation. Quality control is an important 
issue, but it shouldn’t be a barrier to implementing a better model.
Question 3: How can a land-grant university balance the need for institutional revenue 
and the public good?
• The whole burden should not fall on the university, which would be problematic 
in today’s resource-poor environment.
• Public support for public universities is declining, increasing the time faculty 
spend in seeking alternative sources of funding.
• The Wisconsin alumni research Foundation and the University research Park in 
Madison, Wisconsin, provides a good example of balance.
Substantial funding was recommended so that land-grant colleges can address pressing 
societal issues—energy, human and environment health, etc.—not just new funding, but 
new directions from government sources to focus on creating new knowledge-bases and 
new capabilities. Only then can agriculture address new approaches for society’s long-term 
benefit in addition to focussing on today’s or near-term needs for product development 
and commercialization.
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During the early twentieth century, the business models for most industries were vertically 
integrated. For example, agriculture was only about food and fiber. as we moved into 
the twenty-first century the world changed radically, forcing industries to adjust. Vertical 
integration gave  way to horizontal integration models. agriculture has become integrated 
Agricultural Research: Beyond Food And Fiber
H. alan Wood
Boyce Thompson Institute For Plant Research
Ithaca, NY
Agriculture has become integrated into a variety of industrial 
sectors—pharmaceuticals, energy production, chemicals, etc.—
resulting in new challenges and opportunities.
into a variety of industrial sectors—pharmaceuticals, energy production, chemicals, 
etc.—resulting in new challenges and opportunities. The following is a brief discussion 
of these challenges and opportunities with an emphasis on agricultural contributions to 
society beyond food and fiber. The principle influences for this discussion were:
• Thomas Friedman’s national best-selling book The World is Flat (Friedman, 005),
• a recent USDa-research, Education and Economics (rEE) task Force report to 
Congress (Danforth et al., 004) supporting the formation of a National Institute 
for Food and agriculture, and
• a personal survey of NaBC institutions.
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One of the strong influences for moving business models toward horizontal integration 
has been the shrinking world or, as Thomas Friedman would put it, “flattening” of the 
world. as outlined by Friedman (005), rapid advances in technology and communica-
tions during the past two decades have led to a “smaller,” more integrated world with 
greatly increased interaction and interdependence among nations. This has resulted in 
exceptional changes in the global market. For example, world commerce and trade have 
been significantly changed with the wealth created by three billion people in India, China 
and the former Soviet Union. In response to these factors, most major industries have 
made significant changes in their strategic planning, and agriculture is no exception. as 
the world has become smaller, US agriculture has been pressured to make changes to 
meet the new challenges of the global market.
Loss of Competitive Edge
Concurrent with these changes in the world scene, the competitive edge of american 
farmers relative to those of many other nations has begun to be eroded. Historically, 
US farmers enjoyed a leading role in world agricultural production, using innovative 
technologies and products to produce crops with higher yields at lower costs. However, 
many internal factors such as increased land prices, higher labor and fuel costs, and a 
vast array of other economic pressures are increasing the cost of production and reducing 
our competitive advantage.
accordingly, today, US agriculture faces increased levels of international competition in 
the areas of food and fiber production. For instance, cotton producers in the Mississippi 
delta have expressed the opinion that Chinese and Indian agriculture are probably second 
only to the weather in determining US cotton prices. Considering another commodity, the 
United States is no longer the world’s lowest-cost producer of soybeans (Danforth et al., 
004), with Brazilian farmers selling soybeans at competitive prices; this cost advantage 
has resulted in midwest farmers cooperatively buying farms in Brazil to produce soybeans 
for export to the United States.
Ethanol production represents another example. Brazil can export sugarcane ethanol 
at prices below corn-based production in the United States (ribeiro, 005). Clearly, the 
flattening of the world has resulted in a redefinition of agricultural practices and global 
competition.
Genetic Engineering
In the past, US agriculture maintained its competitive advantage in the world market 
through science and technology, most recently through advances in biotechnology and, in 
particular, genetic engineering. With the commercial introduction of genetically modified 
(GM) plants more than a decade ago, US farmers were given a significant competitive 
advantage globally. In 005, approximately 87% of soybean acreage, 5% of corn acre-
age, and 79% of cotton acreage in the United States were planted using GM seeds. The 
advantages of GM soybean, corn and cotton with herbicide resistance and Bt insecticides 
have led to acceptance of the technology in several global markets, resulting in more 
than $7 billion of global economic benefits (Brookes and Barfoot, 005). However, as 
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this technology is more widely accepted nationally and internationally, the competitive 
advantages to US farmers are being lost, resulting in price adjustments and concurrent 
diminishment of the previously enjoyed advantages of GM soybean, corn and cotton. 
Further erosion of the economic advantage of GM plants has occurred as a result of 
their rejection by Europeans and a few other countries. It should be kept in mind that, 
while GM plants have been profitable to those in the agricultural industry, consumers have 
never realized any economic advantage from buying GM foods. Furthermore, because 
many of the companies selling GM seeds also sell chemical herbicides and insecticides, 
the ecological and health benefits of GM foods, as compared to those produced through 
alternative practices, have not been aggressively explained to the public. Hence, the general 
consumer public has not been moved to embrace GM foods as positive technologies.
Despite dwindling economic incentives, there remain several non-pecuniary advan-
tages to the use of herbicide tolerance and insecticide biotechnologies. Farmers use these 
products because of their convenience, value, simplicity and relative heath/environmental 
safety compared with the alternatives (Marra and Piggott, 006). 
Confronted with the economic pressures of increasing international competition, 
diminishing economic value in some of the current agricultural technologies, increasing 
costs of labor, land and fuel, and poor consumer acceptance of GM products, the US 
farming industry is facing significant changes. In the past, US agriculture has used advances 
in science and technology to maintain healthy and competitive business environments. 
However, since the 970s, public funding for agricultural research has been stagnant in 
real terms. Why has this occurred? Well, our grocery stores are well stocked with inex-
pensive food, and americans pay a lower percentage of their gross domestic product for 
food than does any other developed nation. Fewer than % of americans are involved 
in agriculture, compared with approximately 40% of the world population. and last but 
not least, the representatives of farming states are a minority in the US Congress.
NIFa Proposed
Despite these negative factors, several members of Congress have been very concerned 
about the future of US agriculture and the trends in international competition. They called 
for a USDa rEE task Force to consider the possible formation of new National Institutes 
for agricultural research. after several months of interviews, meetings and deliberations, 
the committee recommended that Congress create a new granting agency, the National 
Institute for Food and agriculture (NIFa), which would fuel the technological advances 
required to keep US agriculture strong and competitive. as of the time of this writing, 
NIFa has not been created.
A new granting agency, the National Institute for Food and 
Agriculture (NIFA), would fuel the technological advances 
required to keep US agriculture strong and competitive.
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energy
Corn-based ethanol production systems
Switchgrass biomass energy conversion
Food saFety/diet
Lactose-free milk products
Vaccine development against Campylobacter
Lactococcus lactis resistance to bacteriophage
Human skeletal research
Enhanced sorghum germplasm
Vitamin-D fortification of cheese
rapid detection of food-borne pathogens
replacing antibiotic treatments of poultry
Eggs enriched with omega-3 fatty acids
Plant-derived edible vaccines
Comparative cattle-human genome mapping
Porcine xenotransplantation and 
 drug production
Medical properties of arid-plant compounds
new products
Soy oil-based inks
SuperSlurper; high absorbant starch 
 formulations
Bovine growth hormone
Canine parvovirus vaccine
Hybrid striped bass
Feline leukemia vaccine
Megalac fat utilization by lactating cows
Control of fescue toxicosis in beef
Diagnosis of feline immonodeficiency virus
research on articular cartilage
Vaccines for equine influenza and strangles
Mastitis prevention and management
Table 1. RecenT advances in agRiculTuRe ReseaRch by  
nabc-membeR insTiTuTions.
HealtH
tests for avian influenza
High production of proteins in insect cells
Elastomeric absorbable polymers 
Biolistic gene gun
Mouse model for asthma
Human fertility assessment
Improved amino acid composition of 
 crop plants
Poultry model for human autoimmune 
 diseases
Isoflavonoid content in corn
taxol biosynthesis pathway and genes
environment
Controlled eutrophication remediation
transgenic fish industry risk
Impact of global warming on agriculture
remediation of radionuclides
No-till crop production
Enviropig™ utilization of phosphorus
plant Biology
automated plant tissue-culture system
Peach-tree pest resistance
Sequence of the peach genome
Long-term storage technology
Cold response pathways in plants
Papaya ringspot virus resistance
Soybean resistance to Phytophthora sojae 
resistance to barley yellow dwarf virus
Floral scent research
Sequencing the rice genome
Insect resistance to Bt proteins
Engineering wheat flowering time
Strawberry breeding
Winemaking technology
Porcine cloning
Improved grain handling
New selectable markers in plant breeding
Maize genome sequencing
Plant resistance to the herbicide dicamba
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Societal Contributions
During the course of the USDa study, it became clear that a new institute would garner 
little public support based solely on food and fiber issues, partly because the benefits of 
agricultural research beyond food and fiber are not generally recognized by either the 
public or legislators. Therefore, NaBC member institutions were solicited to submit 
information regarding recent agricultural research beyond food and fiber with significant 
societal impacts. a general description of the submissions received is listed in table , 
revealing some outstanding contributions to society.
Biofuels
One such area of impact is biofuels, which, because of the current energy crisis in the 
United States, have become an important topic in US agriculture. In recognition of this, 
biofuels and energy sustainability will be the subject of the NaBC meeting to be held at 
South Dakota State University in 007. With close to a hundred ethanol plants and an 
annual capacity of nearly 4.5 billion gallons (Karnowski, 006), agriculture is beginning to 
have an impact on US energy problems. about 39% of ethanol capacity is farmer-owned. 
another thirty-five ethanol plants and nine expansions—with a combined capacity of 
more than . billion gallons—are being built in 006.
Currently, 90% of the US ethanol production uses corn kernels as feedstock, contribut-
ing to a decrease in corn exports and a further decline in the agriculture balance of trade. 
In the first quarter of 006, agricultural exports exceeded imports by only 5%, and corn 
prices rose from $ to $.50/bushel. Clearly, as oil prices continue to increase, corn and 
ethanol prices will also increase, as will the acreage of corn planted.
approximately % of today’s transportation fuels are derived from biomass and blended 
fossil fuels; Shell Oil has predicted that “the global market for biofuels such as cellulosic 
ethanol will grow to exceed $0 billion by 0” (Greer, 005). a recent study funded by 
the Energy Foundation and the National Commission on Energy Policy, entitled Grow-
ing Energy: How Biofuels Can Help End America’s Oil Dependence, concluded that, if the 
United States follows an aggressive plan to develop cellulosic biofuel, farmers could see 
profits of $5 billion/year by 05, with the need to import Persian Gulf oil decreased by 
two-thirds. at the same time, increased biofuel usage could reduce US greenhouse-gas 
emissions to .7 billion tons/year (% of 00 emissions) (Greene et al., 004). 
as the United States has been forced to develop new energy strategies, the federal 
government and general public, unlike most areas of agriculture, have taken a serious 
interest in the biofuels industry. In order to promote the industry, the federal government 
NABC member institutions were solicited to submit information 
regarding recent agricultural research beyond food and fiber with 
significant societal impacts.
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currently subsidizes ethanol at $0.5/gallon. In addition, because of the cheap sugarcane 
ethanol available from Brazil, the US government has placed importation tariffs on 
ethanol. according to Kenneth Cook, president of the Environmental Working Group, 
corn is america’s No.  subsidized crop (Grist, 006); the federal government paid $37 
billion in corn subsidies between 995 and 003. These actions point to the long-term 
importance that biofuels will play in future US energy plans.
In the meantime, a debate continues over the scope and impact of biofuels, their sus-
tainability, and their potential impact on greenhouse-gas emissions. Part of this debate 
centers on the use of starch vs. cellulosic feedstocks and fermentation vs. gasification/syngas 
processes. In addition, there are debates regarding food vs. fuel consumption, price sup-
ports and import tariffs. The bottom line for US agriculture is that biofuels hold great 
potential value for the nation, socially, environmentally and economically. Hopefully in 
the next few years the scientific, economic and political issues surrounding biofuels will 
be resolved. Clearly, the biofuels industry will continue to be a growing segment of the 
US farm industry because of contributions to energy security, potential to reduce green-
house-gas emissions, and support for agriculture (Koonin, 006).
Biobased Industrial Materials
While biofuels and prices at the gas pump have been responsible for a public recognition 
of solutions to energy problems through corn, the public is much less aware of other 
industrial uses of farm crops in replacing petroleum imports. For instance, corn sugar and 
other agricultural raw materials are also being used to replace petroleum-based products 
to produce polyhydroxyalkanoate (PHa) plastics. In February of 006, archer Daniels 
Midland Company (aDM) and Metabolix announced that aDM will build the first 
commercial plant to produce a new generation of natural plastics that are eco-friendly 
and based on sustainable, renewable resources; the plant will have a capacity of 50,000 
tons/year. Corn feedstocks are also being used to produce the polyester fabric Sorona® 
and polylactic acid (PLa) plastics. These are just three of the many manufactured goods 
for which plant-derived materials can be substituted for the petroleum products required 
hitherto for their production.
Contributions to Healthcare
In addition to prices at the gas pump, the american public is particularly interested in 
scientific advances in human health. agricultural research at NaBC and other agricultural 
research institutions is also making important contributions in the area of human health. 
americans pay a higher percentage of their gross domestic product for healthcare than 
does any other developed nation (Cowling et al., 996). Many such advances have their 
foundations directly or indirectly in the findings of studies originally aimed at agricultural 
problems. For instance, using an animal model, Michigan State University veterinary re-
searchers are using biotechnology to find the genes responsible for human asthma (Ewart 
et al., 000), which currently affects about 0 million americans (aLa, 006). These 
studies, which are elucidating the common molecular pathways that result in asthma, can 
open the way to treatments directed at the basic mechanisms of this disorder. 
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a procedure now widely used to produce proteins of medical importance was origi-
nally discovered by entomologists at texas a&M University in the course of studies on 
the use of naturally occurring insect viruses as alternatives to chemical insecticides. They 
discovered a method for introducing foreign genes into insect viruses and producing large 
amounts of foreign protein when the virus replicated in insect cells (Smith et al., 983); 
the baculovirus expression vector system (BEVS) is now used in thousands of research 
laboratories and more than seventy commercial licenses have been issued (taMU, 006). 
The BEVS has been used to produce many pharmaceutical proteins including vaccines to 
treat Hong Kong “bird-flu” virus and SarS; most recently it was used to produce a highly 
effective vaccine against human papilloma virus, a known cause of cervical cancer.
Other human vaccines are also being produced in agronomic plants. Worldwide, two 
billion humans are infected with hepatitis B and an estimated one million die each year 
from it and its complications (HBF, 006). researchers at the Boyce Thompson Institute 
and arizona State University have developed plants that produce several recombinant 
proteins including vaccines against Norwalk virus (Mason et al., 996) and hepatitis B 
(Thanavala et al., 995). 
tremendous advances in the assessment of fertility have been made by scientists at 
South Dakota State University through the development of the sperm chromatin structure 
assay (SCSa) (Evenson and Wixon 006). Using bovine sperm models, these researchers 
developed the first computerized, instrument-based test capable of measuring the genetic 
integrity of thousands of sperm cells in just seconds. More than 0% of US couples ex-
perience infertility problems (WebMD, 006), and this method, which can be used to 
rapidly measure abnormalities that relate to defects in paternal genes, is now becoming 
widely used at human fertility clinics. 
researchers at Washington State University are elucidating the enzymes and processes 
involved in taxol biosynthesis. taxol, a drug isolated from the bark of the slow-growing 
Pacific yew in the early 960s, has been proven effective in the treatment of breast, ovar-
ian and other cancers. The researchers are in the process of determining the metabolic 
pathway of the drug, isolating the pathway genes, and investigating the use of yew tissue 
culture as a means of producing the drug (Jennewein et al., 004). The development of a 
high-yielding, low-cost production system for taxol would be a major accomplishment.
a plant physiologist at the Boyce Thompson Institute discovered that vitrification (a 
type of sugar crystallization) is responsible for long-term maintenance of seed viability. 
The vitrification protects seed proteins from denaturation and inactivation (Sun and 
Leopold 994). This protective factor has been applied to many other proteins. Most 
recently it was discovered that insulin could be stabilized by vitrification, making it pos-
The baculovirus expression vector system (BEVS) is now used 
in thousands of research laboratories and more than seventy 
commercial licenses have been issued
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sible to replace injection therapy with inhalation therapy (Potera, 998). according to 
the american Diabetes association approximately  million US adults and children 
deal with diabetes every day.
technological advancements
agricultural research has made many contributions to biotechnology beyond enhancing 
food and fiber production. For example, Cornell University researchers invented the gene 
gun, a “biolistic” method of transforming plant tissue by shooting DNa-coated metal 
particles into cells. It allowed the transformation of plant species that at the time were 
recalcitrant to transformation by the widely utilized ti-plasmid method (Ye et al., 990). 
Having been used to successfully transform agricultural as well as non-agricultural plants, 
animal cells, insect and fish embryos, algae, fungi, pollen, bacteria, and intracellular organ-
elles, it has proven to be a very significant technological advancement in biotechnology.
another extremely significant agriculture-based technology that promises to have a great 
impact on society is the discovery of rNa silencing in plants through rNa interference 
(rNai). Discovered initially by researchers at the John Innes Centre (Baulcombe, 996), 
this has opened the door to blocking the expression of nearly any eukaryotic gene. The 
potential uses, particularly in the treatment of human diseases, are enormous and a large 
number of human clinical trials testing rNai-based drugs are currently underway. The 
006 Nobel Prize in medicine was awarded for the discovery of rNai; however, the vital 
groundwork in plants was ignored. 
Spreading the Word
These are a few of the more recent examples of significant contributions to society through 
agricultural research with application beyond food and fiber production. Except for possibly 
the plant-made vaccines, the general public and—possibly more importantly—Congress 
are unaware of these products of agricultural research. The agricultural industry does not 
have a lobbying group such as the health industry’s research!america (www.researcha-
merica.org), which refers to itself as “an alliance for discoveries in health” and advertises 
the latest discoveries in health science, particularly to legislators. research!america claims 
that its educational activities are responsible for the recent doubling of the NIH budget. 
But, if research!america were to advertise the new human papilloma virus vaccine or the 
new insulin-inhaler therapy, the key contributions of agricultural research would prob-
ably not be emphasized; to the best of the author’s knowledge, only one newspaper, the 
Ithaca Journal, has carried a report of the agricultural connection to the insulin inhaler 
technology to the general public. 
Cornell University researchers invented the gene gun, a “biolistic” 
method of transforming plant tissue by shooting DNA-coated 
metal particles into cells.
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The agricultural community would benefit greatly by emulating the public relations 
strategy of NaSa’s space program. NaSa promotes its research by advertising and pro-
moting discoveries and products that have affected society beyond space travel (NaSa, 
006). among the dozens of spin-off products and technologies are charged coupled 
device (CCD) chips for digital imaging breast biopsies, a device to control chronic pain, 
new golf-ball designs, enriched baby foods, water-purification systems, freeze-dried food 
technology, home-security systems, smoke detectors, flat panel television sets, etc. as 
briefly listed above, agricultural research has similar spin-off products that could be used 
to enhance the public’s recognition of its broad value to society beyond food and fiber. 
When it comes to recognition of scientific value, the most widely accepted measure of 
excellence has been the Nobel Prize awards. In agricultural academic circles, the awards to 
Wendell Stanley for plant viruses in 946, to Norman Borlaug (the “father of the Green 
revolution”) in 970, and to Barbara McClintock for mobile genetic elements in 983 
are well known. Most of the additional fourteen awards listed in tables  and 3, involving 
discoveries in the plant and animal sciences—with significant impacts in other areas of 
human health and well-being—are not generally recognized by the public.
Table 2. agRiculTuRal ReseaRch in planTs: nobel pRize awaRds.
90 Otto Wallach Chemistry Plant smells and tastes  
95 richard M. Willstatter Chemistry Plant pigments, especially chlorophyl  
930 Hans Fischer Chemistry Structure of haemin & chlorophyl  
937 albert Szent-Gyorgyi Physio/Med Structure of vitamin C  
937 Paul Karrer   Chemistry Carotenoids, flavins & vitamin a  
945 artturi I. Virtanen Chemistry Nutrition & fodder preservation  
946 Wendell Stanley Chemistry Plant viruses  
949 John Boyd Orr Peace Global production and distribution of food 
950 robert robinson Chemistry Plant products: alkaloids  
96 Melvin Calvin Chemistry Carbon pathway: photosynthesis  
970 Norman E. Borlaug Peace The Green revolution  
983 Barbara McClintock Physio/Med Mobile genetic elements  
Table 3. agRiculTuRal ReseaRch in animals: nobel pRize awaRds.
966 Peyton rous Physio/Med rous sarcoma virus induced tumors in chicken 
975 Dulbecco, temin &
 Baltimore Physio/Med transformation via rNa-dependent DNa
   polymerase   
989 Bishop & Varmus Physio/Med Cellular origin of retroviral oncogenes  
990 Murray & Thomas Physio/Med Organ and cell transplantation  
997 Stanley Prusiner Physio/Med Prions: scrapie of sheep  
While many scientists are familiar with the rous sarcoma virus and the Nobel Prize 
awards for research with this virus, few realize that it was an agricultural research prob-
lem. The rous sarcoma virus, which affects chickens, served as an ideal model for many 
important discoveries including the first identification of viral-induced tumors and the 
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discovery of rNa-dependent DNa polymerase. Obviously, research on this chicken 
disease has had significant impact in the field of human-cancer research.
The public is also aware of mad cow disease (bovine spongiform encephalopathy, 
BSE) and, to lesser degrees, of kuru and Creutzfeldt-Jacob diseases. Stanley Prusiner was 
awarded a Nobel Prize for his discovery that these diseases are mediated by prions. Less 
well known by the public is that the discovery of prions and their diseases began with 
research on scrapie disease of sheep, another agricultural research problem that led to 
significant contributions to human health.
In Conclusion
agricultural research in the United States continues to contribute substantially to feeding 
the world and in making significant societal contributions beyond food and fiber. In this 
changing world, strategic planning in US agriculture needs to become more global and 
inclusive in nature. and, in this flattened world, there is need to increase investment in 
the development of new products and technologies in order to keep US agriculture strong 
and competitive and to move the agricultural sciences to the next level.
to achieve these goals, the value and significance of US agricultural production and 
research must be effectively communicated to the public and to legislators. This could 
lead to an understanding of the national and global importance of US agriculture and 
its breadth of impact, and an appreciation of its many past and future contributions to 
society beyond food and fiber.
and finally, I think it is worth considering that, from a global standpoint, discoveries 
by US agricultural research can play a role in improving the productivity of subsistence 
farmers and combating hunger in developing countries; well-fed populations foster politi-
cal stability and can contribute to our national security.
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Throughout the nineteenth century, heredity remained a puzzle, even to scientists. How 
was it that after crossing two plants with different characteristics, you often got a plant 
with traits that were not identical to those of either parent? These questions intrigued 
Charles Darwin. He realized that these variations were the raw materials for natural se-
lection. Conversely, uniformity from one generation to the next was the basis by which 
long-term effects were maintained. But Darwin was unable to decipher the underlying 
principles by which variation occurred on the one hand and uniformity was the norm 
on the other (tompkins and Bird, 973).
When Darwin published Origin of Species (Darwin and appleman, 99), Gregor 
Mendel was busy at work in a secluded monastery, occupied with the study of natural 
variation in peas. In this endeavor he was able to gain the first insights into the biological 
machinery behind heredity. His focus was to better understand what kept species distinct 
and what allowed them to be different following crosses. Studying these questions using 
natural variation in peas, Mendel gained an appreciation for the potential power of genetic 
manipulation applied to plants of agricultural importance. This work was extended by 
the findings of Luther Burbank (907), a plant breeder whose prodigious production of 
new varieties of fruits, flowers, vegetables, grains, and grasses moved plant breeding into 
a more sophisticated science driven by an appreciation of genetics. 
The use of genetics to modify plants and animals for agriculture moved into the cur-
rent era with the identification by James Watson and Francis Crick (953) of DNa as 
the element responsible for Mendel’s wrinkled peas. This finding formed the platform 
for the development of recombinant DNa methods, first shown by California scientists 
Stanley Cohen and Herb Boyer who demonstrated a mechanism for moving functional 
DNa between unrelated organisms (Chang and Cohen, 974), commonly referred to as 
biotechnology, recombinant DNa (rDNa) or genetic engineering.
Ag Biotech Pipeline: What’s in the Lineup? 
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Commercial Use of Genetic Engineering in agriculture:  
What’s Out there Now? 
The first use of genetic engineering to modify plants was reported in tobacco in 983 (Be-
van et al., 983) and the first commercial genetically engineered (GE) crop, the FlavrSavr™ 
tomato, was developed by a California company, Calgene (http://www.accessexcellence.
org/rC/aB/Ba/Flavr_Savr_arrives.html). although the tomato was taken off the market, 
other GE crops were commercialized, most notably in large acreage crops like canola, corn, 
cotton, soy and, most recently, alfalfa. If success is measured by the increase in global acre-
age of these GE crops or their acceptance by farmers, certainly they have been successful. 
In 005, the billionth acre was planted (James, 005) by one of 8.5 million farmers in 
twenty-one countries. Most of the acreage is in the United States and almost none is in 
Europe. In the former, the adoption of herbicide-tolerant (Ht) soybean represents 87% 
of total US acreage and Ht cotton is at 60% (Fernandez-Cornejo and Caswell, 006). 
Insect-resistant (Bt) cotton represents 5% and Bt corn 35% of total cotton and corn 
acreage, respectively. a few minor-acreage GE crops have met with commercial success: 
papaya, certain types of squash and sweet corn.
acceptance by consumers has not come so easily. In a 005 poll, 50% of US con-
sumers opposed genetic modification (i.e., genetic engineering) of plants and 33% 
strongly opposed it (http://pewagbiotech.org/resarch/005update). Consumers were 
even more uncomfortable with genetic engineering of animals: 56% opposed GE ani-
mals and 66% opposed animal cloning. Despite the fact that consumers were opposed 
to genetic engineering of plants, 58% of US poll respondents—as recently as October 
005—weren’t even aware that GE foods are being sold in grocery stores, an interesting 
dichotomy. Despite the majority of americans admitting they have little knowledge of 
the regulatory structure governing GE food (55% in September 004; http://pewagbio-
tech.org/research/004update/004summary.pdf ), the majority of americans (87% in 
July 003; http://lists.iatp.org/listarchive/archive.cfm?id=79397) were confident that the 
food they eat is safe. Overall, these figures raise serious questions about the current state 
of consumer acceptance of foods containing GE ingredients and just exactly what is the 
nature of the issues they have with GE foods.
Use of Genetic Engineering in agriculture: the Future? 
Despite the large acreage, the diversity of GE crops and traits in commercially released 
varieties is limited. Nearly all major-acreage, commercial releases of GE crops are based 
on either insect protection via genes from Bacillus thuringiensis or herbicide tolerance, 
predominantly to Monsanto’s roundup® herbicide. More recently, stacked versions of 
these traits have been released, for example maize engineered for resistance to rootworm 
and European corn borer and tolerance of roundup®. In addition, with the exception 
of GE papaya, which was developed by the public sector, all commercial varieties on the 
market in 006 come from the private sector.
Insect-resistance and herbicide-tolerance traits are focused on improving life for the 
farmer. But, if used responsibly, these improved agronomic traits can also be beneficial 
to the environment, by increasing crop yields through the reduction of losses to insects, 
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disease and weeds. This has been most dramatically demonstrated with decreases in insec-
ticide applications with Bt cotton (Benbrook, 004; Sankula et al., 005). Estimates of 
whether herbicide use has increased or decreased vary depending on the particular crop, 
the environment in which it was grown and the calculation method (ibid.). Despite the 
disagreement on the amount of herbicide used in GE vs. conventional crops, it is clear that 
there has been a shift in the herbicides used to more environmentally friendly types. It is 
also true that they are benefiting from the ease of application of herbicide to GE crops.
But what do end-users and consumers think about the future of this technology and 
where it might be most reasonably applied? In September 004, Pew trust poll (http://
pewagbiotech.org/research/004update/) respondents were asked about possible applica-
tions (table ). Clearly, some products of the technology were viewed more favorably 
than others. Producing more-affordable industrial compounds in plants, reducing the 
cost of fish such as salmon, creating fruits and vegetables that last longer and having beef 
with less fat were those applications that appeared least favorable. But consumers were 
in favor of producing more affordable pharmaceuticals using plants, although not by us-
ing animals. also, reducing the need for pesticides, creating less-allergenic peanuts and 
developing vegetable oils with heart-healthy fats were viewed relatively favorably. One of 
the most interesting questions related to whether it is a “good or bad reason to genetically 
modify plants and animals” to “expand our understanding of science and nature”: 46% 
of respondents said yes and only 0% said no.
Table 1. aRe These good oR bad Reasons To geneTically modify 
planTs oR animals?
 Very good Very bad
 ––––– (%) ––––
to reduce the need to use pesticides on crops 43   
to reduce the cost of fish like salmon  7  
to produce more affordable pharmaceuticals using plants 54 8  
to produce more affordable pharmaceuticals using animals 3 9  
to produce more affordable industrial compounds using plants  7  
to create types of grass that require less-frequent mowing 39   
to create fruits and vegetables that last longer 7 30  
to produce beef with less fat 7 3  
to develop heart-healthy vegetable oils 4 8  
to create hypo-allergenic peanuts 4 5  
to expand understanding of science and nature 46 0  
Certainly from a casual look at the scientific literature, scientists are utilizing the modern 
methods of genetically engineering organisms, coupled with genomic information, to 
gain in-depth understanding of living organisms. This information has led to a practice 
referred to as marker-assisted breeding. The term is used to describe the application of 
classical breeding methods coupled with genomics to create crops and animals with 
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different characteristics resulting from new information gained about the location and 
function of genes. This information is normally determined or validated using the tools 
of recombinant DNa either to up- or down-regulate genes in the recipient organism. 
although the technology uses information developed through the use of genetic engineer-
ing to read and manipulate the genome to determine function, the genetic information 
of the plants is not directly modified using recombinant DNa technology.
What’s the Lineup in the ag Biotech Pipeline?
The technologies used for marker-assisted selection can be successful for certain traits 
and certain crops and animals, given a long timeframe. However, when there is a desire 
to control precisely when and where a gene is expressed to achieve a certain outcome, 
manipulating these traits will not be achievable through such methods. Examples might 
include changes that require genes from other organisms, like insect-resistance or her-
bicide-tolerance genes from a bacterium, or other modifications that require genes to 
be linked to specific regulatory elements to control exactly when and where they are 
expressed, like genes mitigating allergenicity or delaying ripening that need to be altered 
only in the edible parts of the plant. These traits may be achieved by using antisense or 
gene-silencing mechanisms. 
although commercialized GE crops are limited in traits used, proof-of-concept for 
many other traits has been reported. These can be divided into a number of categories: 
pest resistance, improved agronomic performance, tolerance to environmental stresses, 
increased food, feed and environmental quality, and medical and other applications. 
Pest resistance
a number of examples demonstrate the capability to improve the performance of crops 
through protection against pests. Starting in 845, late blight disease attacked the potato 
crops that fed the densely populated island of Ireland, resulting in the infamous Irish potato 
famine. Now, with the globe much more crowded, potato experts report that the same 
disease, caused by the fungus Phytophthora infestans, is returning. But scientists, looking 
in the genome of a wild Mexican potato, discovered a gene that, when engineered into 
cultivated potato, allows the potato to survive exposure to the many races of P. infestans 
(Song et al., 003). although GE potatoes show promise in resisting late blight, in May 
006 the world’s largest chemical company, BaSF, relinquished its plans for a GE-potato 
field experiment in County Meath (http://www.gmfreeireland.org/potato/), demonstrat-
ing the fear with which some European governments view GE crops, even if they address 
serious agricultural problems.
Although commercialized GE crops are limited in traits used, 
proof-of-concept for many other traits has been reported.
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another example is the identification of a native gene, Mi, in tomato that protects 
against root-knot nematodes (Milligan et al., 998). Surprisingly, at the time the gene was 
cloned, they discovered that the gene most similar to Mi-1.2 is Prf, another tomato gene 
required for resistance to the bacterial pathogen Pseudomonas syringae. It turned out that 
the Prf and Mi-. proteins share several structural motifs, including a nucleotide-bind-
ing site and a leucine-rich repeat region (NBS-Lrr), characteristic of a family of plant 
proteins required for resistance to viruses, bacteria, fungi and nematodes.
although Europe has been reluctant to embrace engineered crops, the first field trial 
of GE grapes took place in the northern alsace region of France in 005. This plant was 
engineered against fanleaf virus, which is transmitted by a small root-feeding nematode. 
Scientists inserted into rootstocks a coat-protein gene that stops replication of the virus 
(Bouquet et al., 003), while the scion—the portion grafted to the rootstock and which 
bears the fruit—is free of the foreign gene. Without a GE approach, growers must fight the 
fanleaf virus with a pesticide that has been banned in Germany, Switzerland and in some 
US states. another viral target utilizing a GE approach was addressed with watermelon 
rootstocks engineered for resistance to cucumber green mottle mosaic virus (CGMMV) 
infection (Park et al., 005a).
Other examples outside the United States include relatively small acreage crops engi-
neered with Bt genes. Indian, Canadian and French scientists collaborated to engineer 
cabbage with a fusion gene encoding two Bacillus thuringiensis crystal-endotoxin genes, 
which led to resistance to the diamondback moth (anderson et al., 005). In 000, sci-
entists at the Centre de Coopération Internationale en recherche agronomique pour le 
Développement (CIraD) in France planted in French Guiana GE coffee engineered with 
a Bt gene to test for protection against leaf-miner damage. In 004 vandals removed the 
trial owing to fears that the engineered strains would enable richer farmers to put small 
farmers out of business (http://www.newscientist.com/channel/life/gm-food/). In 005, 
scientists at the International Crops research Institute for the Semi-arid tropics (ICrI-
Sat) in India engineered and field-tested chickpea for resistance to legume pod-borer, 
Helicoverpa armigera (http://www.icrisat.org/gt-bt/GeneticEngineering.htm). 
Improved agronomic Performance
Such improvements are aimed primarily at the farmer, but could, given responsible usage, 
also have positive effects on the environment. One aspect of crop performance is yield. 
In 00, transgenic rice plants expressing the maize proteins phosphoenolpyruvate car-
boxylase (PEPC) and pyruvate orthophosphate dikinase (PPDK) were found to exhibit 
higher photosynthetic capacity (up to 35%) compared to untransformed plants (Ku et al., 
00). The simplicity of the change that resulted in the increased photosynthetic capacity 
in rice surprised many who had thought that such a dramatic increase in yield in a C3 
plant relative to a C4 plant would require more complex modifications. 
another agronomic improvement involves the efficiency of utilization of nitrogen, 
resulting in less use of fertilizer and increased sustainability of farming practices. Japanese 
scientists introduced into the model organism, Arabidopsis, the plant-specific transcrip-
tion factor, Dof, to improve nitrogen assimilation (Yanagisawa et al., 004). Expressing 
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Dof induced up-regulation of genes encoding enzymes for carbon-skeleton production, 
a marked increase of amino acid content, and reduction in glucose level. Elementary 
analysis revealed that the nitrogen content increased by ~30%, and the engineered plants 
exhibited improved growth under low-nitrogen conditions.
tolerance to Environmental Stresses
These traits aid the ability of plants to survive environmental stresses, like salinity, exces-
sive and deficient water availability and high and low temperatures. Prior to developing 
a thorough molecular understanding of the regulatory mechanisms governing the plant’s 
responses to these stresses, it appeared that strategies would have to focus independently 
on each individually. However, with the development of a detailed understanding of the 
mechanisms involved and their regulatory networks, it became possible to enable plants 
to deal with multiple environmental factors simultaneously with change in one gene. 
an example is the demonstration that the CBF genes, which are rapidly induced in 
response to low temperature, encode transcriptional activators that control the expres-
sion of genes containing C-repeat/dehydration-responsive regulatory elements in their 
promoters (Gilmour et al., 000). Constitutive expression of either CBF1 or CBF3 (also 
known as DREB1b and DREB1a, respectively) in engineered Arabidopsis was shown to 
induce the expression of target COR (cold-regulated) genes and to enhance freezing toler-
ance in nonacclimated plants.
Later, a homologue of the CBF/DrEB proteins (CBF4) was shown to play an equiva-
lent role during drought adaptation; CBF4 gene expression is upregulated by drought 
stress, but not by low temperatures (Haake et al., 00). Over-expression of CBF4 in 
engineered Arabidopsis resulted in activation of downstream genes involved in cold ac-
climation and drought adaptation and, as a result, engineered plants were more tolerant 
to freezing and drought stress. This approach was expanded to crop plants with the intro-
duction of DREB1A into wheat for drought tolerance; field trials were conducted at the 
International Maize and Wheat Improvement Center (CIMMYt) in 004 (http://www.
cimmyt.org/english/webp/support/news/dreb.htm).
In another example, transgenic tomato plants over-expressing a vacuolar Na+/H+ antiport 
were able to grow, flower, and produce fruit in the presence of 00 mM sodium chloride, 
approximately 40% of sea-water concentration (Zhang and Blumwald, 00). although 
leaves accumulated high concentrations of sodium, the tomato fruit displayed very low 
sodium content. This confirmed that—contrary to prevailing thought—multiple traits 
do not have to be introduced by breeding to obtain salt-tolerance. 
It became possible to enable plants to deal with multiple 
environmental factors simultaneously with change in one gene.
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Increased Food and Feed Quality
The first demonstration of the use of GE to alter nutritional quality was the introduction 
of three genes into rice to create the much publicized Golden rice, enriched in pro-vitamin 
a (Ye et al., 000). More recently one of the genes from daffodil, used in the original 
event, was replaced with a maize gene and the level of pro-vitamin a was thus increased 
3-fold (Paine et al., 005) to a level likely to supply 50% of a child’s recommended daily 
allowance in 7 g of dry rice.
Efforts have also been made to increase calcium levels three-fold in potato (Park et 
al., 005b). Levels of folate, an important vitamin for women of childbearing age, were 
increased in Arabidopsis to those in spinach by the introduction of a single bacterial gene 
(Hossain et al., 004). Indian scientists improved the nutritional quality of a staple in their 
diet, the potato, by introducing a nonallergenic protein from Amaranthus, thus increasing 
both total protein content and the amounts of essential amino acids (Chakraborty et al., 
000). recently, corn for animal feed was engineered for higher lysine content in order 
to reduce the need for lysine supplements (http://www.renessen.com/news/0.06.006.
eng.pdf ).
Plants have been engineered to produce the heart-healthy omega-3 and omega-6 oils, 
previously supplied mainly from fish sources (Qi et al., 004). another area of intense 
interest relating to human consumption is engineering foods for decreased allergenicity, for 
example in rice (Nakamura and Matsuda, 996) and wheat (Buchanan et al., 997). 
Medical applications
Many applications in this arena relate to the production of vaccines, both for animals 
and for humans. In one early application aimed at animal husbandry in australia, clover 
was engineered to provide protection against shipping fever (Lee et al., 003). In 006, 
the USDa approved a plant-based vaccine against Newcastle disease of chickens (http://
www.checkbiotech.org/ blocks/dsp_document.cfm?doc_id=54). another approach to 
improved animal husbandry involved the actual engineering of a cow with higher levels 
of lysostaphin to lower the rate of mastitis infection by Staphylococcus aureus (Wall et al., 
005).  
approaches utilizing GE plants to combat human disease include the development 
of a subunit vaccine against pneumonic and bubonic plague, which has been shown to 
be immunogenic in mice (alvarez et al., 006), a potato-based vaccine for hepatitis B 
demonstrated to raise an immunological response in human test subjects (Thanavala et 
al., 005), a GE pollen vaccine that reduces allergy symptoms in sufferers (Niederberger 
et al., 004), and an edible rice-based vaccine targeted at allergic diseases like asthma, 
Plants have been engineered to produce the heart-healthy 
omega-3 and omega-6 oils.
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seasonal allergies and atopic dermatitis (takaiwa 006). The most successful commercial 
application of plant-produced protection was the synthesis in tobacco of a patient-specific 
vaccine for lymphoma (McCormick et al., 999); however, Large Scale Biology Inc., the 
commercial developer, was unable to identify investors for this approach, although proven 
successful in Phase-II clinical trials, and has since closed down. 
Environmental Improvement
This category of applications includes examples that extend from the EnviropigtM to 
engineering plants to detect landmines. researchers in Canada have developed a new 
breed of Yorkshire pig—the EnviropigtM—that utilizes plant phosphorus more efficiently 
(Golovan et al., 00). Non-engineered pigs cannot use phytate, a form of phosphorus 
present in cereal grains. accordingly, producers add to the diet supplemental phosphate 
or an enzyme, phytase, to meet phosphorus needs for optimal growth and development. 
The EnviropigtM has an enzyme in its saliva that allows it to degrade phytate and absorb 
the phosphate, thereby negating the need for supplemental phosphate or phytase, and as 
a result, phosphorus content of manure is reduced by as much as 60%. 
Several efforts have been made to improve the ability of plants to remove heavy metals 
and other pollutants from the soil. One example is the engineering of the poplar tree to 
remediate soils contaminated with ionic and methylmercury (rugh et al., 998). another 
improves the ability of a member of the mustard family to take up selenium from the soil 
and transport it to the upper portions of the plant for harvest (Banuelos et al., 005).
The utilization of plants to produce alternative sources of fuels has recently become 
a focus of attention given the rise in energy prices in the United States. One approach 
involves the engineering of green algae to produce hydrogen gas, a renewable, clean fuel 
source (Melis and Happe, 00). One of the most serious environmental pollutants is 
paper waste, particularly newspapers that, because of compaction, can remain in landfills 
for decades without decomposing. recently, bacteria were engineered to help alleviate the 
global wastepaper glut (Fierobe et al., 005). One extremely dangerous environmental 
contaminant is the presence of landmines in specific areas; the problem is how to detect 
their presence without having them explode. University of alberta and Duke University 
scientists are trying to develop plants that will indicate the location of landmines by 
changing color when their roots detect explosive compounds like tNt (http://cnews.
canoe.ca/CNEWS/Science/006/05/07/56870-cp.html).
Examples extend from the Enviropig™ to engineering plants to 
detect landmines.
The Scotts Company has introduced a gene that slows the growth 
of grass, so-called Slo-Mow™, and reduces watering needs.
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Other applications
Countless amounts of energy and time are spent each year keeping the grass in home 
yards and on golf courses mowed. The Scotts Company has introduced a gene that slows 
the growth of grass, so-called Slo-Mow™, and reduces watering needs. Horticultural 
crops, like ornamental flowers, have also been a focus of engineering efforts. In australia, 
Florigene Pty Ltd. succeeded in creating a number of new, vibrantly colored carnations, 
like Moonshadow™, some with delayed senescence (http://www.florigene.com.au/prod-
ucts/products.php?product_ name=Moonshadow). Long the “holy grail” of breeders, 
the blue rose was created by scientists in the Japanese company, Suntory (http://www.
physorg.com/news358.html). Breeders had attempted to make true blue roses for many 
years—prizes were even offered to anyone who could create them—but none were suc-
cessful until they used genetic engineering technologies. First, rNai was used to remove 
the gene encoding dihydroflavonol reductase (DFr) and then the delphinidin gene was 
introduced from pansy and the DFr gene from iris: voilà, a blue rose! another aesthetic 
effort, this time at the pet store, was the creation of the GloFish™, accomplished by in-
troducing a fluorescence gene into the aquarium zebra fish (http://www.glofish.com/). 
Under a black light, the fish appears to glow in the dark. an effort focused on eliminat-
ing the need for moths is the engineering of plants to produce silk-like proteins (Janaki 
Krishna, 006).
Closing thoughts
a look at the lineup of future applications of genetic engineering in agriculture certainly 
makes it clear that, at this point, applications are not limited by the technology. rather, 
progress is clouded by a number of factors that are outside the control of scientists, 
particularly academic scientists. although public-sector scientists have played a role in 
variety development of plants and animals in the past—using classical breeding and 
mutational approaches—their ability to participate effectively in this arena is limited by 
issues like very high regulatory costs and limited access to key technologies because of 
intellectual-property protection. These factors, in addition to consumer-acceptance issues, 
will determine the future applications of genetic engineering of crops and animals. Will 
such approaches be used to address the specific problems of agriculture in the United 
States? Even if this is not the case in the near term, it is likely that these technologies will 
play an important role in other countries, for example China, where these issues are not 
likely to be key factors in their utilization.
A look at the lineup of future applications of genetic engineering 
in agriculture certainly makes it clear that, at this point, 
applications are not limited by the technology. Rather, 
progress is clouded by a number of factors that are outside 
the control of scientists.
Lemaux 39
references
alvarez ML et al. (006) Plant-made subunit vaccine against pneumonic and bubonic 
plague is orally immunogenic in mice. Vaccine 4 477–490.
anderson P et al. (005) transgenic cabbage (Brassica oleracea var. capitata) resistant to 
Diamondback moth (Plutella xylostella). Indian Journal of Biotechnology 4 7–77.
Banuelos G et al. (005) Field trial of transgenic indian mustard plants shows enhanced 
phytoremediation of selenium-contaminated sediment. Environmental Science and 
technology 5 77–777.
Benbrook CM (004) Genetically engineered crops and pesticide use in the United States: 
The first nine years. Northwest Science and Environmental Policy Center Sandpoint 
ID. (http://www.biotech-info.net/technicalpaper7.html)
Bevan MW et al. (983) a chimaeric antibiotic resistance gene as a selectable marker for 
plant cell transformation. Nature 304 84–87.
Bouquet a et al. (003) transfer of grape fanleaf virus coat protein gene through hybrid-
ization with Xiphinema index resistant genotypes to obtain rootstocks resistant to virus 
spread. VIII International Conference on Grape Genetics and Breeding, International 
Society for Horticultural Science acta Horticulturae 603.
Buchanan BB et al. (997) Thioredoxin-linked mitigation of allergic responses to wheat. 
Proceedings of the National academy of Sciences of the USa 94 537–5377.
Burbank L (907) The training of the Human Plant. New York: De Vinne Press.
Chakraborty S et al. (000) Increased Nutritive Value of transgenic Potato by Expressing 
a Nonallergenic seed albumin Gene from Amaranthus hypochondriacus. Proceedings 
of the National academy of Sciences of the USa 97 374–379.
Chang aC Cohen SN (974) Genome construction between bacterial species in vitro: 
replication and expression of Staphylococcus plasmid genes in Escherichia coli. Proceed-
ings of the National academy of Sciences of the USa 7 030–034.
Darwin C appleman P (99) Origin of the Species: revised Edition. amherst, NY: 
Prometheus Books.
Fernandez-Cornejo J Caswell M (006) The first decade of genetically engineered crops in 
the United States. Economic research Service Economic Information Bulletin Number 
. (http://www.ers.usda.gov/publications/eib/eib.pdf )
Fierobe HP et al. (005) action of designer cellulosomes on homogeneous versus complex 
substrates: controlled incorporation of three distinct enzymes into a defined trifunc-
tional scaffolding. Journal of Biological Chemistry 80 635–6334.
Gilmour SJ et al. (000) Overexpression of the Arabidopsis CBF3 transcriptional activator 
mimics multiple biochemical changes associated with cold acclimation. Plant Physiol-
ogy 4 854–865.
Golovan SP et al. (00) Pigs expressing salivary phytase produce low phosphorus manure. 
Nature Biotechnology 9 74–745.
Haake V et al. (00) transcription factor CBF4 is a regulator of drought adaptation in 
Arabidopsis. Plant Physiology 30 639–648.
Hossain t et al. (004) Enhancement of folates in plants through metabolic engineering. 
Proceedings of the National academy of Sciences of the USa 0 558–563.
James C (005) Global Status of Commercialized GE/Biotech Crops. Ithaca, NY: Inter-
national Service for the acquisition of agri-Biotech applications. (http://www.isaaa.
org/main.htm)
40 agricultural Biotechnology: Economic Growth Through New Products, Partnerships and Workforce Development
Janaki Krishna PS (006) transgenic plants for spider silk-like protein production. 
Information Systems for Biotechnology News report, May 006. (http://www.isb.
vt.edu/news/006/news06.May.htm)
Ku MS et al. (00) Introduction of genes encoding C4 photosynthesis enzymes into rice 
plants: Physiological consequences. Novartis Foundation Symposium 36 00–0.
Lee rWH et al. (003) Edible Vaccine Development: Stability of Mannheimia haemolytica 
a leukotoxin50 during post-harvest processing and storage of field-grown transgenic 
white clover. Molecular Breeding  59–66.
McCormick aa et al. (999) rapid production of specific vaccines for lymphoma by 
expression of the tumor-derived single-chain Fv epitopes in tobacco plants. Proceedings 
of the National academy of Sciences 96 703–708.
Melis a Happe t (00) Hydrogen production: Green algae as a source of energy. Plant 
Physiology 7 740–748.
Milligan aB et al. (998) The root knot nematode resistance gene Mi from tomato is a 
member of the leucine zipper, nucleotide binding, leucine-rich repeat family of plant 
genes. Plant Cell 0 307–30.
Nakamura r Matsuda t (996) rice allergenic protein and molecular-genetic approach 
for hypoallergenic rice. Bioscience Biotechnology and Biochemistry 60 5–.
Niederberger V et al. (004) Vaccination with genetically engineered allergens prevents 
progression of allergic disease. Proceedings of the National academy of Sciences 0 
4677–468. 
Paine Ja et al. (005) Improving the nutritional value of golden rice through increased 
pro-vitamin a content. Nature Biotechnology 3 48–487.
Park S et al. (005a) transgenic watermelon rootstock resistant to CGMMV (cucumber 
green mottle mosaic virus) infection. Plant Cell reports 4 350–356.
Park S et al. (005b). Genetic manipulation for enhancing calcium content in potato 
tuber. Journal of agricultural and Food Chemistry 53 5598–5603.
Qi B (004) transgenic plants produce omega-3 and omega-6 fatty scids. Information 
Systems for Biotechnology News report July 004. (http://www.isb.vt.edu/news/004/
news04.Jul.html)
rugh CL et al. (998) Development of transgenic yellow poplar for mercury phytore-
mediation. Nature Biotechnology 6 95–98.
Sankula S et al. (005) Biotechnology-derived crops planted in 004: Impacts on US 
agriculture. Washington, DC: National Center for Food and agricultural Policy. 
(http://www.ncfap.org/whatwedo/biotech-us.php)
Song J et al. (003) Gene rB cloned from Solanum bulbocastanum confers broad spectrum 
resistance to potato late blight. Proceedings of the National academy of Sciences of 
the USa 00 98–933.
takaiwa F (006) Development of rice seed-based edible vaccine for allergic immunother-
apy. Information Systems for Biotechnology News report, March 006. (http://www.
isb.vt.edu/news/006/news06.Mar.htm)
Thanavala Y et al. (005) Immunogenicity in humans of an edible vaccine for hepatitis 
B. Proceedings of the National academy of Sciences of the USa 0 3378–338.
tompkins P Bird C (973) The Secret Life of Plants. New York: Harper & row.
Wall rJ et al. (005) Genetically enhanced cows resist intramammary Staphylococcus 
aureus infection. Nature Biotechnology 3 445–45. 
Lemaux 4
peggy g. lemaux is a cooperative extension specialist in 
the Department of Plant and Microbial Biology at the 
University of California, Berkeley. She has a Ba from 
Miami University in Ohio, a PhD in microbiology and 
immunology from the University of Michigan and had 
postdoctoral training at Stanford University under Stanley 
Cohen. Her attention turned to plants and agriculture after 
joining arthur Grossman at the Carnegie Institution of Washington to study 
light-harvesting in algae. She then joined DeKalb Plant Genetics where she and 
coworkers were the first to publish a successful strategy to engineer corn. From 
there she went to UC Berkeley, where she is involved in research, teaching and 
public outreach.
Dr. Lemaux’s research group focuses on both basic and practical questions 
relating to the genetic engineering of cereal crops. Her group has worked on 
projects aimed at reducing allergenicity in wheat and increasing digestibility of 
sorghum, the latter project to improve human nutrition in developing countries. 
She devotes a significant portion of her time to educational outreach aimed at 
public understanding of agricultural practices and food production and the im-
pact of new technologies on food and agriculture. These efforts have increased 
owing to efforts in California counties to pass anti- and pro-GMO ordinances 
and resolutions. She spearheaded the development of an award-winning educa-
tional website (http://ucbiotech.org) that provides science-based information on 
biotechnology.
Watson JD Crick FHC (953) a structure for deoxyribose nucleic acid. Nature 7: 
737–738.
Yanagisawa S et al. (004) Metabolic engineering with Dof transcription factor in plants: 
Improved nitrogen assimilation and growth under low-nitrogen conditions. Proceedings 
of the National academy of Sciences of the USa 0:7833–7838.
Ye X et al. (000) Engineering the provitamin a (beta-carotene) biosynthetic pathway 
into (carotenoid-free) rice endosperm. Science 87 303–305.
Zhang HX Blumwald E (00) transgenic salt-tolerant tomato plants accumulate salt 
in foliage but not in fruit. Nature Biotechnology 9 765–768.
4 agricultural Biotechnology: Economic Growth Through New Products, Partnerships and Workforce Development
This presentation provides an overview of the NaBC-8 theme, Economic Development 
Through New Products, Partnerships and Workforce Development, from an economic per-
spective. With special reference to agricultural (bio)technology, specifically it outlines 
methods used for science/technology transfer to markets and public good, provides public 
and private sector examples of venture capital for early commercialization of agricultural 
science and technology, and describes issues and recommendations for effective technol-
ogy transfer to market including public good.
The views expressed in this presentation are mine based on experience in academia, 
large and start-up industry, and government including as a board member of a government 
venture-capital corporation [alternative agricultural research and Commercialization 
(aarC) Corporation] and as an advisory board member of a private venture-capital cor-
poration (Foragen technologies, Inc.). as president of NaBC and a last-minute substitute 
speaker for roger Wyse of Burrill & Company, a life sciences merchant bank, I emphasize 
that the views expressed here are not necessarily those of NaBC.
Economic Methods Used for technology transfer
Licensing
Much of the research by not-for-profit institutions, e.g. universities, government labo-
ratories, research institutes, is to generate knowledge, but such research also results in 
innovation with potential for commercial products and processes and public good. The 
majority of not-for-profit research is in this area, with most funding from the public sec-
tor. Based on the source of the funding and the mission of the not-for-profit institutions, 
it is their obligation to provide benefits to the public. In the past, plant breeding utilized 
Research to Market/Public Good: 
Economic Perspectives
ralph W.F. Hardy
National Agricultural Biotechnology Council
Ithaca, NY
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public varieties as the transfer vehicle, but such transfer nowadays usually is done by 
licensing. In 004, the top ten US universities (based on $$ of sponsored research) had 
$0 billion of sponsored research and gross licensing revenues of less than $300 million, 
or less than 3% of the sponsored research, ranging from 0.4% to 7% (Laurence, 006). 
Licensing revenue makes a very small contribution to not-for-profit research, is highly 
variable and is not very predictable. The historic examples are the University of Wisconsin 
vitamin-D irradiation of milk and the rodent poison and human blood thinner warfarin, 
and more recently the Stanford/University of California fundamental process for making 
transgenics. Most not-for-profit institutions have established technology-transfer offices. 
In Issues and Recommendations below, I will recommend that maximization of public good 
should be the objective of technology transfer, not maximization of revenue. This view 
will be amplified by Mark Crowell in his presentation on Knowledge Transfer and Economic 
Development: The Role of the Engaged University in the Twenty-First Century.
Research Contracts
For-profit corporations provide contract support for not-for-profit research with the 
objective of generation of technology/know-how for improvement of existing products 
or processes or development of new products and processes. research contracts may rep-
resent 5% to 0% of research support for more-applied not-for-profit research, such as 
agriculture and biotechnology. In most cases, the funder will obtain exclusive commercial 
rights to the technology, including patents for a license fee that is probably predetermined. 
It is preferable that the not-for-profit entity, not the funding industry, be the owner of 
the intellectual property, with licensing of rights to the industry. research rights should 
be maintained by the not-for-profit. The government uses Cooperative research and 
Development agreements (CraDas) and these will be discussed by richard Brenner 
in his presentation, Technology Transfer in ARS: Implications of Federal/Private Sector and 
Federal/University Partnerships to Commercialization Strategies.
Maximization of public good should be the objective of 
technology transfer, not maximization of revenue.
It is preferable that the not-for-profit entity, not the funding 
industry, be the owner of the intellectual property, with licensing 
of rights to the industry.
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Various Government Grants to Facilitate Early Development and 
Commercialization
These include Small Business Innovation research (SBIr) grants to facilitate small-
company product and process development, such as feasibility studies and business-plan 
development. William Goldner will describe this program (The USDA Small Business 
Innovative Research Program: Vision, Challenge, and Opportunity). The Defence advanced 
research Projects agency (DarPa) has a similar grants program. These programs are 
important for cash-strapped new companies since they do not require repayment, and 
Michael adang (From the Bench to a Product: Academics and Entrepreneurship) will provide 
a real example. The Department of Energy (DOE) has used major grants to drive biobased 
industrial products with major industry often the lead organization with subcontracts to 
other industries and not-for-profits; a recent example is the multifold reduction in cost 
of cellulase enzymes for use with cellulosics for ethanol production.
Technology Parks
technology parks have been shown to be useful in bridging the so-called “valley of death,” 
the gap between laboratory research and resultant potential technology and conversion 
to a commercial endeavor. Such parks enable direct interaction between the scientific 
innovator and the company seeking to develop and commercialize the product or pro-
cess. Presentations by allen Dines (From Equines to Economic Development: The Story of 
University Research Park) will describe the highly successful three-pronged approach in 
Wisconsin with over 80 years of highly successful experience and by ashley O’Sullivan 
(From Tools to Products and Processes: The Evolution of Saskatchewan’s Ag Biotech Cluster) 
who will describe what is probably the most successful agriculturally focussed technol-
ogy park with about 0 years experience. Our visit to the Cornell agricultural and Food 
technology Park (CaFtP) in Geneva, NY, will provide an opportunity to explore issues 
facing a “just born” technology park.
International Examples
Other presentations at this meeting will provide examples from other countries of the 
transfer of research to market and the public. Zhangliang Chen (Innovation: The Chinese 
Experience) will describe the connected relationship between the university and the es-
tablishment and operation of major businesses, with substantial economic benefit to the 
university; such a relationship probably would not be acceptable in the United States. Wim 
Jongen (Food for Innovation) will describe the Wageningen Business Generator, which 
has similarities to Canadian and US research parks. Other examples include India, Brazil 
and Germany. This broad experience-base, and their respective strengths and weaknesses 
should guide future activities in this emerging area of technology transfer. a reality check 
is provided by richard Broglie (Translating Discovery Research into Commercial Products), 
presenting the perspective of a major agri-food-chemical company.
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Various Forms of Investment in New Companies
Equity investment is more useful for new companies than loans; new companies are 
almost always strapped for cash and, therefore, interest payments consume money that 
is needed to invest in the business. I have had several years’ personal experience with a 
government-funded venture-capital corporation and with a privately funded venture-
capital corporation. Both were investors in early-stage commercialization.
The aarC Corporation was authorized by the 990 Farm Bill as a wholly owned 
government corporation within USDa. Its mission was to commercialize industrial uses 
of ag and forestry materials to create, in the long term, new markets and reduce subsidies 
for agriculture. aarC had many strengths, including a mainly non-bureaucrat board with 
initially over 50% having been presidents or vice-presidents of for-profit corporations. 
It was operated as a business, making investments in the most promising companies, 
with little emphasis on geographic location and with ability to make equity investments, 
which was unique to government where grants and low-interest loans were the norm, 
requiring matches of at least : of non-aarC to aarC investments, and in-depth due 
diligence with external expert review of proposals and on-site reviews by staff and at least 
one board member, prior to investment, with subsequent on-site annual or more-frequent 
monitoring. The weaknesses were the inexperience of government with venture-capital and 
the venture-capital approach where projected return is directly variant with risk, impact 
of shifting political “winds” on funding, ability only to invest if private funds were not 
available (in other words, the source of last resort) and, finally, the inability to move the 
“aarC activity” to a non-government-funded corporation with expanded resources for 
continuing and expanded equity investments in biobased products and processes. Equity 
funding for agriculture-related new companies is minimal; an exception may be occurring 
with the current exploding interest of Wall Street in cornstarch-ethanol investment where 
the possibility of too much/too fast is a real concern. There is a major continuing need 
for government to play a role with early venture capital, but it would need to avoid the 
above weaknesses. Up-front endowment-type government funding may work, as with the 
very successful Canadian Foundation for Innovation in the late 990s.
Examples of products/processes funded by aarC [e.g. aarC Corporation (997)] 
included milkweed fiber for hypoallergenic comforters and pillows, D-ribose for cardio-
vascular function, biodegradable plant oils for engine lubrication, capsaicins from hot 
peppers to keep mammals out of avian food, e.g. squirrel-free birdseed, and gasification 
of biomass and its high-yield biological conversion to ethanol.
Foragen technologies, Inc., is a Canada-based venture-capital company founded in the 
late 990s. Funding came from the private sector. It funded very early commercialization 
as mainly not-for-profit innovations were evaluated and developed as new businesses. a 
number of promising investments were made. However, a second round of investment in 
Foragen technologies by the private sector did not occur, probably based on the percep-
tion that agriculture is not an attractive area for venture capital. This is in contrast to the 
abundant venture capital for human-health-related innovations.
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Issues and recommendations
Several issues and recommendations will be noted, with the hope of stimulating discussion 
and improving efficacy of research to market/public good transfers.
Maximize Public Good from Public-Sector Research
Licensing income is small. technology transfer should maximize public good not maxi-
mize licensing income1. Evaluations by and of technology-transfer offices should use the 
public-good metric, not the income metric.
Intellectual Property
Seeking protection of IP should be based on a realistic assessment of potential. Business-
experienced alumni can be helpful in providing guidance on decision-making regarding 
filing of patents. When it is decided not to file a patent, the right to file could be assigned 
to the inventors. The most promising patents should be filed broadly and patent estates 
built around them. Failure to find business interest in a patent within a reasonable time 
should lead to timely abandonment so as to avoid continuing maintenance costs. although 
universities file and are awarded large numbers of patents (rovner, 006), only a few 
result in significant products and/or processes
Venture Capital
Venture capital for agricultural innovations, other than human-health uses—is inadequate. 
a method is needed for significant government funding of this area without the variability 
of political impact. Up-front endowment funding may be such a method.
1robert E. armstrong, senior research fellow at the National Defence University, suggests that the apache 
“open source” community in the computer-software industry, as described by tom Friedman in The World 
is Flat (New York: Farrar, Straus and Giroux, 005), illustrates maximizing the public good while enabling 
economic return to industry. The apache “open source” community is a collaboration of computer scientists 
self-organized to develop programming to run Web services. In the apache collaborative community you could 
use community technology, but were required to make any improvements available to the community. In 
addition, industry could build a patented commercial product utilizing the “apache code,” but were required 
to include a copyright citation in their patent. Substantial revenue has been generated by IBM utilizing this 
approach in the Web-server business, while the base technology is broadly available. Plant breeding public 
research with seed-company development of commercial products is an earlier example. The recent collaboration 
of several not-for-profit research institutions to retain research uses and applications for developing-country 
uses of biotechnology patents is another example.
Path to Market
My experience is that the path to market is the single most decisive factor for success 
of a new company, more so than any other factor, such as entrepreneurial leadership, 
funding or technology.
The path to market is the single most decisive factor for success of 
a new company.
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Deal Yield
a large number of deals need to be assessed to find the few that are worthy of investment. 
The yield is in the range of one out of every twenty-five to fifty considered. “Back-of-the-
envelope” calculations eliminate many deals.
Business CEOs
Scientist innovators usually are not successful as business CEOs. a rule of one venture-
capital manager was “Shoot the inventor.” There are exceptions, but business CEOs need 
to focus, focus, focus on the business objectives, whereas scientists’ success usually results 
from broad curiosity.
Difficult Areas for New Businesses
Some examples where failure is common (based on my experience) are construction and 
building materials that require a huge scale of production, e.g. the 00 million ft straw-
based particleboard plant in Manitoba, most recently operated by Dow, was closed in 
early 006. another difficult area is new crops. Most are long-term efforts and need the 
staying power of the public sector. Canola, as described by Keith Downey (Rapeseed to 
Canola: Rags to Riches), is an example of relatively rapid development of a new crop, but 
there are many other oil (and other) crops for which development has been tortuous. 
another area with a low success rate is microbial pesticides. While plant-based biopesticide 
products have been quite successful, microbial pesticide-based companies have a history 
of failure. technology platforms are difficult in defining the business path to market.
There are other issues that I am sure will be discussed at the breakout sessions. I hope 
the above will help stimulate your discussions. Improving the transfer of research to the 
market/public good has major opportunities for improvement
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The problems for biotechnology vary according to who you are—a large company that deals 
with important crops and developed-country farmers, a small private company, a public 
sector entity, university, national agricultural system or a CGIar institution—which I 
will come back to. as far as public/private partnerships are concerned, the rockefeller 
Foundation has seen success in collaboration with the Gates Foundation in creating such 
partnerships to tackle medical problems, such as aIDS, tB and malaria, but so far we 
have not had a single similar success for agriculture. Where you are is important also—the 
northern markets or australia is one story and genetically engineered (GE) crops are really 
taking off in some dynamic developing countries benefiting rich and poor farmers. In 
africa, where we spend a lot of our time, the problems are different again.
I am not in the private sector and can only guess as to what is worrying big industry 
at this point, and whether the Europeans will ever sort it out is an ongoing question that 
I will not dwell upon; however, there are signs of progress, with GE crops now planted 
in a few countries within the European Union.
the Next Generation
Some large companies are getting close to marketing the next generation of traits, beyond 
Bt and herbicide tolerance. The big questions will be:
• How do you capture value for quality traits?
• Will they require market segregation?
• Will genes for value-added traits be stacked with “conventional” insect resistance 
and herbicide tolerance?
Clearly, stacking is “in,” to the benefit of companies like Monsanto and companies 
like Pioneer need to form partnerships to obtain enough traits to stack effectively and be 
competitive. From the point of view of those of us who support projects on Golden rice 
and other nutritional improvements, it is hoped that the private sector will lead the way 
on stacking of traits and get the regulatory systems to accept them, because when you alter 
nutrition it is probable that little will be achieved by changing one trait at a time.
Road Bumps and Pitfalls for Agricultural 
Biotechnology
Deborah Delmer
Rockefeller Foundation
New York, NY
5
Liability issues are of particular concern to smaller companies, with the effect of de-
laying the release of new products. Multinational companies have invested significant 
time in Latin america in particular and India in discussions on protection of intellectual 
property (IP). Interesting models are emerging from argentina and Brazil in conjunction 
with Monsanto; where patents have not been filed it may be possible to collect revenue 
from the end-user.
India is causing concern in demanding pricing structures, resulting in lowering of 
technology fees. On the positive side, large US companies see India—and China—as 
possible new markets including for GE products, which may have particular utility in 
the developing world. For the longer term, there is worry over competition from local 
producers of GE foods. 
1Pages 3–4
2Pages 43–50
The large private-sector companies face many challenges in dealing with issues specific 
to the developing world and africa in particular. Clearly, these companies would like to 
build long-term markets for maize and cotton and are trying to balance humanitarian 
interests with commercial interests. We are trying to facilitate public/private partnership 
discussions, but the issues are complex and the cultures of the public and the private 
sectors are very different. It’s a huge challenge.
Where are the public sector and the small private sector in terms of bringing promising 
new GE products to the market-place? Where are the products listed by Peggy Lemaux1? 
Very few have come to market. Salient also is the issue of moving innovations efficiently 
downstream from universities; I agree with ralph Hardy2 that many scientists in public-
sector research lack business skills and know little about developing products that would 
have market-appeal for the common good.
Freedom to operate is a perpetual problem as is the high cost of regulation, particu-
larly so for smaller-market specialty crops that university and small private companies 
are interested in.
Public Perception
It is difficult to judge the degree to which negative public perception of GE foods remains 
a significant issue. It is noteworthy that very strong research programs on developing 
GE crops are in progress in China, India and Brazil. On one hand, EMBraPa in Brazil 
and India have a number of strong research institutes, but, on the other hand, there 
is a dearth of experience in bringing GE crops to market, at least by the public sector. 
Bt rice may be approved for commercial production soon in China and India and it is 
The cultures of the public and the private sectors are 
very different.
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hoped that Bt eggplant—an example of a new GE crop resulting from a public/private 
(Mahyco, India) partnership—will be available to farmers in India, Bangladesh and the 
Philippines late in 006.
The public sector has to strike the right balance between commercial and noncommercial 
delivery systems. It is the issue of public good and even at the rockefeller Foundation, 
which has a history in dealing with issues such as the Green revolution as well as noncom-
mercial aspects of agriculture, almost everything we talk about now is in terms of building 
dynamic national economies rather than stabilizing subsistence agriculture as the means of 
achieving sustainability. We are no longer talking in terms of just giving away GE crops. 
In any case, liability concerns and lack of adequate distribution systems preclude giving 
them away. Finding commercial models and developing seed systems beyond maize will 
be a challenge certainly in the poorer developing countries but may be a struggle also for 
minor crops in dynamic countries in the developing world.
as far as regulatory aspects are concerned, many countries started by following the US 
model with a conservative bent, placing restrictions where there was room for doubt. With 
experience, a risk vs. benefit philosophy has become more prevalent with the realization 
that if the approach is too strict no new products would see commercialization.
In the least developed countries where the rockefeller Foundation does a lot of funding, 
particularly in africa, we have to consider public perception and the NGOs. However, I 
am becoming more optimistic in this regard. I think that people are tiring of this debate 
and that there is opportunity for progress. a huge problem is weak research capacity in 
these small least-developed countries; seldom should you expect to fund projects for 
development in those countries in isolation. and it’s a challenge to find good partners in 
universities willing to train postdoctorals and build long-term research capacity in those 
countries. Finding the models for training and partners for projects is a challenge.
In terms of defining the relationship with the private sector, we’ve seen some public 
sector projects that are trying to repeat what large private sector companies are doing. For 
example, developing Bt maize for africa doesn’t make sense for the public sector when 
Monsanto has a perfectly good product. We have to be strategic and examine what the 
private sector will not tackle.
Many donors who are extremely timid about funding GE projects in the developing 
world, with the notable exception of the US agency for International Development, 
The rockefeller Foundation and, to some extent, the McKnight Foundation. For this 
reason, the CGIar centers are not at the cutting edge of biotech research. None of the 
Almost everything we talk about now is in terms of building 
dynamic national economies rather than stabilizing subsistence 
agriculture as the means of achieving sustainability.
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European donors are interested in funding this work. However, the good news is the 
Gates Foundation is quietly tip-toeing in and it is to be hoped that they will fund suc-
cessful projects that will encourage them to remain involved, which could significantly 
change the dynamics.
Intellectual Property
These issues may be simple or complicated. In Malawi, for example, developers of GE 
crops wouldn’t need to worry about patents. a developed-country counterpart interested 
in partnering with scientists in Malawi might be able to manage the IP, depending on how 
the project is structured. I was happy to see NaBC’s guidelines for field-research trials 
with GE crops (NaBC, 006). My biggest push in africa is not to convince countries 
to release GE crops to farmers. It is to encourage countries to let their scientists enter 
partnerships and develop new crops themselves that are locally appropriate. In order to 
participate in that development they have to be able to do simple research trials on site, in 
their own countries. In no other way will this move forward. africans, Indians, Chinese, 
all want ownership of these crops as they develop them and if those trials cannot be done, 
it will never happen. Simple research trials and understanding of how to do them safely 
and responsibly are required, at low cost and with minimal effort. It should not take  or 
3 years to obtain a permit for a simple trial, as it does now in Kenya.
Event-specific regulation is a real challenge. If you consider how difficult they are to 
breed and if we follow the US model of event-specific regulations, then we have a real 
problem in moving traits to locally adapted varieties of cassava and banana. We need a 
new model.
and we need regional harmonization in africa. although that continent will not be the 
breadbasket of Europe any time in the near future, there are tremendous opportunities for 
regional markets in africa with the growing urban populations. regional harmonization 
of biosafety regimes, quarantine restrictions, seed certification and so on will facilitate 
access to new regional markets.
On the sharing of IP, the Public Intellectual Property resource for agriculture (PIPra) 
has the objective of assisting public-sector institutions in garnering IP and strengthening 
management skills. PIPra now encompasses thirty-seven institutions in six countries. 
They will meet in the spring of 007 to explore bringing Europe into the fold, and more 
countries. They have got an IP database online where they list the licensing for all of their 
technologies. For anyone interested in obtaining vectors with freedom to operate, PIPra 
is now constructing them using its own public-sector IP. We hope that it will become 
available in a year or two.
My biggest push in Africa is to encourage countries to let their 
scientists enter partnerships and develop new crops themselves that 
are locally appropriate.
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The african agricultural technology Foundation is a fledgling organization learning 
how to broker technology transfer in africa. Some very smart africans running it have 
already had some success. Cambia Biosys has devised another model for possible open-
source licensing.
Good News
There is some good news and some bad news. The good news is the rapidly increasing 
global acreage planted to GE crops. and it’s noteworthy that GE crops are now being 
planted in five EU countries. Certainly poor farmers are beginning to benefit along with 
large farmers in some of the dynamic developing countries, as indicated in published 
data from South africa, China, India, Brazil and argentina. Interestingly, in africa it is 
happening in Burkina Faso; Monsanto is partnering tactfully with local scientists there in 
a series of trials of Bt cotton. They are moving the Bollgard-® trait into locally adapted 
varieties with very promising results. Working with their most advanced trait is smart 
management. This approach has changed the mindset of West african farmers to whom 
we have spoken. Suddenly they are saying, “Hey, if they have it in Burkina Faso then 
we must have it too.” and that is how this will work in africa: the people have to see it. 
and even though Monsanto will never get rich from Burkina Faso, it’s the kind of thing 
we need to see happen.
Not So Good
On the other hand, no GE food crop has been released for commercial use in China or 
India and it is unclear when this will happen, despite its expectation in recent years. In 
all of africa, South africa is the only country where GE crops are growing, but we are 
seeing movement in East and West africa: a lot more interest and a lot less fear. Illegal 
sale of GE seeds has been a problem, e.g. in India with Bt cotton and in Brazil with 
roundup ready® soy. It may be less of a problem with the next generation of GE traits, 
as companies learn how to handle this.
an article out of Pretoria, in South africa reported that poor farmers were doing well 
in the early days of Bt cotton when only one gin was accessible. The owners of the gin 
loaned the farmers the money to pay the high cost of the seed, and at the end of the season 
the loan was returned in kind when the farmers brought their cotton to the gin. Then, a 
second gin opened and the farmers said, “We’ll take the loan and the seed from the first 
gin but we’ll sell our cotton to the second gin.” Well, guess what, micro-credit is no longer 
available for these farmers. These are how institutional problems can create difficulties. 
We are still trying to get it right between the public and the private sectors.
The AATF is a fledgling organization learning how to broker 
technology transfer in Africa.
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In Summary
We need many skills to strengthen IP regimes. Similarly on regulatory issues, the Specialty 
Crops Initiative promises to provide cheaper field trials. The need to harmonize in West, 
East and South africa is becoming clear; individual countries are too poor to do this on 
their own. For a long time, 0% of the people have said this is great stuff and another 
0% have expressed distaste. In the middle is a vast disengaged majority who really don’t 
care, including many farmers in the developing world. I think that people are just tired 
of it. Let’s get on with it. Let’s just move on. It may not be an overflowing cup, but I’d 
say it’s more than half-full.
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Bob Seem: The floor is open. Questions?
Audience member: For alan Wood—did the USDa task force consider obesity?
Alan Wood (Boyce Thompson Institute): Obesity was mentioned as a problem that needs 
to be dealt with, but it was not one of the very specific things that we dealt with. It had 
to do with research in areas of health that we need more of in the agricultural sector. The 
USDa already has programs dealing with this. What we were looking at was something 
beyond current programs in agriculture. We felt that many issues are not being addressed. 
We were looking forward to the future in agriculture. and the future in agriculture is 
that we need to come up with new ways of doing business. We need to come up with 
new products and new technologies and understand where the competition lies. When 
we go to the grocery store, my wife always looks to see where things come from. Thirty 
years ago you didn’t need to look at a label to know where something came from. The 
feeling on that committee was that US agriculture is going to move beyond food and 
fiber into other technologies, and that’s where the future of agriculture really lies, the 
most promising part.
Ralph Hardy (National Agricultural Biotechnology Council): Let me add a comment. In 
00 the NaBC meeting was held in Minneapolis and the focus was Foods for Health.1 
We made a start at looking at this area, the connect between agriculture, food, medicine 
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US agriculture is going to move beyond food and fiber into other 
technologies, and that’s where the future of agriculture really lies, 
the most promising part.
1Eaglesham a Carlson C Hardy rWF (00) NaBC report 4 on Foods For Health: Integrating agriculture, 
Medicine and Food for Future Health, 340 pp. Ithaca, NY: National agricultural Biotechnology Council.
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and health. There have been other attempts to connect these, but they haven’t “gelled” to 
the degree they should. We are going to need to maximize the food-input nutritional side 
to contain healthcare costs, which are soaring. at NaBC, we see this as a focal point; a 
document is planned to help bring visibility to, and generate traction for, this important 
area. Efforts are ongoing in Canada in the same vein, because budgets are going to increas-
ingly be cramped, be limited, by increasing healthcare costs if we don’t deal with obesity, 
cardiovascular disease, diabetes, some cancers, in all of which, agriculture—through 
input—has a significant role to play.
Keith Downey (Agriculture Canada): Something that concerns me is the very high cost of 
regulation, yet we talk about the small crops that we are going to improve. If those small 
crops are to be grown in multiple countries then you have to go through that regulation 
time after time after time, and I see that as a major stumbling block for biotechnology 
exploitation in the near and long terms.
Debbie Delmer (Rockefeller Foundation): With regional harmonization discussions in africa, 
people are beginning to realize that small countries just can’t afford the delays and the 
costs. Part of the regional process would be accepting regulatory information that comes 
from other countries. also very important for public-sector efforts is having the private 
sector share their information whenever they can. as I said, the more people deal with 
this the more sensible they become.
2Public Intellectual Property resource for agriculture.
As far as regulatory costs are concerned, there’s no way the 
academic sector is going to play a role.
Peggy Lemaux (University of California at Berkeley): In some ways California is a develop-
ing country in that we deal in so many smaller food crops. We grow 300 different crops. 
Of course public perception is also an issue, but as far as regulatory costs are concerned, 
there’s no way the academic sector is going to play a role. I wish it were otherwise, but I 
don’t see a way. We have worked on developing hypo-allergenic wheat—but go to your 
dean and say that $3 million will do it. There’s no way!
There is an issue regarding something that is eaten five times a day. How often are 
eggplant, papaya or artichokes, for example, eaten? I hope that we can get around that 
or the public sector will not play a direct role, and I think we should.
Peter Welters (Phytowelt, Germany): Deborah when you were talking about PIPra2, you 
said that the Europeans are not in there and you want to get them in. Does that mean 
that the transgenic vectors you are constructing have no freedom to operate in Europe?
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Delmer: I’m not sure if PIPra has members in Europe. There have been enquiries about 
it from institutions in Europe. Discussions have been held with universities and public-
sector institutions, so we will devote September 006 Bellagio Conference to PIPra. 
They may not join PIPra, but they may use it as a model to form their own alliances or 
a consortium. PIPra has a couple of Latin american members and one african, and is 
beginning to pick up some of the CGIar3 centers. The Europeans will have to decide 
whether their IP systems are so different that it would not work to put them together. 
It’s at the discussion stage.
Yongfei Zhang (Cornell University): This is a question for Peggy. I’m interested to know 
what are the major concerns of the public and potato industry regarding GM potatoes? 
Do you see any signs of change for the near future?
Lemaux: It’s difficult to know. It requires major players coming forward. a few have come 
forward and said, “We see a benefit and we’re going to put them out there,” then failed 
to follow through. When I first took this job in 99 I said that the way to win people 
over is to get McDonald’s to use genetically engineered potatoes as French fries. The little 
kids say, “Mommy we want fries,” and she says, “No honey, it’s GMO.” Then they cry and 
she gets them the French fries and they’re okay and they have ketchup with genetically 
engineered tomatoes and they are still okay. But the food companies were scared. at some 
point it’s going to work out, but when it’s going to happen, I don’t know. and I don’t 
know the potato industry like I know the cereal industry. Maybe someone else does.
Dalia Abbas (University of Minnesota): This question is for ralph. How you would construct 
an economic model that can assess the cost and benefits of agricultural biotechnology? 
You mentioned it’s an important phase. I’m trying to visualize inputs and outputs and 
I’m trying to find where are the barriers and what are the main inputs there?
Ralph Hardy (National Agricultural Biotechnology Council): Well most commercial prod-
ucts in the United States are based on traditional costs, not life-cycle costs. and so, what 
models that we have experience with have worked? What are their limitations? Where 
might we improve them? I also said that we need to refocus to maximize public good, 
not necessarily to maximize economic return to the inventing institute or to the inven-
tor. The public paid for the research, therefore the public should benefit most from the 
research—that should be the priority.
We had a presentation a couple of years ago from the inventor of virus-resistant papaya4 
and that was an example that was totally done within the public sector. Surprisingly, the 
cost through the regulatory hoops was significantly less than a million dollars. That’s one 
of the models that I’m surprised we haven’t used more. What relevance does the papaya 
3Consultative Group on International agricultural research.
4Dennis Gonsalvez (003) The papaya story: a special case or a generic approach? In: Eaglesham a et al. 
(eds.) NaBC report 5, Biotechnology: Science and Society at a Crossroad, 3–30. Ithaca, NY: National 
agricultural Biotechnology Council.
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story have? It is a small crop, with the research and commercialization within the public 
sector. They were able to get the genetic materials licensed in Hawaii. Why isn’t that story 
relevant to some of these other areas?
Lemaux: Flax is another, done in Canada within the public sector. I’ve talked to both 
of those people—Dennis Gonsalves and alan McHughen—and they believe it is pos-
sible. Things have changed. They weren’t on the radar screen at the time. They talked 
to government officials and it went a lot easier. There might be a few other instances 
where they could get something like that through, but I don’t know if it’s going to be a 
generalized model.
Delmer: I think Dennis Gonsalvez would say that they weren’t much on the radar screen 
at that time. They went to Monsanto and said, “Hey, give us these rights, come on,” and 
the IP negotiations weren’t difficult. regulatory restrictions were minimal for what they 
needed to do. Now Dennis wants approval to sell in Japan and he’s had to jump through 
a lot more hoops. But he thinks—or thought—that he will be able to do it; I don’t know 
where it stands now. Maybe Dr. Vijayaraghavan can say something about Indonesia and 
the Philippines—but the papaya is on the move there. They are optimistic for the Phil-
ippines where field trials are expected soon. as I said, there is a new wave. Maybe we’ve 
been through the worst.
Ajay Garg (Cornell University): Thomas Friedman was on CSPaN being interviewed on 
his book The World is Flat. Since the world is flat I am wondering if there is opportunity 
for transparency in this genetically modified business. Is it possible to bring together 
the leaders of agbiotech to achieve transparency in evaluating transgenic material? Can 
eminent scientists, irrespective of their countries, come together to critically evaluate the 
technology?
Wood: One of Friedman’s points is that this type of thing is occurring because the world 
has gotten so small through communications. He doesn’t deal specifically with agriculture, 
but it’s easy to extrapolate from the examples that he gives for industry and academic 
institutions where exchange of information and resources has just gone wild in such a way 
that barriers between countries are being broken down. Within industries, one of which of 
course is the agriculture industry, in the past, we didn’t think much about what was going 
on half way around the world. In contrast, in today’s agriculture a smart farmer worries 
about what’s going on around the world, and he has access to the information.
Delmer: One of the activities of the Gates Foundation is in putting money into five of 
the national academies of science in africa, to try to strengthen the role of science in 
policy decisions in africa in much the same way that our National academies of Science 
serve as advisors to the government on many issues. That may be close to what you are 
suggesting. If the academies could be strengthened and their voices heard, it could well 
be of some help, particularly in these policy decisions.
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Tony Shelton (Cornell University): It’s interesting that you mention The World is Flat. Bt 
cotton moved into India and roundup ready soybeans moved into South america because 
the world is flat. “Stealth” seeds, moved from one country to another, actually forced the 
regulatory agencies in those countries to address what at least the farmers wanted there. 
So, the world is flat and it’s changing things in ways that cannot always be predicted.
Bt cotton moved into India and Roundup Ready soybeans moved 
into South America because the world is flat.
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This story began some 65 years ago, during World War II. It is a story of successful genetic 
manipulation of an introduced crop by a small, self-motivated team of chemists, plant 
breeders and animal nutritionists. as a result of their efforts, the crop now rivals wheat as 
Canada’s most valuable agricultural commodity and is the world’s third most important 
source of edible vegetable oil (table ). 
Rapeseed to Canola: Rags to Riches
r. Keith Downey
Agriculture and Agri-Food Canada Research Centre
Saskatoon, SK
Table 1. woRld edible vegeTable oil pRoducTion by cRop  
(millions of Tonnes).
Production year
 Oil crop % growth
  83–84 93–94 0–03 in 20 years
 Soybean 3 8 3 4  
 Palm 6.3 3 8 343  
 Canola/rape 4.9 9.  5  
 Sunflower 5.4 7. 8.6 59  
 Cotton 3.0 3.4 3.9 30  
 Peanut .9 3.6 4.4 5  
 Other* 4.7 6.4 9.5 03
  
 total 40 6 98 44
*Olive, coconut, palm kernel, corn, etc.
A story of successful genetic manipulation of an introduced crop 
by a small, self-motivated team of chemists, plant breeders and 
animal nutritionists.
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Critical Need for Lubricants
During World War II, all trains and ships were steam-powdered and rapeseed-oil lubri-
cation was essential to keep them running. When metal surfaces are washed with steam 
or water, rape oil clings better than any other natural or synthetic lubricant. When 
supplies of the oil from Europe and asia were cut off, Canada was asked to attempt to 
grow the crop. Experimental plantings showed that with minor adjustments to seeding 
and harvesting equipment the crop could be grown in the cooler, moister regions of the 
Canadian prairies.
two species of the crop, Brassica napus and B. rapa were marketed as a single commod-
ity. The black, brown or yellow seed is small and round and when crushed yields 40 to 
46% oil and a nutritionally well balanced, high protein (36–37%) meal. The seed looks 
like those of turnip, mustard or cabbage, to which they are closely related.
Commercial production began in 943 with a government-guaranteed price of $.06/lb 
and production expanded from a few acres in 943 to 79,000 by 948 when the price 
support was withdrawn and steam power was displaced by diesel. The crop almost disap-
peared in 950 until an edible oil market was established in Japan where rapeseed oil was 
preferred for deep frying (tempura). after the war, the Japanese no longer had the farm 
labor to transplant rapeseed into the rice stubble to obtain two crops per year. Thus, the 
Canadian crop was saved while providing time to develop a domestic market.
Edible Oil from rapeseed?
From the beginning it was recognized by scientists that rapeseed could be an important 
domestic source of edible oil. at the time, Canada was importing 90% of its edible oil 
needs. Indeed some local companies began to market the liquid oil in the early 950s. 
However, the fatty acid composition of rapeseed oil differed from those of other edible 
oils in having a substantial quantity of the long-chain monoenoic fatty acids, eicosenoic 
and erucic (table ). This difference sparked the interest of nutritionists. Initially they 
reported that rats fed high levels of rapeseed oil performed poorly under stress and had 
enlarged adrenals. to counter these reports, it was pointed out that asian peoples had 
consumed rapeseed oil for centuries with no ill effects. Thus, the domestic market was 
allowed to grow.
Table 2. peRcenT faTTy acid composiTion of canadian vegeTable oils.
Rapeseed
 Fatty Acid Symbol Soybean Sunflower
  napus rapa canola
 Palmitic C6:0 4.0 4.9 4.7  7.  
 Stearic C8:0 .5 .6 .8 3.9 4.  
 Oleic C8: 7 33 63 5 6  
 Linoleic C8: 3 0 0 5 73  
 Linolenic C8:3 9.0 7.6 8.6 8.0 0.0  
 Eicosenoic C0: 5 9.9 .9 0.0 0.0  
 Erucic C: 4 3 0.0 0.0 0.0
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Decreased Erucic acid
Because of the nutritional concerns, chemists and breeders turned their attention to 
developing techniques to search for and develop germplasm with little or no-long chain 
fatty acids. at the time it required  lb of seed and a technician  week just to determine 
the fatty acid chain lengths of an oil. Gas chromatography (GC) was being developed, 
and home-made instruments were built to screen the world’s rapeseed germplasm. With 
no computers or integrators, each GC peak had to be triangulated and measured by 
hand. We were fortunate to identify a poorly adapted European forage variety with a 
much-reduced level of erucic acid. Through selection and breeding the first low-erucic 
B. napus variety, ‘Oro,’ was developed in 968, producing an entirely new but natural 
oil (table ). The change in fatty acid composition was achieved by genetically blocking 
the biosynthetic pathway for fatty acid carbon-chain elongation, from oleic to eicosenoic 
to erucic, as the oil is laid down in the developing seed. Pilot-plant tests indicated that 
the new oil was ideal as a salad and cooking oil, and steps were taken to contract its 
production. Unfortunately, that year tanker loads of sunflower oil were dumped by the 
Soviet Union on the world market and those plans were shelved. Despite this setback, 
the breeding program to develop a low erucic B. rapa variety was continued, producing 
the first low erucic variety, ‘Span,’ in 97.
Nutritional studies on rapeseed oil continued and in the fall of 970 the Second In-
ternational rapeseed Congress was held in Canada. Nutritionists in Europe and Canada 
reported abnormal numbers of heart lesions in laboratory animals fed high levels of 
rapeseed oil. The high content of erucic acid was considered the cause. again we were in 
danger of losing our markets. agriculture Canada immediately made the decision to take 
what little seed we had of the low-erucic varieties of both species for winter increase in 
California. The returning seed was sown in the spring of 97 and the total conversion 
of the 4-million-acre crop was underway. With the cooperation of the entire industry, 
the conversion was complete by 973. as indicated by the earlier pilot-plant tests this 
entirely new, edible oil was found to have superior properties as a salad and cooking oil 
as well as being suitable for margarine and shortening blends. as a result, domestic use 
increased from 9% in 970 to 49% in 997 (Fig. ).
Opening of the US Market
although the switch to the low-erucic oil removed the stigma from Canadian rapeseed 
oil, the United States market was closed to canola because rapeseed oil had never been 
in widespread use there and was not included in the US “GraS” list of foods (generally 
regarded as safe). Since the US market was potentially very large, the industry requested 
that research required to obtain GraS status be undertaken. a large body of nutritional 
data was assembled and the petition was successful; GraS status was granted in 985. 
The results of these studies were compiled and published in a book, High and Low Erucic 
Acid Rapeseed Oils (Kramer et al., 983).
The opening of the US market brought a surprise. We breeders had bred better than we 
knew. Nutritionists decided that oils high in polyunsaturated fatty acids were no longer 
the “best” for human consumption. Further, for good health, saturated fatty acids were to 
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be avoided. Since low erucic rapeseed oil had the lowest content of saturated fatty acids of 
any vegetable oil (Fig. ) it attracted the interest of large food companies. In addition to 
the low saturate level, the new oil also had a high concentration of the monounsaturated 
fatty acid oleic, which lowers the undesirable low density lipoproteins (LDLs) without 
affecting the desirable high density lipoproteins (HDL’s) while retaining suitable levels of 
the essential, polyunsaturated fatty acids, linoleic and linolenic. Thus the oil was quickly 
promoted as a highly nutritious specialty oil, receiving the american Heart Foundation’s 
989 Food Product of the Year award and the american College of Nutrition’s 989 
Product acceptance award.
Decreased Linolenic acid
as successful as the new oil was, the industry wanted a reduction in the level of linole-
nic acid from the standard 8 to 0% to less than 3% of the total fatty acids to improve 
its keeping quality and to reduce the need for hydrogenation. This was accomplished 
through mutation breeding and the first low-linolenic variety, ‘Steller,’ was released in 
985. Now company breeders have taken it one step further and produced varieties with 
an even higher level of oleic acid coupled with low linolenic acid values (table 3). This 
oil is gaining rapid acceptance both in North america and Japan and in time will likely 
make up about half the canola market. a further nutritional improvement will likely 
soon appear since Dow agroSciences has patented a canola oil for which they claim zero 
saturates (table 3).
Figure . Canadian vegetable-oil usage
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Meal Utilization
although the development of a superior edible oil was achieved by 97, a major market 
constraint remained, namely the utilization of the high-protein meal remaining after oil 
extraction. Even though the protein quality of rapeseed meal was equal to that of soy meal, 
feed efficiency and weight gains with swine and poultry were well below expected levels. 
This restricted the amount of meal that could be fed and, in turn, limited the amount of 
seed that could be processed. The problem was associated with the presence in the seed 
of glucosinolates. These sulphur compounds, of which about ninety are known, give the 
Figure . Comparison of dietary fats.
Table 3. faTTy acid composiTion of noRmal and modified 
Rapeseed/canola oil in commeRcial pRoducTion
    Fatty acid composition (%)
Oil type 16:0 16:1 18:0 18:1 18:2 18:3 20:1 22:1
Canola 4 <  6 0 9  <  
Low linolenic 5 <  64 5 <3  <  
High oleic/Low linolenic 4 <  78   < <  
Zero saturate < < < 85   < <  
High erucic  <  3  9 7 54  
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desired flavor and odor to cabbage, turnips, mustard and other cruciferous crops. However, 
the plant accumulates and concentrates these compounds in the seed, typically at 00 to 
50 μmoles/g. as a result, the nutritional value and palatability of the meal is reduced 
when fed to non-ruminants such as swine and poultry.
When the cells of rapeseed are broken with moisture present, the glucosinolates are 
hydrolyzed by myrosinase—an enzyme present in all cruciferous seeds—and sulphur, 
glucose and isothiocynates are released (Fig. 3). The isothiocyanates are active goitrogens 
that interfere with iodine uptake by the thyroid gland in swine and poultry, resulting in 
goiter and poor growth. Early studies showed that the problem could be partly overcome 
by heat inactivation of the enzyme as the first step in the oil-extraction process. However, 
some hydrolysis still occurred in the gut. Thus, the ultimate objective was to breed varieties 
Figure 3. Products of myrosinase hydrolysis of the glucosinolates.
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free of glucosinolates. again, new chemical methodologies had to be developed to rapidly 
and accurately measure the amounts of the various glucosinolates in small samples of 
seed. Using these new techniques, breeders were able to genetically block the glucosino-
late biosynthetic pathway from the methionine and tryptophane precursor amino acids, 
resulting in the first low-erucic, low-glucosinolate variety of B. napus, ‘tower,’ in 974. 
However, it took another 3 years to produce the first double-low B. rapa variety, ‘Candle,’ 
so that the second complete crop changeover could occur.
Global-Market acceptance
By 980, the 5-million acre commercial crop was largely converted to the new double-low 
varieties, thus removing the constraint associated with the feeding of the meal. animal 
nutritionists at several universities conducted extensive studies to convince both domestic 
and foreign feed formulators that the low glucosinolate meal was, indeed, a safe, wholesome 
and economic high-protein supplement. Eventually Europe, using Canadian germplasm, 
converted to canola-quality varieties in 988–989 and australia in 990, while China, 
India and Pakistan are expected to achieve conversion within the next decade. The market 
impact of these quality modifications was dramatic, not only domestically (Fig. ) but also 
for exports of oil and meal (Fig. 4) as well as seed (Fig. 5). Improvements in seed yield 
as well as quality resulted in a better return to producers and an expanding production 
base (Fig. 6). Surprisingly, these significant quality changes were made without adversely 
affecting the overall agronomic performance of the crop. From the outset in this series 
of crop changes, Canada consulted closely with its major customer, Japan, meeting with 
counterparts at least twice a year.
Figure 4. Five-year averages of Canadian rapeseed/canola oil and meal exports.
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“Canola” Coined
as a result of the nutritional upgrading of the oil and meal, a new name was required 
to distinguish these products from the old-style rapeseed. “Canola” was coined, trade-
marked and defined as seed, oil or meal having less than % erucic acid in the oil and 
less than 30 μmole/g of aliphatic glucosinolate in the oil-free, moisture-free meal. This 
definition is due to be further refined to better reflect today’s commercial crop. The new 
definition reduces the erucic acid content to less than % and establishes a maximum of 
8 μmole/g of all glucosinolates in whole seed. In the oil-free meal, the maximum will 
be 30 μmole/g, with both seed and meal at 8.5% moisture. as a result of reducing the 
glucosinolate content from the original 00 to 50 μmole/g, canola meal can now be fed 
as an economic high-protein supplement.
Figure 5. Five-year averages of Canadian rapeseed/canola exports.
As a result of the nutritional upgrading of the oil and meal, 
a new name was required to distinguish these products 
from the old-style rapeseed. “Canola” was coined, 
trademarked and defined.
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The development of canola is considered a success story because it diversified Canada’s 
agriculture base, eliminating dependence on oil imports and increasing returns to producers 
while expanding markets at home and abroad. In addition, it resulted in the establish-
ment of a large rural-based, value-added oilseed crushing and refining industry. Eight 
canola-oil extraction plants are now distributed across the prairie provinces, processing 
some 3 million tonnes/year of seed, with expansion planned or under way. Canola has 
also responded to all the biotechnologies with 90% of the crop herbicide-tolerant; hybrid 
varieties now occupy about 30% of the area planted. The story is not over yet as canola 
is a preferred biodiesel oil source for northern climates because of its low content of 
saturated fatty acids.
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Figure 6. Five-year averages of area sown and yield of rapeseed/canola.
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India’s economy is among the fastest growing in the world. During the past 0 years, it 
has grown consistently at 6% to 8% annually. However, although growth in the industrial 
and services sectors has been above the national average gross domestic product growth 
rate, the rate of growth in agriculture in the recent past has been less than %. a national 
mission is to revive the under-performing agriculture sector by:
• Enhancing farm production and food quality
• reducing waste.
The strategy involves:
• attracting investments that will trigger high growth in agriculture and in the 
processed-food industry
• Partnering in global research initiatives that will help India to acquire as well as 
provide technologies
• Nurturing innovation that will help to create competition and provide opportu-
nity for development of commercialization of new products.
Embracement of agricultural Biotechnology
Early on, India realized the need to apply tools and techniques of agricultural biotech-
nology to enhance agriculture and increase food production. accordingly, the country 
has permitted growing of bollworm-resistant transgenic cotton since 003, with wide 
adoption of the technology by farmers. During the year 006, about 3 million hectares 
of transgenic cotton are expected to be planted, making the country the second-largest 
grower of genetically engineered cotton in the world.
Some fourteen crops are currently being developed with various traits incorporated 
for mitigating biotic and abiotic stress factors. There are also efforts to enhance nutrition 
that can provide relief to mal-nourished children.
India: New Products and Opportunities
Vijay Vijayaraghavan
Sathguru Management Consultants
Hyderabad, India
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The fruit- and shoot-borer-resistant eggplant is an early food crop being tested in farm-
ers’ fields in 006. The fruit and shoot borer can cause crop losses of 30% to 60%.
This single transgenic event in eggplant has the potential to bring 
economic gains of over $300 million for the region.
The consortium approach now being adopted by many Indian research enterprises—
sharing technologies and co-operating in product development—has resulted in conserving 
precious resources, enhancing ability to develop products and sharing research outcomes 
for public-good application.
Socio-Political Issues
While transgenic technologies are certain to provide gains for Indian agriculture, to maxi-
mize these gains it is essential to address certain currently prevailing constraints. Extensive 
creation of public awareness, educating science writers and journalists appropriately in 
terms of risk and benefit factors and harmonizing the regulatory framework will help to 
ensure systemic adoption of the technology.
The consortium approach has resulted in conserving precious 
resources, enhancing ability to develop products and sharing 
research outcomes for public-good application.
Consortium approach
This single transgenic event in eggplant has the potential to bring economic gains of 
over $300 million for the region. This project is supported by the Cornell-managed ag-
ricultural Biotechnology Support Project II (aBSPII), funded by USaID and regionally 
supervised by Sathguru, a consortium partner within aBSPII. The project aims for the 
first time to provide technologies to the public sector by delivering transgenic seeds to 
resource-constrained farmers who would otherwise be denied such access. aBSPII has 
also facilitated transfer of technologies to other asian countries including Bangladesh 
and the Philippines.
Scientists in India, the United States, Bangladesh, Indonesia and the Philippines 
have combined their efforts and expertise to develop drought- and salinity-tolerant rice, 
virus-resistant groundnut and sunflower, late-blight-resistant potato and virus-resistant 
papaya.
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a Key Player regionally and Globally
India will be a key player in harnessing and applying agriculture biotechnology inventions, 
tools and techniques to enhance food production and also to contribute to alleviating 
global poverty by providing access to invaluable technologies to other needy nations. 
Young, multi-faceted talent provides the opportunity for India to be the research desti-
nation of the world.
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In Brazil, the production of ethanol from sugar cane has increased 3-fold in the past 5 
years. The current average yield is 6,000 L/ha. However, in line with the Kyoto Protocols, 
we will have to increase production at least 3-fold again by 00 to satisfy projected 
needs.
Production of ethanol from sugar cane in Brazil results in an output of eight times 
more energy than is put in. In contrast, ethanol from corn kernels results in an energy 
output of .3–.8 compared to .0 invested. We can produce up to 7,000 L/ha, which 
again compares favorably with corn kernels at 3,500 L/ha. Brazil also has greater sugar-
cane production at lower prices in comparison with australia, South africa, India and 
Cuba. 
These advantages accrue from Brazil’s geographical location and plentiful supply of 
rainfall, with ideal conditions of sunlight availability and temperature. Plenty of arable 
land is available and labor costs are low, which will contribute to increased production. 
also we have scientific expertise in genetics and agriculture technology that has contrib-
uted to the increased productivity of sugar cane as a crop and improved efficiency of 
ethanol synthesis.
Need for Greater Productivity
However, even greater productivity will be needed to produce enough ethanol to meet 
global demands in the near future. One possibility is to use cane bagasse as a source of 
cellulose for fermentation to produce sugars and then ethanol. This will be similar to how 
corn starch is being used in the United States.
an alternative means of using cellulose to produce ethanol is to employ enzymes that 
can hydrolyze it for conversion to sugar. Bagasse, the residue after sugar extraction, is a 
good source of lignocellulosic material and a positive aspect is that it is already at the mill. 
There is no need to transport it for processing. Bagasse represents about 30% of the total 
biomass of sugar cane. Currently it is burned to produce steam for electricity.
New Perspectives for Agricultural Biotechnology 
in Brazil
ana Claudia rasera da Silva
Alellyx Applied Genomics
Campinas, SP, Brazil
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today,  ha yields 85 tons of cane that is mashed to produce juice. The juice is fermented 
to produce up to 7,00 L of ethanol. Including bagasse, this could be increased to 5,000 
L/ha. another -fold increase might be gained by breeding cane of higher fiber content, 
so-called “energy cane.” Conventional cane produces around 70 to 0 tons/ha. High-fiber 
or energy cane might provide 40 to 40 tons/ha, doubling the yield of ethanol.
New Biotech Companies
With these objectives in mind, two new companies were established in Brazil with the aid 
of venture capital. allelyx, a plant-biotech company, was founded in 00 by scientists 
at the Universities of Sao Paulo, Campinas, and Sao Paolo State who had sequenced the 
genome of Xilella fastidiosa, the causative agent of variegated chlorosis in citrus. CanaVialis 
is a sugar-cane breeding company, founded in 003 by scientists at the Federal University 
of Sao Carlos. CanaVialis scientists, with over 30 years experience in sugar-cane breeding, 
have created the varieties that today make up over 60% of the sugar cane now planted in 
Sao Paulo state. These varieties are responsible for recent increases in sugar and ethanol 
productivity.
allelyx is located at Campinas with about 30 employees, a third of whom are respon-
sible for plant transformations. We are also strong in bioinformatic analyses with foci on 
sugar cane, citrus and eucalyptus. CanaVialis is using traditional breeding methods to 
generate new varieties of sugar cane; it has the world’s largest breeding program for sugar 
cane. They have an experiment station with a huge stock of germplasm, close to the equator 
in a climate ideal for crossing cane varieties and maximizing breeding efficiency.
Two new companies were established in Brazil with the aid of 
venture capital: Allelyx and CanaVialis.
Allelyx provides the genes while CanaVialis provides 
the germplasm.
allelyx deals with gene discovery, proof-of-concept and also with product development 
and regulatory issues, while CanaVialis works directly with producers to facilitate future 
commercialization of new varieties. In short, allelyx provides the genes while CanaVialis 
provides the germplasm.
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Proving Concepts
at this stage we are working mostly with model plants to prove concepts while develop-
ing protocols for efficiently transforming our target crops. We are leaders in terms of 
transformation protocols for sugar cane, citrus and eucalyptus, and have already proven 
some concepts in plant models:
• genes introduced in tomato and sugar cane increase sucrose content,
• sugar cane has been made resistant to the mosaic virus,
• lignin content in tobacco has been decreased, and
• xylem-bundle thickness and cellulose content in tobacco has been increased.
We are now working to introduce these traits to the target crops.
Some promising results have been obtained in terms of increasing sucrose content 
of sugar cane. Preliminary Brix data indicate that we have almost doubled it. also, we 
have interesting results for drought tolerance in tobacco, which will be important for the 
expansion of sugar-cane production into the Cerrado, where rainfall is significantly less 
than in Sao Paulo to the south.
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China, one of the largest agricultural countries in the world, has made significant achieve-
ments in agricultural production. We use about 70% of arable land to feed 0% of our 
population. However, since 000, production has been stable, whereas the population 
continues to increase, therefore we face challenges, as in India. The first is population. 
We estimate that it will increase to .6 billion around the year 00, therefore we need to 
increase agricultural production commensurately. and then we have challenges in terms 
of arable land and water resources.
Imports and Exports
after China joined the World trade Organization in 00, importation of agricultural 
products increased dramatically and the trade deficit climbed to over US$5 billion in 
005. Three major problems characterize US/China trade relations. First is the United 
States-to-China deficit in agricultural goods. Second is the China-to-United States deficit, 
which includes textiles and other industrial goods. The second trade issue is the value of 
Chinese money. The third problem is intellectual property (IP) rights.
In 005, China imported 7 million tons of soybean from the United States, Brazil 
and argentina, almost 40% of the total consumption in China (which produced about 
60 million tons). Importation of soy from the United States began in 995, mostly from 
Iowa and Wisconsin. 
In 00, China made labeling of GM seed mandatory. US companies were unable 
to quickly meet the imposed standard, importation dropped precipitously in that year; 
however, it came back in 00, 003 and 004. 
Cotton is the second most important crop imported by China. although we are one of 
the largest producers of cotton, involving 00 million farmers, 5% of exports are textiles. 
In 005, China’s cotton importation increased dramatically; it increased from 3 million 
to 5 million tons between 000 and 005. Corn and rice are also imported.
Chinese Agricultural Biotechnology in the Field
Zhangliang Chen
Agricultural University
Beijing, China
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Investments in agricultural Biotechnology
The Chinese government has made significant investments in agricultural biotechnology. 
In an attempt to ensure food security, research funding has been doubling every 5 years. 
China is second only to the United States in terms of federal funding of plant biotech-
nology. In contrast to India, in which multinational companies including Monsanto are 
operating, China has little investment in plant biotechnology from the private sector, 
possibly due to concerns over IP. 
Thus, plant biotechnology is developing rapidly, with much activity in field trials 
and the process of commercialization. China is number five in terms of production and 
commercialization of transgenic crops (i.e. cotton) in the world after the United States, 
argentina, Brazil and Canada. after the government approves transgenic rice for com-
mercial production, China will quickly occupy the number-two position.
In total, about 700 applications have been approved for field trials and about seventy-
five commercialization licenses have been granted. The largest number is of transgenic 
cotton, which has been released in more than ten provinces. However, about thirty 
species of transgenic plants being tested in the field, including cotton, rice, wheat, corn, 
soybean, potato, oilseed rape and tobacco. also, over 30,000 transgenic poplar trees are 
under trial in the Beijing area. 
China is second only to the United States in terms of federal 
funding of plant biotechnology.
transgenic cotton was first grown commercially in 996, and today over 60% of cotton 
grown in China is genetically engineered. It is close to 00% transgenic in the Yangtze 
river basin. transgenics are not used in Xingjian province, although it is  a major produc-
tion area for cotton, because nematode infestation is not a serious problem.
Imported Concerns
as in other asian countries, public concern over the safety of GMOs is a problem in 
China. This problem came from Europe; 998 and 999 were difficult years. Greenpeace 
published a magazine, available free of charge, which was sent to officials in China and 
members of the scientific community. Particular attention was focused on transgenic 
rice. China is the major rice producer globally. Over 600 million Chinese farmers live 
on rice and it is also vitally important globally. research on transgenic rice has been in 
Over 60% of cotton grown in China is genetically engineered.
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progress for over 0 years. Genetically engineered rice is being field-tested for resistance 
to insects, bacterial blight, and fungal rust, and for salt and herbicide tolerances, and with 
nutritional improvements including golden rice resulting from collaboration with Ingo 
Potrykus, and varieties resistant to rice dwarf virus from my laboratory. 
We are now in the last phases of preproduction trials of transgenic rice. In November 
004, the final committee of scientists approved transgenic rice for commercialization, 
and we await approval by the Ministerial Conference, which consists of representatives 
of seven ministries including agriculture, Science and technology Involvement, and Im-
port/Export. We expected approval in May 005, but Greenpeace acquired seeds and sent 
them to GeneScan, an analytical laboratory in Germany. a PCr assay revealed a Bt gene, 
which drew press attention globally. Immediately, Japan and Korea, banned importation 
of rice from China, in response to which the Conference postponed commercialization 
and we still await approval, despite the fact that our scientific committee again approved 
Bt rice in November, 005.
In early 006, Greenpeace announced detection of GM rice in Chinese-made baby food 
and is publicizing the “scandal of illegal GM rice” on their website. Thus, the situation in 
China is getting more and more difficult. In contrast, the situation is good in the United 
States; however, it remains difficult in Europe and increasingly so in China.
a common complaint is that GM food is unsafe, yet Bt toxin has been used in China 
since the 960s for insect control on vegetables, with no reports of poisoning. Over  
billion people in the Unites States, argentina and China have been exposed to transgenic 
soybean with no reports of toxicity. (We import transgenic soybean, but are not allowed 
to grow it.)
Environmental safety is also a concern. Greenpeace has attempted to convince the 
government that genetically engineered crops adversely affect the environment. The fact 
that many people have been poisoned by ingestion of pesticides is generally ignored. It 
can be argued that since Bt crops save human life, they actually improve the environ-
ment. Significantly more insects are present and increased insect diversity exists in fields 
of transgenic cotton because less pesticide is applied. More people are poisoned and die 
as a result of exposure to insecticides used on non-transgenic cotton and rice than with 
Bt counterparts. 
The issue of beneficiary is another source of complaint. Benefits accrue to farmers and 
to the production company—often Monsanto is the focus of discontent—rather than 
to the consumer.
Labeling
Labeling is another contentious issue. In the United States, labeling is voluntary on the 
part of the producer, therefore the situation becomes complicated where products are being 
exported. China enacted a law in 00 enforcing labeling. Soybean oil has to be labeled 
to indicate its GM source even though it does not contain any transgenic component. 
This can be confusing for consumers. Furthermore, many people in China are illiterate; 
the extra cost involved in labeling is, in many cases, of no utility.
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agbiotech and Global Needs
Part of my job is to convince people that this technology is useful, which has become 
difficult as a result of Europe’s influence. If the European Union would be accepting of 
GMOs, China, India, Thailand and african countries would benefit. In many parts of 
the world people are hungry, yet their ability to feed themselves is being compromised 
by others who live in abundance. I hope that more attention will be paid to these poor 
countries, especially to hungry countries, so that this technology can be made available 
to help people help themselves and help the environment.
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agricultural biotechnology has its roots in Europe. The basic technology–Agrobacterium 
tumefaciens-mediated gene transfer into plants—was discovered and developed by Jeff 
Schell and Marc van Montagu in Cologne, Germany, and Ghent, Belgium. Despite 
these successful research activities and patenting of the technology, efforts to put these 
inventions into practice and launch profitable products on the European market were 
unsuccessful due to fierce and continued protests from non-governmental organizations 
(NGOs) prejudicing the general public and political leaders against genetically modified 
(GM) plants. 
Globalization of European Biotechnology:
Commercialization of Agbiotech Products 
Despite Political and Legal Restrictions 
Peter Welters
Phytowelt GreenTechnologies GmbH
Nettetal, Germany
The EU moratorium on approval of GM plants in 1998 was a 
particularly serious blow.
The first commercial cultivation of GM plants took place in 995 in the United States. 
Since then, the industry has seen double-digit growth every year, but only outside of Eu-
rope. The EU moratorium on approval of GM plants in 998 was a particularly serious 
blow. Most biotechnology companies, especially those financed by venture capital, went 
out of business, lacking strategies for surviving a 6-year-period without launching products. 
Even large multinationals fell victim, and had to merge or were sold to competitors to 
increase shareholders’ values. Small and medium-sized companies survived only if they 
had products other than GM plants in their portfolios and with global markets. 
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Successful Business Strategy 
Phytowelt Greentechnologies offered services and contract research in addition to de-
veloping products for industry and consumers. Our main technologies—the proprietary 
genetic marker system IStr, patented genes to improve plants and tissue-culture tech-
nologies such as somatic hybridization—led to projects with ornamental, food and fodder 
plants. Furthermore, we improved procedures for the production of phytopharmaceuticals 
and platform chemicals for our clients in the chemical and pharmaceutical industries. 
The success and steady development of the company are based on an international 
orientation and embracement of globalization since the beginning. Clients in Japan, New 
Zealand, Canada, United States and Europe are proof of this strategy. another critical 
factor was the self-sustained financing by private shareholders, assignments and contracts. 
Grants from public institutions were used to implement new technologies. 
Political Obstacles
Nowadays, the European biotech landscape shows an uneven distribution of companies, 
with concentrations along the rhine and the river Thames as well as uneven application. 
Medical and pharmaceutical biotech companies outnumber, by a factor of five, those with 
an agricultural orientation. 
Besides the lack of consumer acceptance, absence of consistent and reliable legislation 
prevent commercialization of GM products in Europe. The discussion revolves around 
thresholds, labelling, traceability, monitoring, coexistence, admixture, liability and bio-
patents without reaching firm conclusions to provide a legislative framework. Instead, 
more research has been demanded to prove the safety of GM crops, serving to postpone 
their introduction. Interest on the part of the industry to conduct appropriate research 
has declined in recent years. The number of field trials (Figure ) reached its peak in 
997/998, and since then has decreased significantly. a small increase in 006 may 
indicate a turning point, but it is too early to be certain.
Spain leads the current EU member states with 53,000 ha planted to GM crops in 
005, and with an increase in 006. romania, which will become an EU member in 
007, has an even greater area, of GM soybean. However, because the cultivar is not 
approved within the EU, its cultivation will be forbidden once romania enters EU-5. 
Three other European states, Germany, France and the Czech republic, together had 
around ,000 ha of GM crops in 005. This probably hit the 0,000-ha threshold in 
006, largely because of ten-fold increases in France and the Czech republic; Germany 
planned only a doubling to around 900 ha. 
More research has been demanded to prove the safety of GM 
crops, serving to postpone their introduction.
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End of the Moratorium
a turning point occurred in 004 when the EU ended its moratorium and approved 
importation of GM corn. In 005, Germany turned its attention to GM after the Green 
party failed to win re-election in their last two strongholds, the NrW state government 
and the federal government of Germany; three varieties of GM corn were approved for 
cultivation within the first 00 days of the new federal government. Coincidentally, 
Phytowelt sold the first license of its proprietary parthenocarpy technology to a US seed 
company. But the general situation in Europe is unchanged: to stay in business, produce 
either non-GM products (Figure ) or  non-food value-added products like monoterpenes 
(Figure 3). This is also the strategic line of the European Commission. In their Plants for 
the Future program, the emphasis is on bioenergy and biobased chemicals to promote 
development of a biobased economy. Their decade-long timeframe indicates that even in 
Figure . The number of field trials of GM plants increased steadily until 997. The 
European Commission’s 998 moratorium, preventing commercialization of GM 
plants, adversely affected r&D. 
In the European Commission’s Plants for the Future program, 
the emphasis is on bioenergy and biobased chemicals to promote 
development of a biobased economy.
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the Commission no one expects short-term implementation of the technology in Europe. 
and to avoid the term “genetic engineering” “precision breeding of renewable resources” 
has become the fashionable, politically correct term. 
Industrial Plant Biotechnology
a fairly new trend, but not a new industry, is so-called “white” or “industrial” biotechnol-
ogy in Europe. Because of the success of some European companies (e.g. DSM, Novozymes, 
BraIN), this field is considered as more promising than biotechnology of plants for 
food and feed. In the beginning, companies tried to avoid being connected with genetic 
engineering of plants. But it is becoming accepted that industrial biotechnology needs 
to be combined with plant biotechnology to fully exploit its potential. 
Instead of using agriculture only as a source of feedstock for fermenters in the form 
of sugar and other low-value commodities, it was realized that plants can deliver a whole 
range of complex chemical entities. Precursors for steroid hormones and cancer medication 
(e.g. taxol) for the pharmaceutical industry and polymers like caoutchouc, a polyterpene, 
for the rubber industry are already being delivered by plants. Mint plants can produce a 
Figure . Non-genetically engineered, non-food products currently have the best 
chances of success on the European market. Despite the end of the moratorium, GM 
plants are still underrepresented.
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Figure 3. The biosynthesis of menthol as an example of the production of platform 
chemicals in mint plants exploiting their biodiversity for the sustained production of 
chemicals; a, b, c and d are known enzymes of the biosynthetic pathway that can be 
genetically modified to direct the production of a particular monoterpene.
whole range of monoterpenes depending on the variety, thus biodiversity may be exploited 
to increase the use of renewable resources for sustained production of chemicals (Figure 
3). With genetic engineering, plant biotechnology can combine the primary produc-
tion of agriculture and the conversion technology in fermenters to shorten the process 
and reduce costs. By providing higher concentrations of basic precursors, such plants 
will improve fermentation processes. Due to removal of contaminating by-products by 
inhibiting their synthesis in planta, the higher purity of products from GM plants will 
secure their usefulness to the chemical industry. 
Financial aspects
Encouraging signals from the technological side are supported by recent news of mergers 
and acquisitions. Plant biotechnology companies are again the target for multinational 
corporations to improve their pipelines, e.g. BaYEr incorporated Icon Genetics, BaSF 
bought CropDesign in Belgium, and Biolex (USa) acquired Lemnagene (France). The 
formation of Phytowelt Greentechnologies was a merger of equal partners, Phytowelt and 
Greentec, the latter a spin-off of the Max-Planck-Institute for Plant Breeding research 
Plant biotechnology companies are again the target for 
multinational corporations to improve their pipelines.
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Figure 4. GO indicating modern, 
 innovative genetic engineering 
to improve a product labelled 
 according to quality standards 
 defined by the academic and 
 industrial communities.
in Cologne. The increased interest in plant biotechnology from the financial community 
is also shown in a new round of financing for Novoplant, Germany: they raised 3 mil-
lion euros. and new companies are being founded, such as Solucel, a combined effort 
involving Finnish and Belgian governmental institutions.
Conclusion
These examples show that biotechnology is on the rise again in Europe. Instead of being 
paralyzed by the scaremongering of anti-GMO-activists, we should spread the good news. 
There are enough examples to show the benefits of applying genetic engineering of plants 
and thereby convince the general public. We 
have only to inform people correctly and 
constantly about the progress and the benefits 
of this new technology. Millions of farmers 
worldwide cannot be wrong!
Labelling should be mandatory for prod-
ucts improved by genetic engineering (Figure 
4) to show that we are proud of the technolo-
gy and convinced of its benefits. Conferences 
like NaBC’s and aBIC’s are important and 
supporting them helps to improve acceptance 
and distribution of this beneficial technology. 
NaBC 9 will convene in Brookings, South 
Dakota, May –4, 007, and aBIC007 
in Calgary, September 3–6, 007.
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aFter studying chemistry, biochemistry and food 
chemistry in Germany, Peter Welters spent 4 years at the 
Max-Planck-Institute for Plant Breeding research, there 
obtaining his Diploma and PhD. He worked in Jeff Schell’s 
group on promoter control in the legume/rhizobia nitrogen-
fixing symbiosis. after 3 years at the University of California, 
San Diego, in the laboratories of Maarten Chrispeels and 
Scott Emr, researching protein-transport regulation in plants and yeasts, he was 
chosen as head of the Production of Pharmaceutical Proteins in Plants project in 
rouen, France. 
Dr. Welters’s innovative ideas led to the foundation of Biotechnology and 
Molecular Biology, which became Phytowelt GmbH in 998. Four years later, 
he became CEO of Greentec GmbH, a spin-off company of the Max-Planck-
Institute, founded by Schell, Klaus Hahlbrock, Frederico Salamini, and Heinz 
Saedler.
Since January 006, Welters has been CEO of Phytowelt Greentechnologies 
GmbH, a fusion of Greentec and Phytowelt, located in Nettetal (head office) 
and Cologne (r&D). The company offers laboratory and know-how services 
in agricultural biotechnology, e.g. somatic hybridization, tissue culture, marker 
technologies, contract studies and project coordination. He is also a board member 
of the aBIC Foundation, Canada, and BioCologne eV, Germany.
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Peggy Lemaux (University of California at Berkeley): For Vijay. I have two Indians in my 
lab and when the issue of problems with Bt cotton came up I asked them to find out 
what was going on. They mentioned, along with some other people, that there is a black 
market in Bt cotton seed. and sometimes seed that is supposedly Bt, but is not, is being 
sold. Can you either confirm or deny that?
K. Vijayaraghavan (Sathguru Management Consultants, India): Initially just one company, 
Mahyco, produced Bt cotton seeds in India, in a joint venture with Monsanto. But their 
ability to satisfy demand was limited. In the second and third years it was realized that 
they needed distribution across the country so they took a strategic decision to sub-license 
various companies that produced locally adapted hybrids for different regions. The price 
of a regular pack of seeds is about 400 rupees, whereas transgenic seed sold at about 600 
to 700 rupees. This steep increase in price made it difficult for many small farmers to 
procure them. to satisfy demand for transgenic seed, “informally” crossed genotypes 
became available, But then they realized in the second and third seasons that some of 
the Fs were not performing well and there was huge disappointment. That’s where the 
government intervened. There is a considerable social factor in this. You have farmers 
Past Successes, Future Prospects and Hurdles
Session II Q&A
Moderator: ralph W.F. Hardy
National Agricultural Biotechnology Council
Ithaca, NY
There is a black market in Bt cotton seed. And sometimes seed 
that is supposedly Bt, but is not, is being sold.
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who can afford the seed and are able to increase their income many-fold. and you have a 
huge segment of farmers who have no access to transgenic seed because the public sector 
has not adopted any strategy to bring out transgenic seeds there. It’s going to take a lot 
of time to convert them to hybrids. The affordability of hybrids can only be increased 
by increasing the credit to farmers. There are no data on “informal” seed adoption, so 
it’s difficult to determine precisely to what extent it takes place; but there is considerable 
acreage with informal seed cultivation.
Steve Pueppke (Michigan State University): ana, I was interested to hear you say that you 
can double the yield of ethanol from sugar cane by digesting and fermenting the fiber. 
Have you compared that yield to a process that converts the fiber to syn gas then the syn 
gas to ethanol?
Ana Claudia Rasera da Silva (Alellyx Applied Genomics, Brazil): The enzymatic process is 
best. One approach is to add enzymes to the bagasse, a second approach is to engineer the 
microorganism to digest the cellulose and the third is to put the enzyme inside the sugar 
cane such that when the cane is crushed the enzyme is released. We are still developing 
the technology to put the enzymes inside the plant.
Dalia Abbas (University of Minnesota): For ana: how do higher sugar-cane yields affect 
soil nutrient status?
Da Silva: actually it’s not a problem at all because we just increased the capability of 
converting fibers to sugar. There is a balance between sugar and fibers, and in the energy 
cane you have more fibers than sugar. So there is no impact for the soil. and also for 
all the field trials that have been done in Brazil we have regulatory approval from the 
government.
Ralph Hardy: Can the panel offer guidance on aspects of industrial biotechnology that 
may produce problems similar to those that arose in food biotechnology?
Vijayaraghavan: From the Indian perspective, one area we have been heavily investing in, 
in the recent past, is the application of technologies for alternative fuels. There are several 
options for farmers to go with when talking about fuel from farm produce, fuel from 
non-farm produce, fuel from food produce, fuel from non-food produce. as of now, we 
don’t have any clear scientific approach in accessing the economic compatibilities of these 
options. We may find a farmer growing tapioca then he gets to know that sorghum is 
better so he gets into sweet sorghum but then he gets to know that sugar cane is a better 
option and he jumps into sugar cane. We need to marry good economics with good sci-
ence and say that these are the options that are worth exploring in these environments, 
rather than seeing science as an independent analysis. We need to entice investments 
with a clear economic analysis that reflects compatible application of science in different 
environments. That’s essential when considering industrial applications. 
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Peter Welters (Phytowelt, Germany): One of the mistakes we should not repeat is to keep 
things secret. Industrial biotechnology people like to keep things secret where they are 
not forced to label their products. If they were forced to label, you would have labeling 
on nearly 70% of all of the processed food in Europe. Washing powders contain enzymes 
produced in genetically engineered microorganisms for cleaning of apple juice, also for 
bread baking and cheese making. Even organic food shops sell cheese produced with chy-
mosin from genetically engineered microorganisms. I think we should tell the consumer 
where genetic engineering is already making positive contributions.  
Hardy: I appreciate your comments.
One of the mistakes we should not repeat is to keep things secret.
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Saskatchewan is one of the three prairie provinces of Canada. although the population 
is less than a million, it boasts 47% of Canada’s arable land and is home to one of the 
largest and fastest-growing agricultural biotechnology clusters in the country (Lauter-
milch, 00).
The core of the ag-biotech infrastructure is the University of Saskatchewan (U of S), 
the agriculture and agri-food Canada research Centre (aaFC-SrC), the National 
research Council’s Plant Biotechnology Institute (NrC-PBI), and the Saskatchewan 
research Council (SrC).
The U of S has five life-science colleges on campus:
• Western College of Veterinary Medicine,
• College of Pharmacy and Nutrition,
• College of Medicine,
• College of agriculture, and
• College of arts and Science.
The university has additional research capacity with the College of Engineering, as well 
as major institutions such as the Vaccine and Infectious Diseases Organization (VIDO) 
and the Canadian Light Source Synchrotron (CLS).
From Tools to Products and Processes:  
The Evolution of Saskatchewan’s  
Agricultural Biotechnology Cluster
ashley O’Sullivan
Ag-West Bio Inc.
Saskatoon, SK
In 1977, the provincial government leased land from the 
University to establish Innovation Place.
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In 977, the provincial government leased land from the U of S to establish Innova-
tion Place (Beggs, 006), a research and development park immediately adjacent to the 
campus that currently:
• is home to 37 companies and agencies,
• has eighteen buildings and supporting infrastructure with over a million square 
feet of laboratory and office space,
• has a staff of ,00, and
• contributes approximately $50 million/yr to the GDP of the province
Early research activity
The early focus of research activity in the community included:
• plant breeding, genetics, protection, nutrition,
 — cereals (wheat, barley, oats)
 — oilseeds (canola, flax)
 — pulses (peas, beans, lentils)
 — forages (grasses and legumes)
• animal health and nutrition,
 — beef, swine, poultry
With respect to crops research, the major emphasis was on the development of new 
varieties of commodities for food and feed applications as well as crop-production tech-
nologies.
In the 980s, our science and political leaders—with great foresight—realized that the 
emerging science of agricultural biotechnology was potentially a key driver of value for the 
agriculture sector. ag-West Bio was established in 988 by the province of Saskatchewan 
to provide leadership in the development of this sector. During the period 99–00, 
more than $700 million were invested in the region’s infrastructure (McCann, 00).
also in the 980s, there was the realization that genes controlling economically im-
portant input traits, such as herbicide tolerance and insect resistance, that were under 
development—plus other emerging tools, e.g. plant-transformation protocols and increas-
ing knowledge of the regulation of gene expression—when commercially introduced, 
would have a profound impact on the business of food production.
Agricultural biotechnology was potentially a key driver of value 
for the agriculture sector. Ag-West Bio was established in 1988 
by the province of Saskatchewan to provide leadership in 
the development of this sector.
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Success Stories
Saskatoon has had many ag-biotech success stories over the years, for example the develop-
ment of novel vaccines by VIDO (VIDO report, 00) and a bloat-reducing alfalfa by 
agriculture and agri-Food Canada (Coulman et al., 000). However, the greatest economic 
impact came from the development of canola, now Canada’s second most important crop. 
The canola story has been reviewed in detail by Phillips et al. (00) and by Keith Downey 
in this volume1. With significant research work at NrC-PBI and aaFC-SrC, Saskatoon 
became the national centre of excellence for Brassica development. Considerable work 
was also done in collaboration with the University of Manitoba.
The NrC and aaFC laboratories had major r&D activity in breeding, molecular 
biology, chemistry, entomology, pathology and agronomy with strong teaching and re-
search support from the U of S. as a result of this concentration of expertise, a number 
of multi-national companies moved components of their r&D programs to Saskatoon 
to be in proximity to the publicly funded infrastructure [scientific expertise, intellectual 
property (IP), facilities, equipment and money]. Strong public/private collaborations 
developed and public/private IP was bundled to create commercial products. The first 
commercial field-planting of a genetically engineered (glufosinate-resistant) canola crop 
occurred in 995 (Bijman, 00) as a result of the collaboration among agrEvo-PGS, 
aaFC and NrC-PBI.
and so, the Saskatchewan ag-biotech cluster was born. The reasons for the early success 
with respect to the canola example include: 
• excellent scientists in public institutions with significant IP assets and a highly 
transformable, economically important crop (canola),
• provincial government foresight in establishing Innovation Place research and 
development park immediately adjacent to the U of S, and support for the estab-
lishment of ag-West Bio in 988,
• the concentration of institutions and scientists on the same campus and immedi-
ately adjacent research and development park (Innovation Place),
• the excellent communication, networking and spirit of cooperation among all of 
the players; and a “can-do” attitude,
• excellent infrastructure (laboratories, equipment and operating dollars),
• strong provincial and federal government support,
The Saskatchewan ag-biotech cluster was born.
1Pages 67–76.
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• the potential for making money attracted multinational companies to locate some 
r&D capacity to Saskatoon [agrEvo (aventis, Bayer), Monsanto, Dow, DuPont/
Pioneer, etc.], and
• successful commercial products in the marketplace with significant revenue po-
tential.
Dynamic Clusters
Biotech clusters are not static; they are dynamic communities, constantly evolving. Our 
Saskatoon cluster is no different. The major opportunity for the cluster is to capitalize 
on our comparative advantages by identifying and pursuing opportunities at which we 
can be globally the best. In that regard, there are potentially huge opportunities in the 
emerging bio-economy. 
So, what is the bio-economy? From the perspective of ag-West Bio Inc. (aWB), the 
bio-economy simply involves creating and capturing value from “biological systems.”
The oval in Fig.  represents the genetic code of a biological system (plant, animal 
or microbe). Many tools, such those listed on the left side of Fig. , have evolved over 
the years to create value in biological systems for humankind. They include everything 
from naturally occurring biological systems without any modification through to the use 
of modern biotechnology to modify the genetic code to create value, such as herbicide 
Figure . a schematic showing how value is created and captured in the 
emerging bio-economy.
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tolerance in crops. after the research has been completed to create the value, advances in 
bio-informatics and analytical and bioprocessing technologies can be used to produce a 
range of products: from natural health products through to biofuels and bio-industrial 
platforms such as the corn-sugar based platforms [e.g. DuPont’s ,3 propanediol (PDO) 
(DuPont, 000), aDM’s polyhydroxyalkanoate (PHa) (Peterson, 006), and Cargill’s 
polylactic acid-PLa (Brady et al. 005)].
Strategies and Strengths
The challenge and the opportunity for each region are the ability to understand and to 
effectively exploit global comparative advantage. Our strategy at ag-West Bio for Sas-
katchewan is twofold:
• marketing our excellent bio-economic infrastructure, and
• identifying and targeting strategic opportunity sectors.
In terms of marketing the infrastructure globally, we promote ourselves as a solution-
provider:
Looking for reliable, quality ingredients, analytical or processing capabilities, 
innovative research, or a path to commercialization? From research to market, 
Saskatchewan offers the Solution! 
We have an extensive list of assets throughout the full spectrum of the research-to-
market value chain. These include a robust r&D capacity; analytical, bioprocessing and 
bio-informatics capacity; and support services and private industry. Examples of these 
assets include:
• Research and development capacity
 — Environmental technologies
 – Biological controls (weeds, insects and diseases)—U of S Department of 
Plant Sciences, aaFC-SrC, NrC-PBI, Saskatchewan Wheat Pool (SWP)
 – Biotic / abiotic Stress resistance—U of S Department of Plant Sciences, 
aaFC-SrC, NrC-PBI, SWP
 – Seed oil modification—U of S Departments of Plant Sciences and 
 Chemical Engineering, aaFC-SrC, NrC-PBI
 – Plant Pathology—U of S Department of Plant Sciences, aaFC-SrC, 
NrC-PBI
 — Bioenergy, bioproducts, renewable industrial feedstocks/biorefineries
 – Bio-energy/fuels—U of S College of agriculture and Chemical 
 Engineering, Petroleum technology research Centre (PtrC)
 – Bioproducts—U of S Departments of Plant Sciences and Chemical 
 Engineering, aaFC-SrC, NrC-PBI, SrC
 – renewable feedstock platform—U of S, aaFC-SrC, NrC, SrC
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 — Health and nutrition technologies
 – Human health and nutrition—U of S Department of Microbiology & 
Food Science, Colleges of Nutrition & Pharmacy and Medicine
 – animal health and nutrition—U of S Department of animal & Poultry 
Science, College of Pharmacy & Nutrition, Western College of Veterinary 
Medicine (WCVM), VIDO, SrC 
• Analytical and bio-processing capacity
 — Canadian Light Source Inc.
 — Innovation Place Bio-Processing Centre
 — Saskatchewan research Council
 — Phenomenome Discoveries
 — Saskatchewan Food Industry Development Centre
• Support services
 — Greenhouse/field trials—agQuest, ICMS, aaFC, Prairie Plant Systems, 
 Innovation Place
 — Diagnostics—Phenomenome Discoveries, Bio-ID, Prairie Diagnostics, CFIa, 
Genserve, Bovacan
 — Funding—aWB, Foragen, Golden Opportunities, agriculture Development 
Fund (aDF), NrC’s industrial research assistance program (IraP), Crown 
Investment Corporation (CIC), others
 — Economic development—aWB, Saskatoon regional and Economic Develop-
ment authority (SrEDa), Innovation Place, U of S Industry Liaison Office
• Private-sector companies
 — Environmental technologies
 – Inoculants—Philom Bios, Becker Underwood
 – ag-Biotech—Bayer, Monsanto, BaSF, Pioneer, Performance Plants, 
 Syngene, agrisoma, aDNadvance
 – Biocontrol—Heads-up Plant Protectants, Peacock Industries
 – Organic waste digestor—Clear-Green Environmental
 — Bioenergy, bioproducts, renewable industrial feedstocks/biorefineries
 – Biomass energy—Zelensky’s Saw Mill; Nipawin NewGen Co-op
 – Grain ethanol—Poundmaker, Noramera Energy, Husky, others planned
 – Fiber and composites—Biolin, Bio-Fibre Industries, Bio-Hemp 
 technologies, Hemptown
 – Biodiesel—Milligan Biotech, Saskatoon DSG 
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 — Health and nutrition technologies
 – Feed—MCN Bioproducts, GNC BioFerm, Guardian Phenomenome, 
Bio-ID
 – Health and nutraceuticals—Bioriginal, Fytokem, Emerald Seeds, Infra-
ready, BioNatCom, Bio-Diagnostics, Phenomenome, Bio-ID
In considering our general areas of strength, we look at some of the current global eco-
nomic drivers and consider how transitioning to a renewable bio-economy either solves 
problems or adds value in some way. Major global economic drivers that will be impacted 
by the transition to a bio-economy—where Saskatchewan can be a leader—are:
• energy
• health
• environment
In terms of bio-energy opportunities, Saskatchewan will be a major player in ethanol 
and biodiesel production. We also have the capacity to be a player in biogas and a bio-
mass-based hydrogen economy.
With respect to the environment, our renewable fuels will contribute to reduced 
greenhouse-gas production. We will develop alternatives to petroleum-based feedstocks 
for the production of a range of industrial and consumer products. These will be carbohy-
drate- and oil-based platforms. and we will continue to introduce biological alternatives 
to pesticides and chemical fertilizers.
We will also be a major player in bringing Canada’s healthcare system back from the 
brink. Currently, it is primarily a reactive system: one gets sick, goes to the doctor, gets 
some kind of intervention and gets well. When one looks at the skyrocketing cost of this 
system to our public treasuries and the age demographics of our population, clearly it 
is not sustainable. We believe that the future healthcare system will involve a shift to a 
more-balanced wellness model that will include better nutrition, better understanding of 
the relationship between the food that we eat and the benefit or disease that it may cause 
(nutrigenomics), diagnostic tools to understand disease predisposition, and the greater 
use of natural health products, nutraceuticals and functional foods. The Saskatchewan 
bio-economic cluster is well poised to exploit the agriculture- and nutrition-anchored 
wellness opportunity for the benefit of Canada.
Saskatchewan is evolving from a tool-based ag-biotech cluster to 
an outcome-based bio-economic cluster.
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In Conclusion
Saskatchewan is evolving from a tool-based ag-biotech cluster to an outcome-based bio-
economic cluster based on: 
• global marketing of the infrastructure (Solutions), and
• becoming a global leader in specific strategic technology outcomes:
 — energy
 — health 
 — environment
This is an extremely exciting time when agriculture and other renewable-resource-based 
sectors are undergoing transformational change. For agriculture, advances in science are 
creating opportunities for Saskatchewan to:
• develop innovative, environmentally sustainable production systems,
• reposition agriculture as part a wellness solution to the healthcare crisis in 
Canada,
• move towards energy security through the exploitation of biobased feedstocks,
• expand agriculture beyond traditional food and feed to include biobased renewable 
feedstock platforms for the production of industrial and consumer products, bio-
composites, natural health products, biochemicals and biopharmaceuticals, and
• facilitate the development of a number of biorefineries to maximize economic 
impact.
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as president and CEO of ag-West Bio, asHley o’sullivan 
is responsible for working with the board of directors to 
establish the strategic direction and focus for ag-West Bio 
in support of the growth of the bio-economic sector in 
Saskatchewan.
Born in Cork City, Ireland, he completed a BSc and PhD 
at the University College Cork before moving to Canada 
in 973 for a research associate position at the University of alberta in the Plant 
Sciences Department. at Monsanto Canada he was responsible for r&D in 
Western Canada. In 978, Dr. O’Sullivan joined the team at agriculture Canada 
and served as research head at the Lacombe research Station; assistant director at 
the Lethbridge research Station; Director of the Swift Current research Station; 
and director of the Saskatoon research Centre.
While with agriculture and agri-Food Canada, he obtained a wealth of interna-
tional experience as the Canadian principal advisor for the India Dryland Project 
in Hyderabad; managing a CIDa-sponsored research project at rio Grande do 
Sul, Brazil; and as research advisor to the Hebei Dryland Project in China.
O’Sullivan also spent a year as the managing director of CaBI Bioscience in 
the United Kingdom and has served on a number of management boards and 
advisory committees. 
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It is widely understood and even expected that commercialization of research coming out 
of university research laboratories should make strong positive contributions to economic 
development (e.g. Fischer, 005; Palmintera, 005). Moreover university-associated 
research parks, where they provide a favorable environment for research commercializa-
tion and growth and development of small companies spun out from university research, 
are often net contributors to the economy of their regions while serving to foster the 
university’s role of service and outreach. The story of the University research Park (UrP 
or “the Park”) in Madison provides an instructive case study of how favorable outcomes 
can arise from university-established parks focused on fostering commercialization of 
university research.
The operant word in the term “University research Park” is university. Without its af-
filiation with UW-Madison, UrP would be just another modern office park that may or 
may not house technologically innovative companies or companies focused on developing 
novel, cutting-edge products. research parks can and do exist without the involvement 
of a university but close proximity to, and association with, a research university greatly 
enhances potential for local economic growth while serving to enhance the development 
of emerging young companies that take up residence within the park.
From Equines to Economic Development:  
The Story of the University Research Park
allen J. Dines
University of Madison
Madison, WI
The story of the University Research Park in Madison provides 
an instructive case study of how favorable outcomes can 
arise from university-established parks focused on fostering 
commercialization of university research.
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Before moving to specifics of the UW-Madison and the UrP, we need to back up 
several steps to place the story in a twenty-first century economic development context. 
We live in a knowledge economy and it is commonly understood that the first step in 
the path to economic growth is new knowledge. For convenience, we borrow here from 
a characterization drawn from a publication of the Wisconsin technology Council in 
its Vision 2020 plan for growth for the high-tech economy in Wisconsin (Wisconsin 
technology Council, 00). In that report, the path from knowledge to growth included 
four major steps:
• New knowledge. Otherwise known as technology or more simply put: know-how. 
New knowledge is the raw material that drives the subsequent steps. It is the abil-
ity to do something—usually something that had not been done before, or not 
done before as quickly or cheaply.
• technology innovation. The key next step is the application of the knowledge to a 
practical problem to create a new and novel way of doing something.
• Competitive advantage. Competitive advantage is added to the mix when an in-
novation uniquely solves a problem better than other prior or current approaches. 
Implicit with competitive advantage is the understanding that someone is willing 
to pay to have access to this new innovative solution.
• Economic growth. This is the end-point of technological innovation. It is where 
the three preceding components come together to enable the growth of a sustain-
able business that expands the workforce, generates income for employees and 
wealth for investors.
New knowledge can come from anywhere. Similarly, technology innovation can arise 
from anywhere independent of the source of the new knowledge. But universities are 
fundamentally in the knowledge business. They transfer knowledge (primarily in the 
form of graduates from varied degree programs) and they create knowledge (in the form 
of research). Thus, it is not surprising that universities, particularly research universities, 
are associated with regions having strong economic growth.
the Essential University
Let us take the idea that today universities and economic development are, in fact, closely 
linked and go a step further. If we think about what a university is, it tends to be in terms 
of observable characteristic phenomena. For example, a university might be thought of as 
a collection of facilities—classroom buildings, lecture halls, laboratories, sports facilities, 
arts facilities, housing for students and offices for faculty and staff. On top of that view, 
we might layer a vision of a university in terms of its academics—a collection of programs 
related to degrees conferred, curricula, courses, the myriad academic departments that 
dispense teaching and learning. a university might also be understood in terms of its 
people—the faculty, students, staff and visiting scholars. For those in the research-associ-
ated fields, a university may even be thought of in terms of its research capabilities, its 
research accomplishments, its intellectual property and centers and institutes.
4 agricultural Biotechnology: Economic Growth Through New Products, Partnerships and Workforce Development
In light of our topic about the link between universities and economic growth, I sug-
gest a different approach about how to conceptualize a university. It can be thought of 
as a community where bright people come together to exchange ideas. In this view, the 
essence of a university is its role as a center to facilitate the free flow of ideas—a center 
where ideas are born and exchanged. In a knowledge economy, this phenomenon takes on 
special importance. The collective creative energies of actively inquisitive people associated 
with the university community generate new knowledge. That new knowledge, when 
channeled or facilitated by appropriate institutions, flows as a benefit to the local com-
munity and to society at large. The quantity and quality of the new knowledge generated 
is a function of the diversity of talent and expertise associated with the multiple schools 
and colleges that populate the campus. a great university is not just the sum total of the 
capabilities of its faculty staff and students in its component colleges. What distinguishes 
a great university is the synergistic excellence that occurs as a result of the co-location 
and cross-fertilization of so many talented and inquisitive people. One could argue that 
the broader the representation of disciplines housed at a university and the greater their 
skills, the greater will be the potential for creation of new knowledge.
This is important because innovations—the novel integration of new ways of thinking 
about “what we do” and “how we do”—are integral to growth in the twenty-first century 
economy. Therefore, universities—particularly research universities—are significant gen-
erators of new knowledge in an era in which innovation and incorporation of new ideas 
into business and industry are key to growth of the economy.
Then, if a university is in essence a place where people come together to exchange and 
create ideas, then how does one move from the knowledge to the economic growth? In 
other words, what of those other steps? The conventional view is that universities offer 
access to research and new knowledge. But that ignores the other steps needed to produce 
those economic gains. Universities indeed generate new knowledge and provide access 
to their research through tech transfer. But new knowledge is not simply something that 
can be harvested like a ripe peach picked from a tree. New knowledge requires the ad-
dition of innovation and creation of competitive advantage to fulfill its potential. The 
value of a great university is that the convergence of open and inquisitive minds typical 
of that environment serves as a magnet to draw other creative types seeking high-energy 
settings that are open and creativity-friendly. These environments span the arts, culture 
as well as science and they involve entrepreneurs and others who seek opportunities in 
novel ideas.
UW-Madison Snapshot
My first major point is that the university is a key part of a university research park and 
the story of any university-affiliated park is inherently tied closely to the resources, capa-
bilities and culture of its affiliated university.
The story of any university-affiliated park is inherently tied closely 
to the resources, capabilities and culture of its affiliated university.
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as one of the nation’s premiere universities, the University of Wisconsin-Madison fits 
perfectly the above described model of a university community as a magnet for ideas. UW-
Madison offers a broad array of human and educational resources that serve to enrich the 
immediate surrounding community, in this case the city of Madison and the other cities 
and towns that comprise the greater Madison area. The tremendous research advances 
and business resources originating from UW-Madison benefit the local and regional 
economies, impact business development in the state, and provide an ever-growing base 
of knowledge and human capital to Wisconsin. a recent economic study found that the 
UW-Madison has a $4.7 billion economic contribution to the regional economy (Win-
ters, 00). to provide an understanding of the size and scope of the UW-Madison as a 
major institution of higher learning and as a contributor to innovation and technology 
commercialization, consider the following: 
• UW-Madison is ranked as seventh best public university in the United States 
(004)
• More than forty UW-Madison academic programs are ranked in the top ten 
(005)
• 005 total student enrollment was 4,480
 – Undergraduate: 8,458
 – Graduate: 8,84
 – Professional: ,533
 – Special students: ,648
• UW-Madison consistently ranks in the top five nationally on doctorates con-
ferred; Harvard ties UW-Madison in having fifteen grads as CEOs of S&P 500 
companies, according to Bloomberg Markets Magazine.
The University of Wisconsin-Madison ranks fourth among research institutions na-
tionally according to 005 figures available from the National Science Foundation, with 
$7 million in r&D spending. UW-Madison has been engaged in research for a long 
time and key accomplishments over the past 00 years include:
• First test of butterfat content in milk (890)
• Discovery of vitamin a (93), vitamin B (96) and methods to enrich food 
with vitamin D (94) 
• Methods to iodize salt (930s)
• Blood anticoagulants (coumarol, Warfarin) (95)
• First bone marrow transplant (968)
• Creation of the first synthetic gene (970)
• Vitamin D derivatives (97)
• Nation’s first on-campus blood-donation center (973)
• MrI imaging technology (985)
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• Organ transplant solution, used in transplant surgery (989)
• Vitamin D analogues (990s)
• Human embryonic stem cells (998)
The university continues to build on its research excellence. In early 006, it announced 
additional commitment of $50 million, with $50 million each from the Wisconsin 
alumni research Foundation (WarF), the state of Wisconsin and UW-Madison alumni 
John and tashia Morgridge, for the creation of the Wisconsin Institutes for Discovery, a 
public-private research partnership. The private side of this partnership is the establish-
ment of the Morgridge Institute for research modeled on successful research centers on 
the east and west coasts, such as the Whitehead Institute at MIt and the Clark Center 
at Stanford.
In an opinion column by Carl Schramm, President of the Ewing Marion Kauffman 
Foundation, UW-Madison was named as one of the top-five universities in the United 
States for its ability to work proactively with industry (Schramm, 005). This is signifi-
cant because a frequent Schramm thesis is that many university innovations are either 
mired in outdated and inefficient policies or are paralyzed by lack of skills and resources 
needed to apply them. 
UW-Madison has also been long active in generating spinout companies based on uni-
versity research and innovation. UW-Madison technology commercialization has resulted 
in formation of more than 8 new companies with connections to the university. One 
hundred and fourteen of these are direct spin-offs due to UW research, 04 are located in 
the City of Madison, which collectively generate more than $ billion in gross revenues 
and employ 6,700 people.
technology transfer and commercialization at UW-Madison rests with three organiza-
tions:
• WarF
• OCr (Office of Corporate relations)
• UrP
The Office of Corporate relations is the front door to the university for business and 
industry, helping companies access those university resources that can make a difference 
in building their businesses and strengthening their competitiveness. It is organized 
within the chancellor’s office, therefore its operational scope is campus-wide, and it 
serves principally to connect business and industry with resources of the university in 
the following areas: 
A frequent Schramm thesis is that many university innovations 
are either mired in outdated and inefficient policies or are 
paralyzed by lack of skills and resources needed to apply them.
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• Graduate recruitment
• Intern placement
• Continuing education and professional development
• assistance from faculty experts, sponsored research
• access to research centers and consortia
• assistance with International business issues and global markets
• transferring technology to the private sector
The Office of Corporate relations maintains a targeted communications program 
to strengthen recognition of the university by business and industry. Its mission also 
includes fostering growth of startup businesses based on university research. Through its 
New Business Startup Initiative, OCr works with nascent and emerging spinouts from 
the UW-Madison to assist in their growth and development.
The Wisconsin alumni research Foundation patents the discoveries of UW-Madison 
researchers and licenses these technologies to leading companies in Wisconsin, the United 
States and worldwide. Through licensing, WarF facilitates the use of UW-Madison 
research for the maximum benefit of society, business and industry. 
Unlike many university technology-transfer offices, WarF is an independent not-
for-profit foundation. Thus, it is entirely separate from the university and is not an 
organizational entity of state government. Founded by UW alumni in 95, WarF 
operates with the express purpose of benefiting research at UW-Madison and ranks in the 
top ten nationally on technology-transfer metrics almost every year. Currently, it makes 
royalty distributions to more than 300 faculty researchers. Beyond payments of inventor’s 
share of royalty proceeds, WarF’s annual gift to UW-Madison for the last several years 
has been in the $40–55 million range.
The Wisconsin alumni research Foundation operates with a staff of fifty and maintains 
a west coast satellite office in order to be closer to its customer base, which is substantially 
located in California’s life science sector. In 005, WarF was awarded the National Medal 
of technology, the nation’s highest honor in recognition of achievements in technology 
and innovation.
the University research Park
My second main point is that a university-affiliated research park is an excellent tool to 
facilitate the journey from new knowledge to economic development. The UrP is an 
internationally respected research and technology park, the approach and innovative ten-
ant solutions of which help encourage development and commercialization of new ideas. 
A university-affiliated research park is an excellent tool 
to facilitate the journey from new knowledge to economic 
development.
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The UrP’s mission is to encourage technology development and commercialization that 
advances the economy and benefits research and educational programs at UW-Madison. 
In fulfilling this mission, the Park serves to provide the physical lab and office space 
where faculty- and staff-based start-up ventures can take root and grow. In supporting 
this entrepreneurial activity, the Park is creating and building an asset for the UW-Madi-
son, stimulating growth of high-tech jobs in the Madison community and serving as a 
recruitment and retention tool for UW-Madison faculty.
Founded in 984, the Park was more than 0 years in the making and the subject of 
considerable debate by university leaders (Hove, 006). It is built on former university 
research land. The equines referred to in the title of this paper roamed the pastures that are 
now the Park. a small number of horses remain on the site today as part of a facility run 
by the UW School of Veterinary Medicine. tenants in the Park must have some relation-
ship with the UW-Madison and rents have always been at market rates. Strict building 
standards and green-space minimums are in place to assure that the Park remains an 
aesthetically attractive part of the City of Madison. Developments in the Park are limited 
to research facilities and corporate offices with no commercial or retail development. The 
Park is managed by a wholly separate 50 c (3) corporation. although the UrP, Inc., is 
an entity separate from the university, its staff members are university employees.
today the Park’s 55 acres are more than 90% built out with similarly high occupancy. 
Some .5 million square feet of space are under roof in thirty-four buildings, about half 
of which are owned by the Park. The Park pays $3.5 million per year in property taxes 
to the City of Madison based on assessed valuation of the properties of more than $60 
million. The Park’s 4 tenant companies employ more than 4,000 with an annual payroll 
of nearly $60 million.
Because a key part of the Park’s mission is the encouragement of commercialization 
of technology, significant effort has gone into the development of the Madison Gas and 
Electric (MG&E) Innovation Center as the centerpiece of the Park. The local electric and 
gas utility provided significant initial capital to build what has now grown to a 3,000 
square-foot facility providing wet-lab and office space, support equipment and person-
nel to tenant companies. The initial Innovation Center was opened in 989 in an early 
Park building with just 0,000 square feet. The current MG&E Innovation Center, now 
housed in its own building, opened in 999 at more than 50,000 square feet and doubled 
in size  years later. The Center is 00% occupied, with forty companies in eighty-five 
incubator suites. amenities include:
• UW Library access
• DS-3 data connection
• Nine conference rooms
• Dining commons
• admin support
• 4-hour access
• Shared lab equipment
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• Storage
• Machine shop
• Small animal facility
The early growth and success of the UrP have led to the development of a Phase  
location in Madison, which will provide over fifty building sites on 70 acres. The new 
site, 3 miles west of the Park, is also on land owned by UW-Madison and formerly used 
for agricultural research. When fully developed UrP- will be home to more than 00 
tenant companies with estimated employment of 0,000–5,000.
Conclusion
With more than 0 years of operating history, the Park has met its objectives in virtually 
every respect. In terms of economic development, several of the tenant companies of the 
MG&E Innovation Center have grown and moved on to occupy their own buildings 
in the Park or have moved to other larger facilities elsewhere in the Madison area. These 
include Third Wave technologies, tetrionics (now owned by Sigma aldrich), Pan Vera, 
(now owned by Invitrogen), Novagen (now owned by EMD Biosciences) and Epic Sys-
tems. The Park’s role in providing the physical facilities for startup companies to grow has 
served to foster commercialization of UW-Madison research while providing a recruit-
ment tool to attract new faculty. The growth of value of the Park properties themselves 
has created a vastly greater asset for the UW-Madison. Cash flows from Park operations 
are just beginning to enable UrP to make dividend payments back to UW-Madison to 
support research, much in the same way WarF has made annual gifts for years from its 
operations to support research at the university. 
More importantly, the Park has had a broad impact on the area as a whole by helping 
to grow Madison’s biotechnology industry and by contributing to the high-technology 
cluster that has emerged. In 004, Forbes Magazine called Madison a “Hot-bed of Bio-
capitalism” in its annual review of best cities for business (Badenhausen, 004). That year, 
Madison was named the number-one city under 500,000 population as a place in which 
to do business. During the initial years of operation of the Park, tenants were typically 
spinouts from the university. recently, the Park has come to the attention of companies 
interested in relocating to the Madison area because of the high profile of the university 
and the opportunities of being associated with the university research environment. al-
though the Park remains the single largest concentration of high-tech companies in the 
Madison area, the region is showing its growth and viability in that several other centers 
of high-tech company concentration are emerging there.
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For hundreds of years, universities in the various European countries have been the place 
to be for scientific developments. Science developed in an independent manner and 
research was financed by the respective governments supplemented with money from 
special funding bodies. The primary aim was to further the various scientific disciplines, 
to ensure that scientific knowledge was made available for colleagues and the public at 
large, and to educate and train students in thorough scientific methodology. all of this 
was almost totally separated from general economic development.
Development of the sciences has been extremely successful and scientific discoveries 
now form the foundation of economical development such as in the fields of chemistry, 
pharmaceuticals and biotechnology, and, more recently, in the food area. The latter has pre-
sented universities with a new challenge, which in the European context has been termed 
the “knowledge paradox”: developed knowledge cannot necessarily be put to work.
The question is how to combine the general task of informing society of relevant sci-
entific developments with applications for specific economic benefit. This has resulted in 
debate of whether universities should “go commercial” and, if they do, whether they still 
can fulfill their societal role adequately. In my view, these elements should not be con-
sidered contradictory but complementary. In many areas in which science plays a crucial 
role in economic development, the only way to create value from research findings is to 
bring them into an economic context by protecting them as intellectual property (IP). 
to develop an idea into a commercial product usually requires significant investment, 
which will be made by a company only if it creates specific commercial advantage such 
as a monopoly. Consequently, IP formulation and technology transfer are crucial to the 
achievement of societal benefits, through licensing patents. additionally, there are findings 
that will not be picked up by existing companies because the economical risk profile is too 
high or the business fit is insufficient. These findings can result in the establishment of 
spin-out companies that create the desired value. Universities can and should be actively 
engaged in such developments as part of their societal role.
Food for Innovation: The Food Valley Experience
Wim M.F. Jongen
Wageningen Business Generator
Wageningen, the Netherlands
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Food Valley as a Concept of thematic regional Networking
If we accept that science-based economic development is crucial for general economic 
development and competitiveness, then the question arises as to how to organize these 
processes. Food Valley, developed in the Netherlands, is an example of regional-cluster 
development. Originating from an initiative on the part of three local city councils, it 
has developed into a leading regional economic force as a result of collaborations with a 
clear thematic focus. 
Food Valley is needed for a number of reasons:
• to create a network for innovation and business
• to provide solutions for the knowledge paradox
• to create flexible responses to changing market dynamics
• to develop new markets for knowledge application
• to create new jobs
Food Valley is an example of regional-cluster development. 
Originating from an initiative on the part of three local city 
councils, it has developed into a leading regional economic force 
as a result of collaborations with a clear thematic focus.
Figure . Food Valley as a regional concept.
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The agri-food complex is an important economic pillar of the Dutch economy and 
the aim of Food Valley is the creation of a network for innovation and business involving 
companies, research institutes, experimental facilities, incubators and public-private-part-
nership based r&D programs. The focus is on food, health and nutrition. 
The Food Valley organization consists of a small office and a consortium of more than 
sixty companies that participate in collective activities. The organization set itself the 
following targets for the first 4 years: 
• to attract three major r&D centers to the area
• to establish twenty-five r&D-based companies
• to create twenty-five new innovative r&D projects
• to create 500–800 new jobs
Wageningen Ur as a Leading Carrier for Development
Food Valley is in Wageningen at the same location as the offices and laboratories of Wa-
geningen University and research Center (Wageningen Ur). Wageningen Ur, which 
provides education and generates knowledge in the fields of life sciences and natural re-
sources, is a collaborative entity involving Wageningen University, the Van Hall-Larenstein 
Polytechnic and specialized research institutes belonging to the DLO foundation, formerly 
under the Ministry of agriculture. This combination of knowledge and experience has a 
staff of 6,500, a student body of 9,000 students and 86, 500 alumni.
Wageningen Ur is a leading European academic and contract research organization. 
among the top three in the worldwide publication index in the field of agriculture, it 
comprises:
• research
 — agriculture/food-wide portfolio of expertise
 — The continuum from academic to applied research
• Education
 — University (BSc, MSc)
 — Graduate schools (PhD)
 — Polytechnic institute
 — Business School for Life Long Learning
 — Wageningen International, for international products and services 
• Commercialization
 — research Institutes for Industrial Contract research
 — Wageningen International for institutional collaboration and capacity 
 building 
 — Wageningen Business Generator for IP and spin-out companies 
Its central mission is To explore the potential of nature, to improve the quality of life.
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In general, the ways in which scientific developments are commercialized can be char-
acterized by a number of features that add up to the so-called “Wageningen approach.” 
a basic element is that complex problems are addressed using a systems approach. Wa-
geningen Ur’s objective is to impact economic development via research and education 
in the life sciences. Innovation is key. a basic feature of many r&D programs is that 
technological aspects are studied in their societal context to provide not only solutions 
that work but also insight into the possibilities and/or limitations for implementation 
of new findings. 
Wageningen Ur policy includes being open to strategic alliances within Europe and 
globally. 
New initiatives in Food Valley: the Framework of PPPs
The networks of dedicated players within Food Valley and Wageningen Ur recently have 
resulted in a number of new activities, such as the Wageningen Center of Food Sciences 
(WCFS), a virtual research institute. The WCFS has been selected as a focal area for 
increasing the competitiveness of the Dutch economy. Financed by a conglomerate of 
industries, the government and research institutes, with an annual budget of €5 million, 
it carries out a selective number of so-called “pre-competitive” research programs. 
Comparable initiatives are underway in the areas of biobased technology, bio-nano 
technology and green genetics. In addition, the government has established a total of 
five genomics-based research programs, two of which are under the auspices of Food 
Valley, namely Nutrition Biology and Systems Biology. a characteristic of all of these 
activities is that industrial participation is a prerequisite, not only intellectually but also 
financially: public-private partnerships (PPPs). Thus, strong foundations are laid for 
future innovations.
A characteristic of all of these activities is that industrial 
participation is a prerequisite, not only intellectually but also 
financially: public-private partnerships (PPPs).
Pre-Seed activities: Making Science Work
One vital element in connecting science and the economy is the question, “How can we 
make science work?” Of course, an important element is that through intensive collabo-
ration between existing industries and research institutes, the chances for innovation are 
increased and that the translation of science into products that can serve the market is 
taken up by companies. However, they will do so only if the product matches with their 
business plans and if the financial risk profile of the product is acceptable. In practice, a 
large number of potential opportunities are not explored and additional activities would 
be required to justify their exploitation. In addition, within the research environment 
in general, ideas are developed on the basis of individual activities that merit further 
exploration. 
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In general, academic researchers lack experience in translating ideas into products. This 
type of r&D requires a specialized environment. One advantage of Wageningen Ur is 
extensive experience in industrial r&D within its research institutes.
The development of new spin-out activities from academic research within Europe has 
stagnated in recent years. One important reason is unfavorable risk profiles for investors 
who consider these early-stage developments. For example, the promises of early biotech 
developments have simply not been fulfilled; appropriate analyses of the chances of suc-
cessful product development were lacking. Specific technologies were too immature to 
predict successful product development. Early-stage investors had no way of judging the 
state of affairs appropriately. On the other hand, the current situation provides opportuni-
ties for universities and research institutes. In principle, they can develop—or sometimes 
already have in place—the skills to become technological partners for investors. In future, 
partnerships between academia and early-stage investors may result in spin-out companies 
with greater potential for success.
Food Valley Consortium for Pre-Seed activities 
Within the Food Valley community, a consortium of partners for pre-seed loans has been 
set up to address these questions and to provide an environment that stimulates and 
facilitates commercialization. The consortium has selected a number of starting points 
for its work: 
• Bring initiatives together to create synergy 
• Unify patent policy and spin-out policy
• Provide a professional business environment with IP and legal expertise 
• Operate independently and be able to say no
• Have adequate risk management 
• Provide good funding capacity for pre-seed activities 
• Be a professional technology partner for investors 
Wageningen Business Generator has taken the initiative in setting up a consortium together 
with Oost NV, our regional development agency, the Food Valley Foundation and the 
Biopartner Center, our incubator. The aim is to build a sustainable structure that offers 
potential start-ups the means of developing ideas into commercial products. 
Wageningen Business Generator for Pre-Seed Developments
The Wageningen Business Generator (WBG) was set up by the board of Wageningen Ur 
to create an environment for conversion of knowledge into commercially viable prod-
The Wageningen Business Generator was set up by the board 
of Wageningen UR to create an environment for conversion of 
knowledge into commercially viable products.
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ucts. It operates independently and creates economic value from science in the agri-food 
domain by identifying and selecting ideas with business potential, guiding them to the 
market place. In other words: making science work. 
The WBG consists of a small team of domain-specific investment managers responsible 
for scouting and screening ideas and inventions that have business potential. at the same 
time, the investors are responsible for IP development at two levels. Operationally they 
assist in IP formulation based on ongoing research, the regular technology-transfer work. 
Strategically they work on IP development in a selected domain to build technology 
platforms. also, WBG can provide expertise in legal and financial matters. 
annually, WBG aims to set up three to six new companies based on discoveries and 
findings from research within Wageningen Ur. 
target Groups of the Consortium 
The activities of the Food Valley Consortium have a regional focus, targeting two 
groups
• Inside Out—Spin-out activities from academic research, contract-research organi-
zations and companies
• Outside In—Individual techno-starters within the agri-food domain unconnected 
to a Food-Valley organization
and services include:
• Coaching—to create successful spin-out companies neophytes are connected 
with experienced business coaches for advice and support 
• Finance—Pre-seed loans are available to entrepreneurs who have the ambition to 
translate a business opportunity into a business plan, up to €300,000
• Facilities—Wageningen Ur provides access to almost every kind of equipment, 
with housing infrastructure made available at reduced fees
• Patenting—Professional assistance is available for development of adequate IP 
positions in the agri-food domain.
From Science Via Skill to Profit: the Process 
Figure  provides a schematic of the process. It is important to note that, at various stages, 
independent expert judgment is brought to bear, to determine whether the situation is 
“go” or “no go”: at the level of the business challenge, at the start of the business case and 
at the start of the company.
When a business opportunity is screened, the project team makes an intake analysis. 
Following a positive decision, a “business challenge” is made. The initiator has to organize 
a team to prepare and participate in the business challenge and to prepare the plan, taking 
into account the technology, market, business model, benchmark, etc.
For the business challenge, which is a -day session, each team is assigned an expert to 
help explore their idea or invention; other experts are available for consultation in specific 
areas such as IP, financial aspects, etc. Each part of the session closes with presentation of 
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the result. at the end of the entire session, the experts evaluate their findings and observa-
tions. Their opinion forms the basis for the selection process. 
The business case is that part of the process in which the initiators have to achieve “proof 
of concept” (business development) for the product they want to put on the market. That 
can be an r&D period—maximum of 8 months—the establishment of an appropriate IP 
position, in general whatever is needed to reach the stage of proof of concept. at the same 
time they have to write a business plan that can be presented to investors. This approach 
increases the chances for successful spin-out companies: Quality above Quantity.
the Pipeline and Some Experiences
The Food Valley Consortium initiated activities early in 006; so far, fourteen business pro-
posals have been received, ranging from production of industrial oils from plants through 
molecular diagnostics for fresh produce to mucosal application of multivalent vaccines. 
This confirms that the agri-food pipeline is very good source of spin-out companies. 
The “proof of concept” approach works well, and it has become clear that it is attractive 
to investors. Many informal investors and regional development agencies value the concept 
of a technology partner willing to invest. Generally, with better economic prospects, it 
seems that the investment climate is improving. 
The Food Valley concept stimulates the development of an entrepreneurial climate and 
regional developments in general, primarily because it is organized around a theme and 
its activities are recognizable and transparent for possible business partners. It certainly 
helps that Food Valley wants to be a leader for Europe as a whole, within the agri-food 
domain.
Figure . a schematic of the commercialization process.
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Several lessons have already been learned:
• Be patient: it takes 5–7 years to build a company
 – Managers have to realize that success from these activities takes time. return 
On lnvestment (rOI) is, of course, a prerequisite, but it can take longer than 
the longevity of the average manager.
• To make money you have to invest money 
 – tech-transfer offices are in operation in many European universities; their 
success is often hampered by lack of investment funds.
• Build trust among scientists 
 – In academia, success is often defined by the quality of research dictated by a 
group leader. In the process of commercialization release of control is often 
necessary; it is of vital importance that the scientist(s) responsible for the 
original discovery or invention trust(s) the organization.
• Create a professional environment for business development (proof of concept)
 – Further to the previous lesson, trust is built by creating a professional 
environment in which targets are met, with good communication between 
scientists and administration. 
• Be rigorous in decision-making 
 – Communicating a “no go” is always difficult; it causes disappointment and 
frustration, not least because scientists are trained to be creative in finding 
solutions for problems as they arise. However, for business creation, market 
potential is the deciding factor, not problem solving.
• Partnering helps 
 – Input from external industrial experts for coaching and evaluating the 
business-creation processes and results is crucial. They introduce relevant 
experience and alternative perspectives into the process.
• Regional support is most helpful 
 – The networking approach, part of the regional concept, is very useful. 
Innovations are rarely created in someone’s attic; they result usually from 
multi-disciplinary interactions.
For business creation, market potential is the deciding factor, not 
problem solving.
30 agricultural Biotechnology: Economic Growth Through New Products, Partnerships and Workforce Development
wim jongen began his career as a technician at the former 
Institute for Insecticide research in Wageningen, Holland, 
in 97. In January 975, he moved to the toxicology De-
partment of Wageningen University where he became an 
assistant professor in 985. He obtained his PhD in 988 
and took a postdoctoral position at the International agency 
for research on Cancer in Lyon, France. 
at the 990 founding of the agrotechnological research Institute (atO-DLO) 
in Wageningen, Dr. Jongen became head of the Post Harvest and Product Quality 
division and in 994 was appointed professor of Integrated Food technology. In 
999 he became professor of Product Design and Quality Management while 
serving as research director of atO-DLO.
In 00 he was appointed director of Business Development in the animal 
Science Group, responsible for contract research, the IP portfolio and spin-off 
companies. Since January 005 he has served as director of the Wageningen Busi-
ness Generator, an affiliate of Wageningen University, responsible for development 
of the corporate IP portfolio and maximizing the impact of research through 
building business ventures. He also acts as chairman of the board of the Food 
Valley Group for pre-seed activities in building business ventures.
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The Chinese view of university-based research parks contrasts with what is happening 
in the United States and in Europe. When I returned from america after receiving my 
PhD from Washington University, I became a professor at Beijing University and later 
department chair and then vice president. For 7 years as VP, I was in charge of busi-
ness development and ours became the largest university in China—possibly in the 
world—for such enterprises. Visitors to Beijing University are surprised to see that the 
scope of the business enterprises we run. They are not spin-off companies; they belong 
to the university.
High tech Defined
The Chinese government has delineated eight high-tech areas:
• information technology,
• biotechnology, 
• space, 
• lasers, 
• automation, 
• new materials,
• new energy and 
• ocean technology.
The strategy for promoting these high-tech areas was borrowed from Silicon Valley 
and route 8 around Boston, and later triangle Park in North Carolina. The effort was 
initiated in 99, when government investment was significantly increased and domestic 
and foreign (United States) venture capital was sought to encourage new businesses. tax 
preferences was instituted: high-tech companies pay no tax for 3 years, then 50% tax for 
the following 5 years. and new policies were instituted to attract talent from the United 
States, including entrepreneurs.
Innovation: The Chinese Experience
Zhanglian Chen
China Agricultural University
Beijing, China
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Professors as CEOs
The most important aspect of the strategy is that the Chinese government has, since 
99, encouraged university professors to form and run their own companies. Even in 
public universities, a professor can own shares, act as CEO or chair of the board and run 
a company using her/his own lab technology. This is very different from the situations 
in Japan and the United States—the Chinese government has gone significantly further 
than the US Bayh-Dole act.
Our model is similar to the relationship that Stanford University has with Silicon 
Valley—from which we learned a great deal—using campus land for high-tech company 
infrastructure and receiving profits for reinvestment. 
In 999, the government granted building permission for the first university-associated 
science park. Since then, fifty have been constructed. 
Beijing University Park
Plans were initiated in 99 when I was a department chair and dean. The college re-
ceived rMB400,000 (US$400,000 in purchasing power) from the university to form a 
high-tech company. The company groups formed included the Founder Group, which 
now controls 9% of newspaper printing technology; the Weiming Group is one of the 
largest biotechnology companies in the country; and the Science Park Group. The total 
assets of the Beijing University Enterprise stand at US$3.5 billion.
The Chinese government has, since 1991, encouraged university 
professors to form and run their own companies.
Six companies controlled by the Chinese agricultural University are now listed in 
the stock-market, three in Hong Kong and three on mainland China, in both Shenzhen 
and Shanghai. revenue started to accrue in 998 with US$900 million; the total was $3 
billion at the end of 005. This rapid financial success was not expected. The businesses 
run the gamut from computer chips to recombinant DNa. 
I formed a company in 99, using recombinant DNa technology to produce inter-
feron-alpha b. This drug was chosen as treatment for hepatitis C, which is a particular 
problem in China, and this was the first company to produce interferon-alpha b 
Six companies controlled by the Chinese Agricultural University 
are now listed in the stock-market, three in Hong Kong and three 
on mainland China.
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 domestically. In addition to being department chair and dean of the college, I was CEO 
and chairman of the board and the company developed rapidly and soon was the main 
producer in China of interferon-alpha b. We obtained investments from Hambrecht 
& Quist, San Francisco, of about US$0 million. It is a joint venture: we have a 5% 
share and they 49%. We are still the largest producer of interferon-alpha b in China. 
as it is such a large operation, we have come in for some criticism as a public university 
company.
Xinghua and the Chinese agricultural Universities
China’s second largest university, Xinghua University, had business revenues totaling 
rMB.8 billion in 004. I am now the president of the Chinese agricultural University, 
and we have about twenty-five companies. One is listed in the Shenzhen stock-market. We 
have two major businesses. One professor bred a new variety of corn—CaU08, now the 
most widely grown genotype in China—which, through this company, is 00% owned 
by our university. It occupies 5% of the area planted to corn. In a sense, the university 
has become a seed company like Pioneer. 
another professor has bred a new type of chicken—#3 Hen—which consumes much 
less feed than other varieties while maintaining productivity. approximately 3 million 
of these chickens are consumed each year. The Chinese agricultural University’s company 
assets increased seven-fold from 000 to 005. 
Part of the company profits are returned to the host institution. about rMB63 million 
were returned to the agricultural University last year, and it increases yearly. as president, 
I use these so-called “free” funds (because they did not come from the government) to 
subsidize professors’ expenses, to finance research and/or teaching or otherwise fulfilling 
institutional needs. 
about 4,500 companies belong to Chinese universities, of which about 50% are high 
tech. The total annual revenue was US$ billion in 004. accordingly, university com-
panies pay significant taxes to the government, rMB4.8 billion in 004. Some of these 
levies are being used to improve China’s patenting system and to enforce protection of 
intellectual property. 
Fifty percent of patent applications in China are from foreign countries. Japan is 
the leader at 9%, then the United States, South Korea, Germany, Netherlands, France, 
Switzerland, United Kingdom, Italy and Sweden. Of patent applications from within 
China, Xinghua University is the leader, then Beijing. Some ,00 applications in 005 
came from the top-ten universities. Universities in Beijing account for about 0% of 
patent applications.
About 4,500 companies belong to Chinese universities, of which 
about 50% are high tech.
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Challenges
Universities will continue to play a very important role in high-tech business development 
and innovation, making major contributions to a knowledge based economy in China. as 
mentioned, Beijing University now has the largest printing-technology company and the 
biggest for PC producer after Legend/Lenovo computers. and the Chinese agricultural 
University has one of the biggest seed companies. The trend will continue; more university 
companies will be formed and will merge according to marketing patterns.
Management is possibly the biggest challenge. When I left Beijing University as vice 
president, the annual revenue was US$  billion; I had to oversee six companies, including 
attending their quarterly board meetings. Professors running these companies made large 
amounts of money, some of which they gave to their best graduate students. Sometimes 
this created tension not only among the graduate students, but also among the faculty as 
more money was to be made in computer science and biotechnology than in mathemat-
ics or literature, for example. There is no easy means of managing this problem. Perhaps 
eventually lessons from the United States will be learned and spin-off companies will 
be formed. On the other hand, visiting presidents and other representatives from US 
universities, after expressing surprise, sometimes suggest that the Chinese system should 
be adopted in the United States.
Professors running these companies made large amounts of money, 
some of which they gave to their best graduate students.
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ZHangliang cHen—a pioneer in genetic engineering of 
plants—received his PhD in roger Beachy’s laboratory at 
Washington University, St. Louis, in 987. He has served 
as vice president of Peking University and as director of 
the China National Laboratory of Protein Engineering and 
Plant Genetic Engineering, one of China’s largest centers 
for r&D in agricultural biotechnology. actively involved 
in biosafety issues, he is a member of the China National agrobiotechnology 
Biosafety Committee, which approves field trials and commercialization of 
genetically engineered crops. He has (co)authored seven books and some 00 
research papers. 
Dr. Chen has been the president of the China agricultural University since 
003. He also serves as chair of the Plant Biotech Committee of UNESCO, as 
a consultant for the International Society for Plant Molecular Biology, and as a 
member of the Sino-Euro administration Committee for Biotechnology Coopera-
tion. He was recently elected vice chairman of the Council of Scientific advisers of 
the International Center for Genetic Engineering and Biotechnology in Italy.
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Clifton Baile (University of Georgia): Dr. Chen—very interesting story. One thing I didn’t 
understand was the equation that’s used in distributing the profit to the university and 
to the founding professor.
Zhangliang Chen (China Agricultural University): This was a difficult decision because 
technology differs from department to department; for example, information technol-
ogy and biotechnology are very different. actually the policy came from the University 
of North Carolina and Duke. We decided that 5% goes to the inventing professor, 0% 
to the department or college and the rest to the university. Later, professors complained 
that they deserved more as did departments/colleges. So, we changed it, with 40% to 
the university and 60% shared by the research group and the department/college who 
decide how it should be distributed. Some departments decided that the money they take 
will be distributed equally among the professors who have no marketable technology, to 
provide balance. Different departments have different policies. Other universities may 
have different policies.
Cholani Weebadde (Michigan State University): When the departments decide to give the 
funds equally to the professors doesn’t the inventor complain again because he gets an 
equal share?
Chen: No. The inventor gets more money, 5% or 0% for himself. The department chair 
distributes the rest to the people who have nothing to do with that technology otherwise 
it causes lots of problems.
Function and Role of University-Based Parks  
In Economic Development
Q&A
Moderator: Steven Pueppke
Michigan State University
East Lansing, MI
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Bob Seem (Cornell University): In support of the companies that are involved in your vari-
ous institutions and organizations, do you treat the biotech companies any differently? Do 
you provide them any special services? What sort of services might those be, or kinds of 
advice and assistance that might be provided when the path to market is more difficult?
Allen Dines (University of Wisconsin): In Madison, the University research Park is one of 
the few places that actually builds out wet-lab space ready to go for early-stage companies. 
In that sense, we do provide special assistance for biotech companies. typically, the track 
to profitability, the track to products on the market, is a lot faster in It for example, 
so we tend to see most of the biotech companies locating at places like the research 
Park. at our campus, we have a strong life-science component so we mostly see biotech 
companies coming from the campus. In fact, some of the It folks in town get frustrated 
because they think that there is more attention to, and favors for, the biotechs. However, 
my sense is that, other than the availability of that wet-lab space, no special programs 
favor the biotech world and our investors in the Madison area are more interested in the 
life-science and healthcare side than they are in It.
Ashley O’Sullivan (Ag-West Bio, Inc.): In Canada, the companies that we deal with particu-
larly through our investment fund—one of the big issues is money and lack of money. 
These companies live on a day-to-day basis. The CEO of the company usually spends a 
lot of time trying to figure out how they are going to survive past 3 months from now, 
because that’s all the money they have in the bank. So money is a big issue and we help 
them through the early stage through the high-risk investment and that “valley of death” 
space and then we help them to source other capital to begin to move towards the mar-
ketplace. The other area in Canada that is a major issue in the life sciences is regulations. 
Our regulatory system simply does not work and most of our small companies look to 
the United States first as their market because your regulatory system is easier to get 
through and the market is larger. We are in the process of providing enhanced regula-
tory support, to the point of working with the Canadian regulators to try to introduce 
the new “smart” regulation concept that we have in Canada. and the third major issue 
for our small biotech or life-science companies is management. We find that a lot of 
the companies we invest in are technically sound, they are scientifically sound, but they 
don’t understand the marketplace. They don’t understand competition. and they don’t 
really understand how to manage a company and work on the quickest path to revenue 
generation, targeting their most appropriate market opportunities. So, we help them to 
identify appropriate management to help them be successful.
We find that a lot of the companies we invest in are technically 
sound, they are scientifically sound, but they don’t understand the 
marketplace.
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Wim Jongen (Wageningen Business Generator): We don’t make any distinctions in terms of 
type of companies. It’s noteworthy that a number of the companies that have human ap-
plication come from veterinary science; it seems that veterinary biotech is a nice platform 
for human applications. We invest in pre-seed, we invest money, also on a case-by-case 
approach we might co-invest at an early stage to maintain a shareholder position because 
we want to be active shareholders. In addition we encourage the use the name of the 
organization, Wageningen-Ur, as a way to facilitate things in the market. But, at the end 
of the day, the market should do its work.
1Wisconsin alumni research Foundation.
Chen: It seems to me there should no difference in terms of investment in biotechnology 
or It or other areas; a capitalist will invest where money can be made. However there 
are difficulties with plant biotechnology. Investment in plant biotechnology in China is 
very limited. It is supported only by the government mainly because of regulatory aspects. 
as I mentioned before, the commercialization of GM rice remains pending, therefore it 
is hard for capitalists to justify investing in biotechnology and agriculture. In contrast, 
investment in pharmaceutical biotechnology is a hot area.
Ken Swertzel (North Carolina State University): a couple of things I’d like to comment 
on and then I’d like to ask the panel to comment on conflict of interest and conflict of 
commitment. I’m not so sure that the model in China is so different from the model we 
have here in the United States. I see us coming together. We certainly have faculty that 
start companies. We certainly have universities taking equity shares. So universities are 
owning pieces of companies. We see university faculty staying within the university while 
they run those companies, and I see those companies investing back into the university 
in a variety of ways. So, I’m not so sure we are so far apart. Its just more semantics. It 
seems to me like the bottom line is how you manage the conflict of interest, the conflict 
of commitment, how you manage dissemination of the information relative to the news 
media, your state supporters and, of course, the rest of the university community. I’ll be 
interested in your comments.
Dines: We have a special relationship because WarF1 is an independent entity. WarF 
is the entity that holds all of the equity in the start-up companies. The university has no 
equity, so that gives us a kind of a nice, clean starting point with respect to conflict of 
interest issues. For the most part, the conflict of interest we focus on is the individual 
conflict. The issue of institutional conflict is something that many universities have not yet 
waded into. There is a sense of recognition that there are potential pitfalls and problems 
in that area, but I think there is also the sense that they don’t want to kick the sleeping 
Investment in plant biotechnology in China is very limited.
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dog. Because WarF is separate, they can make arm’s-length decisions about whom they 
invest in and when they invest they really just simply take equity in lieu of cash for the 
license agreement. My sense is, there is a substantial difference in what Dr. Chen is talk-
ing about in China. as I mentioned, we do not actually form companies—not within 
the university, not even WarF. WarF takes an interest, but they always let the private 
sector, the founder, the inventor, pretty much take the lead. That’s what I have come 
to characterize as a laissez-faire approach to start-up development. In our institution it 
seems to be working fairly well that way. Our sense is, we don’t want our faculty to be too 
involved in the management of companies. We prefer to have them stay at the university 
and continue to do research. That’s what they are good at. typically, they are not all that 
good at building companies. So we would rather get the faculty person associated with a 
savvy investor and a savvy entrepreneur who knows how to put the company together.
O’Sullivan: From the Canadian perspective and from our own organizational perspective, 
we are arm’s length from the University of Saskatchewan. When we invest in spin-off 
companies from the university we are normally dealing with the industry liaison office, 
which is the arm within the university that licenses all the technologies and establishes 
the spin-off companies. From our perspective, in terms of our due diligence, we really 
would like to see the university professor continue with the company. The professor is 
the key man in the development of the technology and we need that sort of expertise in 
the company—working with the company—to make sure that it’s going to be successful. 
We may have to get the management expertise from somewhere else, but we really need 
the technical and scientific expertise. and then we expect that the university, through the 
industry-liaison office working with the individual professors, will manage any potential 
conflict of interest.
Jongen: In the Netherlands and in most European universities, we have a different approach, 
in part in that we are active in pre-seed activities working towards proof-of-concept and 
also early-stage investment. One of the reasons is that we don’t use governmental money to 
do that; we do it from special funds. My boss is not necessarily happy that the Wageningen 
Business Generator is the 00% shareholder. I’ll give you one example. Last year we had 
a vaccine-developing company in which there was disagreement between shareholders 
and I bought the shares from a shareholder so he could leave the company. Suddenly I 
had more than 50% of the shares so I had to consolidate, and this consolidation within 
the organization meant there was a multimillion-dollar loss. My boss didn’t like that so 
we are discussing the positioning of my organization. One of the things is that if you are 
near the university, the balance between representing public good and making money is 
better guaranteed than when you are more at arm’s length and making money is of higher 
priority. This is a discussion we are currently having in my organization. Professors can take 
equity in the company and it is their personal responsibility how they deal with that.
Chen: Conflict of interest is a public issue. It’s a public university, so on one side you 
have government money and on the other side you run a company. I visited North 
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Carolina State University because it was a pioneer in running enterprises. I also travelled 
quite often to Stanford and to the University of Maryland and to Japanese universities. 
In public universities, the possibilities of owning the shares or running a company are 
limited. But this is what we are doing in China. The people in society are unhappy that 
the university receives money from the government while faculty members take money 
from their companies. This creates some problem. There is also conflict of interest for 
the faculty because you are teaching graduate students while functioning as a CEO. It’s a 
difficult question. It’s an experiment, and we’ll see what happens in due course.
Allan Eaglesham (National Agricultural Biotechnology Council): In the various entities 
represented by the speakers, to what extent is optimization of public perception of GM 
given emphasis?
Dines: In the early 980s, Madison was the home of the two biggest agricultural biotech 
company developments. Cetus Madison located there, and after a deal with Wr Grace 
they became agracetus and about the same time agrigenetics got started there. You might 
have noticed in my talk I didn’t say much about the agricultural biotech component 
in Madison. We do have a very strong agriculture school—agriculture and life science, 
animal science—but because of where the seed money has gone, it’s hard to find a true 
agricultural start-up or early-stage company in Madison. That’s changing a little bit. We’ve 
got an angel investment group now that’s focused expressly on food and agriculture.
to answer your question we have people on the campus that certainly address the policy 
issues associated with GM-based products. That hasn’t been much of an issue in Madison 
for the companies. I had an interesting conversation with ralph Hardy last night at dinner. 
I was at agracetus at the time they did the first field test of the genetically modified plant 
and I managed that test from the regulatory and business sides, Similarly, Biotechnica, 
did the first test of the genetically modified microbe, on the other side of Madison. Both 
of those field-test locations, for what it may be worth as a little factoid for cocktail party 
conversation, are now business parks. I’d like to say research parks, but I don’t think it’s 
quite true. But they are certainly business parks. a big UPS distribution facility has gone 
up on one of those sites. So, for what that may mean, I guess the whole idea of geneti-
cally modified field-testing going on in Madison, which actually has a tradition of being a 
very activist and liberal community, was managed very well. We dealt with the regulatory 
people. We dealt with the public-perception issues and basically it came out very positively. 
Now, pretty much everybody has forgotten about it, but the fact is there are two fairly 
historic sites right there, within a few miles of the UW-Madison campus.
There is conflict of interest for the faculty because you are teaching 
graduate students while functioning as a CEO.
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O’Sullivan: In Saskatchewan and in Canada I think we are over the worst in terms of 
public perception of GM. The rough period that we went through was the late ’90s and 
early 000. My sense is that the new technologies are fairly well accepted. We have a 
long track record. as you heard, 90% of our canola is GM. Nobody has grown a third 
hand or a second head. There is a strong belief that our regulatory system in Canada is 
protecting the public. It’s probably leaning too far on the one side. We need a regulatory 
system to protect the public and the environment but also to be an enabler of innova-
tion; that’s a key piece. We are working with the regulators on that. So, we are really in 
a reactive mode now. If we see something that clearly is erroneous in the media or in the 
literature, we react to that as opposed to being proactive on it. Within Canada, there is 
a $. billion initiative under the auspices of Genome Canada and a number of genome 
centers have been established—six of them now across the country—and within that is 
an initiative that deals with ethics, law and society. Those folks are looking at societal 
issues, legal issues and acceptance issues around GM technology. So, a fair bit of work is 
going on in the academic community at least, to understand the issue and to make sure 
we don’t repeat some of the problems that we’ve had with biotech in Canada. The major 
thing for us at the moment is still the markets and the acceptance of our products in 
markets, and Europe is still the major issue in terms of GM canola. But I think the tide 
is turning, even in Europe.
We need a regulatory system to protect the public and the 
environment but also to be an enabler of innovation.
Jongen: The European perspective on GM was discussed by Peter Welters. The situation 
in the Netherlands is not much different from the German perspective. When we act in 
these matters we try to be transparent. Just tell what you are doing. This is one thing. 
and secondly, as mentioned already, sometimes you rename things to prevent spoilage of 
discussions. You use different names to explain what you are doing. We follow a similar 
approach in large programs, as described for the genomics program in Canada. We have 
a separate program on societal impact discussions; at the initiation of large programs that 
start, we look the societal context and what problems can be envisioned. Lastly, I am 
less pessimistic for the mid/long term—I see a shift in the public perception also in the 
European context towards the good side.
I see a shift in the public perception also in the European context 
towards the good side.
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Chen: Public perception for GM in China, mentioned before, is quite confusing. after I 
returned from roger Beechy’s lab, when I finished my PhD, my own lab carried out the 
first field trial in China with transgenic tobacco and transgenic tomato, against cucumber 
mosaic virus and tobacco mosaic virus, both of which severely affect tobacco production. 
When the experimental area reached a couple thousand hectares, a problem arose. The 
Phillip Morris Company stated its refusal to import leaves from GM plants in China. 
Therefore, we stopped that work. and then for tomato, one difficulty is that farmers keep 
seeds. So, in 000, we formed a company by ourselves in Beijing University using GM 
technology and invested a couple of million rMB. But we got nothing out of it because 
of lack of market demand. today it is very difficult to invest in the GM area. Monsanto 
in China produces about 0% of transgenic cotton seeds. We don’t have much money 
invested in GM—it’s very confusing at the moment.
The Phillip Morris Company stated its refusal to import leaves 
from GM plants in China. Therefore, we stopped that work.
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The Small Business Innovation research (SBIr) Program is a national competitive funding 
program, authorized by the United States Congress in 98 to stimulate and facilitate 
research and development by US-owned and operated for-profit small businesses. all 
executive-branch departments with extramural research budgets exceeding $00 million 
are directed by legislation to provide a .5% set-aside to fund SBIr programs. Small 
businesses are defined as having 500 employees or less.
The United States Department of agriculture (USDa) Cooperative State research, 
Education, and Extension Service (CSrEES) manages the SBIr Program. The USDa-
SBIr Program awards only grants. It is a three-phase program. Phase I is a feasibility 
(proof-of-concept) study, and for FY007 the grant may be for eight months for up to 
$80,000. Successful Phase I award winners are eligible to apply for Phase II funding. 
Phase II proposals are for a full r&D project leading to the development of a working 
product, process, or service that will be ready for final commercial application in the 
private sector. For FY007 Phase II awards are for up to 4 months and up to $350,000. 
Phase III is the actual commercialization phase and no federal funding is used. Histori-
cally, companies winning SBIr grants have been successful in leveraging the SBIr seed 
money and the technical credibility conferred by a confidential and rigorous peer-review 
process to attract additional investment dollars from private sector entities. almost half 
of the companies receiving USDa-SBIr Phase II awards have gone on to have some level 
of commercial sales based on their project.
The USDA Small Business Innovation Research 
Program: Vision, Challenge, and Opportunities
William r. Goldner
USDA
Washington, DC
All executive-branch departments with extramural research 
budgets exceeding $100 million are directed by legislation 
to provide a 2.5% set-aside to fund SBIR programs.
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The USDa-SBIr Program strongly encourages the participation of university and 
government scientists in SBIr projects. These scientists may serve as consultants or 
subcontractors with funding not exceeding a third of Phase I awards or a half of Phase 
II awards. a public-sector scientist may serve as the principal investigator on an SBIr 
grant by reducing employment at her/his home institution to 49% for the duration of 
the grant and if the SBIr research is performed someplace other than her/his lab. It is 
usually not acceptable for a university or government scientist to serve as a consultant 
and have all the research proposed for the grant done in her/his lab.
The funding level for the USDa-SBIr Program FY0006 was $9.7 million (table 
). In 006, 650 Phase I proposals were received and approximately 6% (0) were 
recommended for funding (table ). During the same year thirty-three of sixty-one Phase 
II proposals were funded (54%, table ).
Table 1. usda-sbiR pRogRam funding hisToRy.
 Year Budget Phase I Phase II
  ($million)
 999 3.3 84/45 3/56  
 000 5.6 89/480 36/59  
 00 6.3 90/480 37/63  
 00 5.7 86/449 39/68  
 003 7.7 88/656 38/67  
 004 8. 99/58 38/65  
 005 9. 93/557 40/79  
 006 9. 0/650 33/6`
Proposals funded. Proposals submitted.
Investigator-initiated concepts make up the bulk of the proposals received by the 
USDa-SBIr Program. The Program has twelve broad topic areas that are outlined in the 
request for applications (rFa) form (accessible at http://www.csrees.usda.gov/fo/sbir). Of 
these topic areas, nine routinely field biotechnology proposals (table ). This presentation 
will focus on opportunities and challenges facing researchers submitting biotechnology 
proposals to two USDa-SBIr topic areas, Plant Production and Protection – Biology 
and Industrial applications.
Table 2. bioTechnology-RelevanT usda-sbiR Topic aReas
 Forest & related resources aquaculture  
 Plant Production & Protection–Biology Industrial applications  
 animal Production & Protection animal Manure Management  
 Water & Soil resources Plant Production & Protection–Engineering  
 Food Science & Nutrition
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Plant Production and Protection–Biology
SBIr topic area 8., Plant Production and Protection–Biology (P3B), has three main 
subtopics:
• Improved Crop Quality and Yield Utilizing Innovative applications of Plant 
Breeding, Molecular Biology, Genomics, and Cell and tissue Biology;
• Development of New Crops as Sources of Food, Fiber, or Industrial Products; 
and
• Crop Protection from Insects, Disease, and abiotic Stress.
The USDa-SBIr web site (http://www.csrees.usda.gov/fo/sbir) provides access to abstracts 
of funded research and success stories that are illustrative of the scope of projects receiv-
ing funding in this topic area. From FY005–007 “specialty crops” have been a special 
focus of the P3B topic area solicitation. Examples of specialty crops are fruits, vegetables, 
nuts, ornamental nursery or greenhouse crops, and forest trees (e.g. american chestnut). 
typically, specialty crops have a much lower per-crop market value than the major row 
crops (e.g. corn, soybean). However, taken together they make up fully half of the US 
annual agricultural output, ~$50 billion (Jerardo, 005). The P3B topic area encourages 
submission of FY007 proposals in four specialty-crop focus areas:
• improved plant-disease diagnostics;
• improved disease resistance in specialty crops;
• biological approaches to improve floriculture and ornamental nursery production; 
and
• rapid diagnostic methods for weedy and invasive species.
although there is great opportunity for small businesses to use the tools and methods 
of biotechnology to create valuable new specialty-crop genotypes, there are significant 
challenges, as well. One aspect of the pre-commercial development of any new biotech-
nology-derived crop is navigating the regulatory process, which may involve interacting 
with as many as three federal agencies [USDa-animal and Plant Health Inspection 
Service (aPHIS), Environmental Protection agency (EPa), and Food and Drug admin-
istration (FDa)]. The time involved and the financial expense of developing a complete 
dossier for seeking regulatory approval (deregulation) can be daunting. to date, only a 
small number of transgenic biotechnology-derived specialty crops have been deregulated 
and allowed to proceed to market (Goldner et al., 005).  Even more troubling is the 
trend in research to develop specialty crops. Field-trial requests to aPHIS for transgenic 
vegetables peaked in the mid-late 990s with as many as 0 requests, but by late 004, 
it had fallen to approximately twenty (Figure ). US taxpayers have invested heavily in 
agricultural biotechnology through the USDa agricultural research Service (arS) and 
through funding provided to land-grant universities, other public and private universities, 
and small agricultural biotechnology companies through USDa CSrEES. Where is the 
return on that investment (McHughen, 005)?
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Biotechnology grants funded by the SBIr Program from FY998 through FY006 are 
shown in Figure . One to five Phase I grants in plant biology (P3B) have been funded 
during that period (Figure ). However, Phase II awards in plant biotechnology receiving 
peaked in FY000 (three), with single awards funded in FY00 and FY003 (Figure ). 
Since 003, no Phase II award has been granted to a transgenic-technology project in plant 
Figure . US transgenic fruit and vegetable field trials 987 to October 004 
(redenbaugh, 005)
Figure . USDa-SBIr biotechnology grants.
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biology, despite twelve projects being eligible to apply for Phase II in the FY004–006 
period (Figure ). Only 0% of eligible P3B Phase I projects went to Phase II in the period 
FY999–004 (Figure , Phase I projects awarded in FY005–006 are still eligible to 
apply for Phase II in FY007). Part of the explanation for the low percentage of Phase I 
projects competing successfully for Phase II may be the increased emphasis on commercial 
potential that the SBIr Leadership team developed beginning in FY003. If it could 
not be demonstrated how the results of a project would provide a marketable product, 
overcoming technical and regulatory challenges, there would be reduced incentive for the 
reviewing community to recommend investment. The question is, “How can we improve 
the chances for a broad range of biotechnology-derived specialty crops to reach the market 
place, where market forces will determine their acceptability to the public?”
the Specialty Crops regulatory Initiative
Motivated by concerns and circumstances outlined above, a team of public- and private-
sector scientists and administrators have been working on a program since 003, The 
Specialty Crops regulatory Initiative (SCrI). The over-arching rationale behind SCrI is 
to facilitate realization of potential to make available a broader range of biotech options, 
in a greater diversity of crops, to help meet needs of agriculture, consumers, and the 
environment. toward this end, the approach being considered is to develop an organiza-
tion to assist public-sector and smaller-scale private-sector developers of specialty crops 
through the existing regulatory approval process. Similar programs have been developed 
to facilitate small-market orphan drugs (FDa) and small-acreage pesticides (USDa, Ir-
4). Specialty traits of major crops (e.g. industrial lubricants, value-added proteins) share 
similar developmental challenges with specialty crops (e.g. smaller market size). at this 
time, including specialty traits of major crops under the specialty-crops umbrella has 
neither been ruled in or out.
The over-arching rationale behind SCRI is to facilitate 
realization of potential to make available a broader range of 
biotech options, in a greater diversity of crops, to help meet needs 
of agriculture, consumers, and the environment.
The long-term challenge for SCrI will be to make available a broader range of biotech 
crop options that create public benefit and meet economic and environmental needs 
(Goldner et al., 005). The need for the SCrI is underscored by the diversity of the SCrI 
steering committee including members from the public sector—USDa-CSrEES, arS, 
and aPHIS, and land-grant universities (86s and 890s), as well as technology develop-
ers, commodity groups and growers from the private sector. The SCrI steering committee 
organized and implemented two national workshops to develop the concept and obtain 
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stakeholder input, and have informed numerous scientific and industry groups about the 
SCrI model. a significant milestone in the realization of SCrI was recently achieved 
with the selection and hiring of a consultant, through a contract with the University of 
California-riverside. The consultant will serve as project manager to obtain additional 
stakeholder input and support to develop an action plan for realizing SCrI’s potential 
public benefit. While the SCrI is potentially an important entity for providing guidance 
and assistance in developing critical data sets for specialty crop developers preparing ap-
plications for the deregulation of biotechnology-derived specialty crops under the current 
regulatory system, the implementation of SCrI remains several years in the future.
alternative approaches to Developing Specialty Biotech Crops
Despite the decline in SBIr-funded plant biotechnology projects reaching Phase II in the 
past 3–4 years, there have been some SBIr projects with technical approaches that partially 
mitigate risk through the implementation of confinement technologies. two examples are 
CEa Systems, Ithaca, NY, and Kuehnle agrosystems Co., Honolulu, HI. 
CEa Systems’s technology platform was developed at Cornell University. Essentially, the 
target production of high-value proteins from transgenic plants in controlled environment 
hydroponic systems (i.e. greenhouse, growth chamber). CEa is using SBIr P3B funding 
to understand the effects of environment on protein expression in their target crops. 
The value of the proteins being manufactured is great enough to create a commercially 
viable opportunity on a greenhouse scale (small acreage) using controlled environment 
technology to prevent inadvertent environmental release.
Kuehnle agrosystems (Ka) has developed a system of “green biofactories.” Their pro-
prietary genetic transformation technology—magnetophoresis—was developed through 
funding from SBIr P3B Phase I and Phase II grants. Magnetophoresis allows specific plant 
tissues or organelles to be transformed resulting in new or optimized metabolic function. 
Ka received an SBIr Industrial applications Phase I grant to begin developing the use 
of magnetophoresis to create green biofactories using transgenic unicellular algae that 
are grown and contained in controlled environment systems. These algae will be capable 
of producing high-value proteins and other compounds that will justify their relatively 
small scale of production. The reduced environmental risk conferred by the Ka and 
CEa controlled-environment approach may facilitate the deregulation of their respective 
biotechnology-derived genotypes to be used exclusively in these systems.
Industrial applications
The USDa-SBIr 8.8 Industrial applications topic area provides r&D funding oppor-
tunities to companies that are developing enhanced production technology, improved 
quality control, and new biobased products from agricultural materials and residues. For 
FY007, the Industrial applications program established some specific focus areas: biofu-
els (e.g. ethanol, fuel gas, hydrogen); biobased products improving the economics of the 
biofuel production stream; and the development of new energy crops. USDa plays a lead 
role in the development of biofuel feedstocks and biomass-conversion technology. Con-
sequently, the SBIr Industrial applications program is fertile ground for biotechnology 
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concepts targeting these areas. Figure  shows that Industrial applications biotechnology 
projects funded by SBIr are on the increase.
The current interest in renewable energy research and development by SBIr was em-
phasized at a conference held July 6–7, 006, at Oak ridge National Labs (OrNL), Oak 
ridge, tN. The Department of Energy (DOE)/USDa-SBIr Energy Summit showcased 
alternative and renewable energy research-funding and technology-transfer opportuni-
ties from OrNL and USDa. approximately 0 scientists and administrators (seventy 
from small businesses) attended the -day conference. Both OrNL (DOE) and the 
USDa-arS have extensive research programs on bioenergy, many of which have strong 
biotechnology components. additionally, the USDa rural Development agency provides 
a number of programs supporting bioenergy company development and sustainability. 
CSrEES also funds university bioenergy research programs through the National re-
search Initiative Competitive Grant Program (www.csrees.usda.gov) and through other 
funding mechanisms. These bioenergy programs may afford new opportunities for small 
biotech companies to partner with these public-sector research institutions to bring new 
technologies into application in the private sector.
additional USDa-SBIr Program Information
The USDa-SBIr Program releases one annual solicitation (usually June ) with a closing 
date usually 90 days after the release (usually September ). Phase I proposals are reviewed 
by outside reviewers and funding recommendations are provided by a technical review 
panel. Proposals are submitted electronically. Each applicant receives a verbatim copy of 
the review and a summary of the panel discussion. 
The twelve SBIr topic areas are: Forests and related resources; Plant Production and 
Protection–Biology; animal Production and Protection; Soil and Water resources; Food 
Science and Nutrition: rural and Community Development; aquaculture; Industrial 
applications; Marketing and trade; animal Manure Management; and Small and Mid-
Size Farms. The website (www.csrees.usda.gov/fo/sbir) may be used to access program 
information, the rFa, technical project abstracts, links to the Small Business administra-
tion and other SBIr programs, and USDa-SBIr Success Stories.
Closing thoughts
• USDa-SBIr projects are effective technology-transfer mechanisms for moving 
publicly developed technology into private-sector applications that benefit various 
aspects of american agriculture and rural america.
The USDA Rural Development Agency provides a number 
of programs supporting bioenergy company development and 
sustainability.
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• royalties and licensing revenues from many SBIr projects accrue to our univer-
sity partners and other public technology developers (e.g. arS).
• agricultural biotechnology projects need to be carefully thought out to be com-
petitive in Phase II (commercialization).
• Opportunities are growing for agricultural biotech applications targeting energy-
related industrial applications.
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america’s food and agricultural producers operate in a global, diverse, and highly 
competitive marketplace driven by consumers. american farmers are among the most 
productive in the world and our food and agricultural system provides the nation with 
the safest, highest quality, and lowest cost food and fiber anywhere. Much of the credit 
for this success belongs to our public research system and its success in generating new 
knowledge and technologies that improve productivity and develop new markets for 
agricultural products.
The Department of agriculture helps drive continuous innovation through science and 
technology by forming research and commercialization partnerships with other research 
institutions and the private sector. The Office of technology transfer in USDa’s agricul-
tural research Service (arS) is key in facilitating these partnerships and in transferring 
research outcomes for broad beneficial use by the public and agricultural industries of the 
United States and other nations. Many of these research outcomes include patented or 
otherwise protectable technologies. The partnerships include private-sector corporations 
as well as universities (i.e. other public-sector institutions). The mechanisms arS uses to 
1Mention of product names is for identification pursposes only and does not imply endorsement by USDa.
Technology Transfer in the Agricultural Research 
Service: Implications of Federal / Private 
Sector, and Federal / University Partnerships to 
Commercialization Strategies1
richard J. Brenner & ronald Buckhalt
USDA-ARS
Beltsville, MD
The Office of Technology Transfer is key in facilitating these 
partnerships and in transferring research outcomes for 
broad beneficial use.
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commercialize technologies have evolved over the past 5 years in concert with federal 
legislation that governs federal and non-federal researchers. Federal, state, and private-
sector researchers are all working toward the same goal of adopting research results and 
creating products and services. However, the missions, geographical scope, and account-
ability to their respective institutions create some real challenges. 
This paper describes the “roots” of technology transfer in the United States, the culture 
of arS technology transfer, and some observations on how the intersection of technol-
ogy-transfer authorities has led to convergence as well as divergence among federal and 
non-federal agricultural researchers in the public sector. Furthermore, some metrics and 
successes in technology transfer in arS—some involving partnerships, others strictly in 
USDa—are provided as illustrations. Finally, we offer a glimpse of what we believe is the 
future direction of agricultural research.
the People’s Department and the Land-Grant System
The “roots” of technology transfer can be traced to the earliest activities that can be 
defined broadly as “agricultural research” in the United States. Specifically, in 89 and 
Figure . Frank Meyer.
87 the Secretary of the treasury directed con-
sular and naval officials to transport useful seeds 
and plants to the United States; the subsequent 
western expansion during the nineteenth century 
resulted in the creation of the Section of Foreign 
Seed and Plant Introduction in 897 (Shurtleff 
and aoyagi, 004). Frank Meyer (Figure ) was 
an early explorer who made many contributions 
to those collections. additionally, in 839, the 
Patent Office established an agricultural Divi-
sion to conduct research. Congress designated 
$,000 for “collecting and distributing seeds, 
carrying out agricultural investigations, and 
procuring agricultural statistics” [National ar-
chives and records administration (rG 07-8), 
http://www.nara.gov/].
Federally-financed r&D and technology transfer in agricultural research dates from 
May 5, 86, when President Lincoln signed a bill that established the Department of 
agriculture, or as he coined it, “the People’s Department” (Figure ). The act instructed 
that the Commissioner of Agriculture…acquire and preserve…all information concerning 
agriculture… related bills enacted at the same time included The Homestead act in 86 
and the Morrill acts of 86 and 890 that led to the establishment of major state-oper-
ated agricultural research centers. State experiment stations (SaESs) were first established 
in Connecticut and California in 875, based on a German model observed by american 
scientists. The Hatch act of 887 later authorized one for each state. Finally, the Equity 
in Educational Land-Grant Status act of 994 (sometimes called the tribal Colleges 
act) brought native american schools into the fold. [For a comprehensive review of the 
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enabling legislations cited above, see the website for the National association of State 
Universities and Land Grant Colleges (NaSULGC) at http://www.nasulgc.org.]
Thus, the federal government and the states established an infrastructure for publicly 
funded agricultural research throughout the United States to conduct research and, 
ultimately, to transfer results to the public. The collective results of these legislative acts 
created the 33 land grant colleges and universities in existence today (Figure 3). Even 
from their very beginnings, USDa has had a special relationship with institutions of higher 
education. although USDa scientists have conducted research since the 860s under 
various departmental structures, the agricultural research Service (arS) was formally 
established in 953. today, many of our more than 00 arS facilities are co-located at 
these institutions and we collaborate on many research projects (Figure 4).
Management of Intellectual Property
Various legislative authorizations over the past 5 years created incentives for the govern-
ment, universities and industry to work together to commercialize new technologies for 
the public benefit. However, how intellectual property (IP) is managed depends on the 
legislative authorizations that, in fact, have critical differences. Extramural research funded 
by federal appropriations are managed according to the Bayh-Dole act of 980 that al-
lows institutions performing the research to take title to their inventions and to license 
rights to practice the inventions without constraints and without notifying the public. In 
contrast, inventions arising from intramural research conducted by federal agencies, such 
as arS, are governed by the Stevenson-Wydler act of 980 and subsequent legislation, 
especially the Federal technology transfer act of 986 and other more recent legislation. 
(although these references can be found at many sites, the Defense technology Informa-
Figure . The USDa was established under President Lincoln in 86.
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tion Center has a web site that is linked to the Library of Congress Thomas file and has 
every conceivable legislative action taken in regard to technology transfer: http://www.
dtic.mil/techtransit/refroom/laws/).
Collectively, this legislation frames the functions and actions of our Office of technology 
transfer (Ott). We coordinate the technology-transfer activities in arS, and have the 
authority to develop and sign a very specific federal instrument for partnerships, specifically 
Cooperative research and Development agreements (CraDas). We also represent the 
Secretary of agriculture on IP management, and have the sole authority for licensing any 
inventions developed within any of the USDa agencies conducting intramural research, 
including the US Forest Service, the Food Safety and Inspection Service, and the animal 
Plant Health Inspection Service.
Figure 3. The land-grant network.
We coordinate the technology-transfer activities in ARS, and 
have the authority to develop and sign a very specific federal 
instrument for partnerships, specifically Cooperative Research and 
Development Agreements (CRADAs).
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to evaluate the implications of the various legislative acts to our partnerships, we need 
to frame the context of the arS policies of today. arS integrates technology transfer 
within its research mission, protecting IP when necessary to facilitate technology trans-
fer. However, we favor public releases of plant varieties, and avoid patenting “animals” 
or research tools, and, because we are a public research institution, we promote further 
research by permitting license-free research with any arS technology. Consequently, 
the decisions we make relative to licensing federal technologies are governed largely by 
the goal of facilitating technology transfer for public good in support of US agricultural 
businesses, not a goal of generating revenue for research.
In licensing IP, two mechanisms have processes highly prescribed by federal statute. First, 
(also in reference to CraDa involvement) “background inventions” are those that are 
made by federal researchers under normal intramural research authority with Congressio-
nally-appropriated funds. If a potential licensee requests exclusivity, then we must publish a 
Federal Register notice of our intent to license the specific patent to the applicant company. 
The purpose is to inform the public so that other qualified individuals or businesses who 
also want a license to the technology have an opportunity to object to the exclusivity. 
We then must address all objections. This may result in co-exclusive licenses, or exclusiv-
ity by field of use, or in rare circumstances, non-exclusive licenses to all objectors who 
Figure 4. Locations of arS facilities.
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submit qualified license applications. all of this is prescribed in 37 CFr 404 (Licensing 
of Government Owned Inventions), and we are diligent in following proper procedures. 
Federal agencies cannot deny a license to applicants that meet minimum qualifications, 
except that—all other factors being equal—agencies can grant a preferential license to a 
small business, but cannot select one small business over any other. Thus, no technology 
can be preferentially licensed to a local company and denied to others elsewhere. This is 
a very important distinction between federal and university licensing. 
The second mechanism relates to IP developed under a CraDa with a non-federal 
partner—almost always a private-sector company. This is also a prescribed procedure, 
but by statute and not by the Code of Federal regulation (5 U.S.C. 370a). Inventions 
made under a CraDa are a distinct advantage for the private-sector company for two 
reasons. First, the company has the first right to negotiate an exclusive license to at least 
one predefined field of use without Federal Register notice. Therefore, their competition 
is not only excluded, but remains uninformed. Second, federal agencies can exempt 
jointly developed data from Freedom of Information act requests for up to 5 years, but, 
in practice, arS rarely grants confidentiality for more than  year.
Thus, the laws governing activities of federal intramural research create both synergy 
and conflict with our partners in public-sector universities. Underlying this is the basic 
premise that the challenges of global agricultural markets, free trade, and diminishing 
research funds make these partnerships essential if we are to achieve meaningful research 
results.
Increasingly, however, federal agencies are often in conflict with university partners 
as to the goals of protecting IP. From our federal perspective, the goal is adoption of 
technologies to benefit the public and US industries at minimal transaction costs. We 
protect IP when it is necessary to achieve technology transfer, but preferred mechanisms 
are publication of research findings, or public release of technologies. Universities often 
are forced to make IP decisions on the basis of whether revenues can be generated to 
support research programs that are strapped by spiraling costs, and diminished federal 
research dollars. Unless carefully managed, these conflicts can discourage federal/univer-
sity partnerships.
There is also a degree of conflict in licensing as to regional versus national accountability. 
Many universities have an appropriate mandate to stimulate economic development pref-
erentially within the region or state. In contrast, federal agencies have to justify processes 
to the taxpayers of any given state as well as to the taxpayers of the other forty-nine.
arS is co-located at many educational institutions, and consequently, there is a merg-
ing of intellectual capacity with universities. Co-owned inventions frequently result, and 
unless the federal employee has promptly reported an invention through arS channels, 
the university has often moved forward before we have had the opportunity to formally 
consider options. This can create a problem because our policy not to protect certain IP 
may conflict with the university’s policy. Consequently, should we tell the university that, 
regardless of their intent to issue revenue-bearing licenses, we will make the technology 
available free of charge, we may find ourselves in the position of spoiling opportunities 
for our partners. 
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a final area of potential conflict relates to situations when a USDa researcher uses 
CraDa funds to hire or contract with a university employee. If joint IP results, we 
discover that we truly don’t have consolidated rights to offer exclusively to the CraDa 
partner (as prescribed by law), because the university has Bayh-Dole rights in the co-
owned invention.
Yet, co-owned inventions are common, and we consolidate our rights, usually by li-
censing ours to the university. This may provide greater flexibility in the sublicensing to 
private-sector firms because the university may take equity as part of the licensing terms, 
thereby reducing upfront costs to industry, and no Fr notice is required for exclusive 
licensing.
One disadvantage to co-owned inventions is that universities may prefer to approach 
licensing from a more regional, rather than a national, perspective. appropriately, we 
need to be vigilant to ensure that terms are equitable to commodity groups or industries 
across state lines.
reaching consensus on policies beforehand solves joint ownership issues. When we 
cannot reach agreement, we may choose to go our own way, rather than to consolidate 
rights. alternatively, we may prefer to in-license university rights and then license con-
solidated rights to industry.
There is a simple proactive solution to the issues of joint inventions made with universi-
ties under CraDas. If arS needs the university expertise to meet the research mission, 
we can establish a three-way CraDa to define disposition of IP rights by agreeing that 
the private-sector partner will have the right to negotiate an exclusive license to any subject 
invention, regardless of federal or university ownership.
Fruitful relationships
Despite some of the difficulties described above, these legislative acts have produced ben-
eficial solid relationships. arS has approximately 00 active CraDas with the private 
sector, and separately, over ,600 cooperative projects with universities where Bayh-Dole 
rights apply. a total of 30 active licenses are producing 00 products available to the 
public (Figure 5). Over 0 of these licenses are executed with universities to consolidate 
rights; twenty-seven of these are producing products from utility patents, plant patents, 
and Plant Variety Protection Certificates. Thus, there is a demonstrable benefit to the 
public, to the inventors, and to the publicly funded research institutions conducting the 
research (Figure 6).
Reaching consensus on policies beforehand solves joint 
ownership issues.
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recognizing that agricultural markets are characterized by thin profit margins requiring 
exclusivity of rights to protect investments, the majority of our licenses are exclusive. This 
has not changed over the past 0 years, and additionally, at least 40% of these licenses 
are with small businesses. Our licensees are increasingly successful at commercializing 
products with these exclusive rights to our inventions.
Figure 5. License metrics.
Figure 6. Commercialization of USDa products.
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New Products
We can illustrate a few current technologies 
that are on the road to success. For example, 
arS developed a technology over the past 
several years that began reaching expanded 
markets in 004. Kids’ meals at McDonalds 
now feature “apple Dippers,” as an alterna-
tive to fried potatoes. apple Dippers are 
peeled apple slices served with a cup of low-
fat caramel dipping sauce. Mantrose-Hauser, 
a former CraDa partner and current 
licensee, produces the arS-developed 
coating, which is used by apple processors 
to prevent cut fruits and vegetables from 
turning brown. a product under the trade 
name NatureSeal® is being sold commercially 
to grocery stores, fresh-cut producers and 
food-service industries. The technology has 
been extended for sliced avocados, celery, 
potatoes, carrots, and onions.
a grass roots effort for pear growers to 
add value and create new markets for their 
products resulted in the development of 
Figure 7. apple Dippers: 
Dr. Dominic Wong, one of the arS in-
ventors of the technology sold under the 
name “NatureSeal” by licensee.
restructured fruit bars (Figure 8). arS researchers patented and transferred technology 
using pureed fruit. Licensed to Gorge Delights, Hood river, Oregon, which built a 
manufacturing plant and created new jobs in an area with 30% unemployment. Their 
product line has expanded, and several grocery chains and some US military commissaries 
now offer these products in several hundred stores. This technology permits year-round 
processing of seasonal crops from puree through this intermediate “holding” step, and is 
expected to be used with other crops.
arS researchers in collaboration with red river Commodities, Fargo, North Dakota, 
developed a sunflower butter product—SunButter™—as an alternative to peanut butter. 
This is especially valuable to persons with peanut allergies. It smells, tastes, feels, and 
has the appearance of peanut butter. The market for SunButter is expanding to include 
many uses in baking formerly filled with peanut butter. In January 004, it was made an 
entitlement item and added to the official list of available commodities in the National 
School Lunch Program, and some airlines now include the product in their snack boxes, 
accounting for a large boost in sales. This was a CraDa development, but there is no 
patent or license.
table grape varieties represent an experiment between Ott and the California table 
Grape Commission. In this era of global economic markets, a public release of new variet-
ies makes them available to the world, not just to the US industries that provided the tax 
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base to support the research. Thus, the development of new varieties can inadvertently 
create a competitive advantage for the rest of the world who may undercut prices because 
of cheaper labor or unfair trade practices. Therefore, these varieties were protected, and 
licensed to the California table Grape Commission (CtGC) for nominal fees to US grow-
ers. The CtGC can also sublicense to growers in other countries, thereby gaining some 
management of growers external to the United States, and further support the research 
necessary to develop new varieties that favor US growers and consumers.
arS researchers developed a biodegradable hydraulic fluid made from soybean oil, 
which is now being used to power the Statue of Liberty’s elevator. Until recently, mineral 
oil formulations derived from petroleum-based stocks were used. The National Park 
Service contacted arS scientists requesting development of a biobased fluid that is 
environmentally friendly, produced from a renewable resource, that is economical and 
nonpolluting, and meets all industry standards for safety and performance including 
viscosity, stability, and flame-resistance. arS researchers already had the know-how to 
develop this technology. Though other vegetable oils would work, soy was chosen for its 
low cost, chemical versatility, and availability as a renewable, home-grown resource. Soy 
is the nation’s leading source of food-grade oil, yet only 57 million pounds—3% of 
the total supply—is used for industrial purposes. The invention, jointly developed with 
Figure 8. Pear Bars: a snack developed by licensee using arS technology 
to puree fruits.
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Figure 9. SunButter™: a non-allergenic alternative to peanut butter.
Pennsylvania State University, was licensed to a start-up company that was immediately 
acquired by Bunge, a global food and agricultural commodity company, in early 006; 
first sales were reported by mid-006.
The developments in technology licensing reflect how the landscape of agricultural 
markets has changed during the past 5 years and the growing complexity of our global 
food and agricultural system. agriculture, however still must also meet the basic food and 
fiber needs of people. Interestingly, 70% of the active patent licenses from federal research 
in labs and universities are in the life sciences with products and processes that feed people, 
70% of the active patent licenses from federal research in 
labs and universities are in the life sciences with products and 
processes that feed people, diagnose disease, reduce pain 
and suffering, and save lives.
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Figure 0. George Washington Carver and Henry Ford’s soy-based trunk lid.
diagnose disease, reduce pain and suffering, and save lives. This doesn’t happen, however, 
by accident, and it is increasingly important to nurture these research partnerships. So 
where do public research institutes go from here and what opportunities are emerging?
Chemurgy revisited: agriculture’s reinvigoration
to see the future, we need to look to the past. In the 930s, we were using ethanol to 
power our cars. People like George Washington Carver were working on new uses for 
agricultural materials (Figure 0). In fact, Henry Ford predicted in 937, that “… almost 
all cars will be made of [soy plastic].” In 940 he installed a plastic trunk lid on one of 
his personal cars, demonstrating its durability with the blow of an axe (Figure 0). a 
year later he built an all soy plastic car which was hailed as an“…outstanding industrial 
achievement” (Henry Ford Museum, http://www.hfmgv.org/exhibits/hf/facts.asp).
The movement in which Ford and Carver were involved was called “chemurgy” (Fin-
lay, 004). Unfortunately, cheap oil sent this nation and its research capacity in another 
direction. In the context of 006 issues, the times are indeed changing.
There is an urgent need to become less reliant on imported oil. Biofuels may help 
achieve this goal. In addition to switch grass, other crops may have potential as feedstocks 
for biofuels, such as gamma grass, fast-growing willows and poplars, along with biomass 
residues from traditional agricultural practices.
additionally, the adoption of biobased products can “back out” petroleum usage through 
substitution. The federal government—through its massive procurement of goods—can 
play a role. title IX of the 00 Farm Bill put in place federal “preferred procurement” 
for biobased products (http://www.ers.usda.gov/Features/farmbill/titles/titleIXenergy.
htm). This can have a major impact in creating market demand for biobased products 
and lower unit prices. In cooperation with Iowa State University, a website has been set up 
to serve as a clearing house for listing biobased products for purchase by federal agencies 
(http://www.biobased.oce.usda.gov/public/index.cfm).
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Given 006 concerns about rising petroleum prices, our nation will be increasing re-
search emphasis to seek new crops for biotech industrial uses representing new economic 
opportunities for farmers. Crops that are good for the environment and for rural america 
and that will reduce our dependence on imported fossil fuels may become priorities. Thus, 
as a nation we have come full circle. “Chemurgy” has been superseded by “biobased prod-
ucts” and “bioenergy.” There is renewed hope that with continuing agricultural research 
and private/public partnerships created, the products from agricultural materials will be 
limited only by our imagination: the most prosperous era in american agricultural history 
is dawning to meet the continuing and expanding needs of the public.
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I will provide a case study of my experience in trying to translate basic research discoveries 
into a product via a startup company. as an academic, a university professor—managing a 
grants program and students—why start a company? One of the things that drove me was 
my expertise in the area of Bacillus thuringiensis (Bt) toxins and their applications for insect 
control. If you stay in a research area long enough, you acquire insights into limitations in 
current technology and, if you have an entrepreneurial bent, you look for opportunities 
to apply those insights and solve problems. also, as you do basic research, whether in a 
university or private-sector laboratory, you may ask the question, “Where is it going?” 
You are building blocks of knowledge, but then you begin to look for opportunities to 
commercialize these technologies. In the 980s while at agrigenetics, I was involved in 
the process of patent writing. This experience proved invaluable when, at the University 
of Georgia, I began to evaluate research in my laboratory for potential inventions. My 
university was supportive in paying the costs of patenting, but then another bottleneck in 
the process emerged. You may have an invention, but the technology is at such an early 
stage in development, a large company is not likely to license the technology. So you look 
for ways to bridge the gap between the initial lab results and a product.
Despite the difficulties that plagued agricultural biotechnology in the 990s, I looked 
for opportunities in the agbiotech sector. It seemed that with consolidation in the industry 
dominated by a few large companies, there might be a niche for creating a startup company 
focused on insect control. On the other hand, despite having experience working in a 
biotech company, I questioned whether I had the energy and desire to enter the business 
world. But then things came together, helping me cross that line to form a company with 
the help of colleagues, albeit without a vision of the amount of time it would take. 
From the Bench to a Product: Academics and 
Entrepreneurship
Michael adang
University of Georgia 
Athens, GA
The University of Georgia has a commercial alliance program to 
help professors who desire to be entrepreneurs combine their efforts 
with people who know how to build businesses.
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Seeking New Strategies In Insect Control
In 003, Dr. Clifton Baile (University of Georgia, UGa) and I founded a company called 
InsectiGen, seeking new strategies for insect control. The UGa has a commercial alliance 
program that functions together with the Georgia research alliance to help professors 
who desire to be entrepreneurs combine their efforts with people who know how to build 
businesses. Located on campus at UGa is a Center for applied Genetics technologies, 
which makes available high-tech instrumentation to startup companies. In addition, the 
Georgia BioBusiness Center, directed by Dr. Margaret Wagner Dahl, helped provide 
infrastructure for founding InsectiGen.
InsectiGen went through the traditional startup phases of identifying intellectual 
property and market opportunities and writing a business plan. The Georgia research 
alliance has a program that provided funding to allow us to hire a professional to write 
the business plan. We moved to proof of concept and to development over the last year 
or so, securing capital and building infrastructure to go from a virtual company to a real 
company.
InsectiGen
I am fortunate to have Cliff as a motivational leader who has experience as a university 
professor, as a director of r&D at Monsanto, and as founder of seven biotech startups, as 
well as being director of a fairly large agbiotech company, MetaMorphix. He has provided 
the knowledge-base to make InsectiGen a reality. 
robert Ligon had retired after 5 years in informational technology entrepreneurship 
when he took my class at the University of Georgia on biotechnology. He became more 
interested and involved in the work, and ultimately served as president of InsectiGen. 
During that time, he helped develop the first business plan.
Having worked in the Bt-toxin area for 5 years, I provide scientific leadership. My 
work developing Bt plants has led to a number of patents and their commercialization 
in a small company. My colleague of many years, Don Dean, and I shared an NIH grant 
to design new Bt toxins for mosquito control; Don had the knowledge base, as well as 
the desire, to help me in this business endeavor. Dr. Mohd amir abdullah, who is paid 
from an USDa Small Business Innovation Grant awarded to InsectiGen May , 006, 
has been working in my lab on InsectiGen projects for  years.
Having an Impact
We founded InsectiGen in 003. The question we had to ask, in terms of finding a 
niche, was “How in the world, with such tremendous success with Bt corn, with Bt cot-
ton—with major players involved—can a couple of people in a little company actually 
have an impact and do something useful?”
We think that we can.
We know that there are unmet needs both in controlling insects that are currently 
only partially knocked down by Bt cotton and in developing new targets for Bt crops, 
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for example corn rootworm. We think that our technology will augment what’s already 
available.
I know that we can help improve the efficacy of Bt biopesticides, which is a commod-
ity-based global market of about $50 million. The numbers are a little hard to come by, 
but in the United States it’s a $76 million to $00 million market that has been stagnant 
for the last 0 years, partly due to Bt crops, because of limited biopesticide persistence, 
limited insect-control spectrum and development of insect resistance, but mostly because 
Bt biopesticides are relatively expensive at $5 to $0/acre. Therefore, at InsectiGen we 
are looking for strategies to make Bt biopesticides less expensive and more effective.
BtBooster
We came up with a new technology that was discovered from basic research: we call it 
BtBooster. It’s a protein-based agent that enhances the effect of Bt toxins. Stacked with 
Bt genes in transgenic plants or combined with Bt biopesticides, it improves control of 
insect pests.
In my laboratory we have been focused on the general question of how Bt toxins kill 
insects and how insects adapt to become resistant to Bt. Ingested Bt crystals dissolve in 
the insect gut where they are processed by proteases, converting protoxin to activated 
toxin. The toxins bind receptors located in the insect mid-gut, analogous to a lock-and-
key mechanism. The actual events involved in toxin action are quite complex, involving 
contact with multiple receptors, formation of a pre-pore structure followed by membrane 
insertion and cell death. 
From our basic research, we discovered that a fragment of a receptor protein made 
in E. coli—BtBooster—enhanced toxicity when mixed with Bt protein. This presented 
the possibility of taking a Bt plant that only marginally kills some insects and genetically 
stacking it with BtBooster peptide to achieve more-effective control of those insects. 
Our goal is to combine BtBooster with Bt proteins in transgenic crop plants and with 
Bt biopesticides.
There are many barriers that prevent a startup company from selling genetically engi-
neered cotton and corn. Therefore, it was necessary that InsectiGen license the BtBooster 
technology to a large company. In this case, DuPont licensed the use of BtBooster in 
cotton and other crops. InsectiGen will develop Bt biopesticides using BtBooster.
Funding and Sustainability
Founding partners and friends contributed funds to launch InsectiGen. The company’s 
founding was based on a vision rather than a specific technology, or even BtBooster. With 
a business plan we raised money from friends and “angel investors.” The Georgia research 
alliance was instrumental by matching dollar-for-dollar funds that InsectiGen spent on 
research. InsectiGen received an investment from the Georgia Venture Partner / Georgia 
Biosciences seed capital fund, monies put forth by Georgia as well as by universities to 
stimulate development of startup biotech companies. Having a licensing agreement with 
Dupont-Pioneer greatly enhanced our ability to raise funds.
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recently, InsectiGen was awarded a Phase  Small Business Innovative research (SBIr) 
grant from the USDa1. The Phase  grant supports the testing of a BtBooster-Bt biopesti-
cide in greenhouse trials. Pending a successful outcome of greenhouse studies, InsectiGen 
can apply for a Phase  grant to support field trials. Phase 3, actual commercialization of 
a biopesticide, would then be funded by InsectiGen.
You start out as an individual—a university professor—with entrepreneurial spirit, 
and one of the first things that people ask is, “What is your vision for the company?” 
People would ask, “are you a lifestyle company?” “Will it be a small company that will 
stay within your economic control, for a period of years?” “Or are you going to go the 
route of raising capital, first through investors and then through venture capitalists?” In 
the latter case your vision as the professor-entrepreneur has to be balanced by that of the 
CEO, by your investors, by your directors on your board. You quickly learn that you have 
less control than you ever expected, which you have to be willing to accept.
another thing that I’ve learned is that, in spite of what you may think, professors 
are not the best managers. running an academic research group is quite different than 
managing science in a startup biotech company. In business, even at the scientific level, 
at some point you may need people who are better managers.
Ethics and time Challenges
You also must deal with ethical conflicts between the role of the entrepreneur—which 
can be time-consuming—and the role of the professor with obligations to students, to 
postdocs, to research colleagues, and to others in the university milieu. You must learn 
to balance teaching responsibilities and a university-based research program with time 
spent on company business. Issues of potential conflict between academic responsibilities 
and the biotech startup are addressed through a formal policy system based on open-
disclosure with university administration and researchers in the academic laboratory. In 
my case, the associate dean for research in the College of agriculture and Environmental 
Sciences is the hands-on manager for conflicts, with whom I have to dialogue in order 
to circumvent problems.
time management is one of the major challenges. In my lab we have grants from USDa 
and NIH, and as well as InsectiGen-sponsored research. Between science-management 
issues, research duties, teaching, and company obligations, the process of academics as 
entrepreneurs can be made to work, but it truly is a struggle.
1William Goldner’s description of the SBIr Program is on pp. 49–56.
You also must deal with ethical conflicts between the role of the 
entrepreneur—which can be time-consuming—and the role of 
the professor with obligations to students, etc.
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In Summary
I have tried to provide a snapshot of my personal experience and I will conclude by saying 
that it’s both challenging and rewarding. as a professor you’re never sure what the final 
outcome of these endeavors is going to be. One of the things I’m interested in doing is 
communicating with faculty at other universities to address common issues that come 
up in business-related endeavors.
and then, finally, a parting thought from alejandro Zaffaroni, who has started a number 
of companies including Hybritech: you learn that the business of commercializing products 
is very different from academia, particularly in terms of the number of challenges—and 
failures—that you have to deal with.
The business of commercializing products is very different from 
academia, particularly in terms of the number of challenges—
and failures—that you have to deal with.
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micHael adang received his BS in microbiology from 
Indiana University in 974 and his MSc and PhD in bac-
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as a senior research scientist at agrigenetics Corp. in Madison, Wisconsin, 
98–988, Dr. adang developed transgenic plants expressing proteins from 
Bacillus thuringiensis (Bt). among his inventions are methods for expressing Bt 
genes in plants and a codon-usage method to optimize Bt-gene expression in 
plants. These technologies have been used worldwide with significant impact on 
pest control in agriculture. 
Since 988, his research has focused on receptors that determine Bt toxicity 
to insects. His laboratory was the first to discover a Bt-toxin receptor, with basic 
and applied implications for Bt-plant development and usage.
adang has consulted for the government, Mycogen Corporation and Dow 
agrosciences. His global activities in the intellectual-property area include patent 
preparation and prosecution activities with approximately ten law firms over a 
0-year period. In 003, he co-founded InsectiGen, a start-up company focused 
on discovery and engineering of proteins for insect control.
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Economic and workforce development are unusual topics for the National agricultural 
Biotechnology Council. I will discuss aspects of the workforce in general and the bio-
technology workforce in specific. First are some thought-provoking views about changing 
demographics and global competition; second is information on skills needed in the 
twenty-first century workplace and the mindset of the current generation; and third is 
one California educational institution’s approach to dealing with these changes to provide 
a well-trained biotechnology workforce to serve business and industry.
technology, Demographics and Global Competition 
The effects of technology upon the current generation are significant. according to Martin 
Beam (personal communication, 006), college students today rate their iPODs of more 
importance than beer. Instruction is available electronically through distance-learning, 
blogs (or Web logs), and World Wide Web sites. These new sources of learning widen 
the gap between the generations. technology-savvy youngsters plunge in readily with 
electronic devices whereas oldsters, many of whom are unable to turn on a computer, 
hold the view that formal education is available only outside the home.
Noticeable also are changes in ethnic background of students. In California, there is no 
longer an ethnic majority. although only California statistics are included in this article, 
California can be considered a microcosm of the United States regarding the trends that 
these statistics imply. In California, the demand for highly educated workers combined 
with the loss of retiring highly educated workers is equal to more than 3 million, equal 
to the combined populations of the cities of San Diego, San Jose and San Francisco 
(Campaign for College Opportunity, 006).
Below is a summary of a landmark study by researchers at UC Berkeley—Return on In-
vestment: Educational Choices and Demographic Change in California’s Future—of the state’s 
demographic future and the return on investment for expanding college opportunity.
Thoughts about the Twenty-First Century 
Biotechnology Workforce
Mary Pat Huxley
California Community Colleges
Ventura, CA
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The study finds that for every dollar spent increasing the number of students attend-
ing college and completing degrees, the state gets three dollars in net return on that 
investment. The report also provides critical demographic projections for the State’s 
future population. During the 1990s, California became a minority-majority state as the 
non-Hispanic White population fell below 50%. By 2000, the population of California 
was 47% non-Hispanic Whites, 32% Latino, 12% Asian, and 7% African American. 
The California population is expected to grow to 43 million by the year 2020 and to 
55 million by the year 2050, with most of this growth driven by increases in minority 
populations.
[Here are] a few quick snapshots at some of the trends in the African American, Latino 
and the Asian Pacific Islander population. For more detailed snapshots for each of 
these ethnic groups, visit our website at www.collegecampaign.org.
Key Findings
• Among 18–24 year olds, 28% of African Americans lack a high school diploma 
and only 40% report any college attendance. Although African Americans have 
college-going rates comparable to non-Hispanic Whites, they have extremely 
high drop out rates from college as a group and earn Baccalaureate degrees 
at one of the lowest rates amongst all ethnic groups. Only 45% of 18 year-old 
African Americans are expected to go to a public college in California, only 19% 
will reach a public 4-year university and only 9% earn a Baccalaureate Degree 
there.
• Latinos are the fastest growing population, growing by more than two-thirds 
from 2000–2020. Growth in the Latino population is striking for all age groups 
in the state, but this growth is particularly critical among the college-going age 
group (18–24 year olds). In this age group, Latinos are most likely to have no 
high school diploma and least likely to have entered college. Less than one 
third of 18 year-old Latinos are expected to go to a public college in California, 
only 15% will enter a public 4-year university and only 10% will earn a Bacca-
laureate Degree there.
• The Asian and Pacific Islander population has grown tremendously in the past 
few decades. Their levels of college-going and rates of degree completion are 
the highest amongst all ethnic groups, including non-Hispanic Whites. Nearly 
80% of 18-year old Asians are expected to go to a public college and nearly 
43% will earn a Baccalaureate Degree there. 
For every dollar spent increasing the number of students attending 
college and completing degrees, the state gets three dollars in 
net return on that investment.
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Conclusion
The study makes it clear that the return on investment is very positive for the state. For 
every dollar spent increasing the number of students attending college and completing 
degrees, the state gets three dollars in net return on that investment. This snapshot 
provides sobering information to focus attention on encouraging higher rates of high 
school graduation for Latinos and African Americans, and improving the success of 
those who do graduate from high school and enroll in college. We must continue to 
encourage and support college participation and success amongst Whites and Asian/
Pacific Islanders and we must increase college participation and success amongst all 
our young adults. Given what we know about the positive return on investment, the 
future workforce needs and the growing number of young adults, this information is a 
call to action.” (Brady et al., 2005)
a sobering report from the National association of Manufacturers points out global 
competition issues and that the current US workforce is unprepared.
Yet below the seemingly calm surface [of rising productivity in the US] an undercurrent 
of uncertainty is roiling the emotional waters for American workers. Rapid changes in 
technology and intense global competition—particularly from Asia—have fomented a 
gnawing anxiety about the future. If we are to alleviate this anxiety, keep our economy 
strong and successfully compete in the fiercely competitive international race to the 
top, we must recommit our nation to innovation and the concerted development of a 
more highly educated and skilled workforce.
Indeed, the world has changed over the past decade. In 1993, the United States alone 
accounted for 29 percent of global production.
 
The 10 largest economies accounted 
for three-quarters of the world economic output and, among these top-ten, the only 
developing nations, Brazil and India, ranked 9 and 10, respectively. Fast forward ten 
years to 2003: the United States remained the largest economy, but its share of global 
output had fallen to 21 percent. The 10 largest economies accounted for just two-thirds 
of the world economy and, with China and Russia supplanting Canada and Spain, just 
six of the top 10 countries were traditional industrialized democracies. Today the global 
economy is more competitive across a broader number of nations. Faster growth in 
the developing world has spilled over into global trade…
A more integrated global economy, with more import competition and more export op-
portunities, offers both new challenges and opportunities to the United States and its 
workforce. To succeed, it is essential that the U.S. maintain its position as the world’s 
leading innovator. 
Looking back over the 20th century, American ingenuity has been truly incredible…Go-
ing forward, new innovations will continue to be critical, both in maintaining a solid 
industrial base and increasing our standard of living. In short: 
Innovation leads to new products and processes that sustain our 
industrial base.
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1. Innovation leads to new products and processes that sustain our industrial 
base. 
2. Innovation depends on a solid knowledge base in math, science and engineer-
ing. 
3. Without this knowledge base, innovation as well as our industrial base will 
erode. 
Our economy’s ability to compete in the 21st
 
century will not be influenced by past 
performance. Success or failure will be determined primarily by our capacity to invent 
and innovate. Unfortunately, there are troubling signs that the American workforce 
is not ready to meet innovation’s challenge, and our position as leader of the global 
economy is threatened.” (Labor Day Report, 2005, pages 1 and 2)
Skills and Mindset Changes 
Skills
Workplace competency and technical skills sets have changed, as outlined in table . For 
instance, computer literacy was not a required workplace skill in the twentieth century, 
whereas, in this century, not only do workers need to know how to operate a computer, 
they need advanced computer literacy to function as a bank teller, auto mechanic, nano-
technology specialist, scientist, delivery truck driver, or quality-control specialist.
In biotechnology, including agricultural biotechnology, skills sets include the technical 
aspects. However, rated more important by employers are the so-called “soft” skills, which 
are actually sometimes more difficult than technical skills: working in teams, communi-
cating in written and verbal English, presenting data to groups, getting to work on time, 
putting in a full day of work, and having competency with a computer (Koehler and 
Koehler-Jones, 006). These “soft” skills are also named workplace competency skills.
Basic technical skills in biotechnology include:
Table 1. diffeRences in woRkplace skills and compeTencies: 
TwenTieTh vs. TwenTy-fiRsT cenTuRy (koehleR, 2006).
 Twentieth century Twenty-first century
 General literacy Science literacy  
 arithmetic literacy Math literacy, equations  
 No computer literacy advanced computer literacy  
 Basic shop equipment Scientific laboratory equipment  
 Conversational English Specialized technical English  
 Follow instructions Innovation and problem-solving  
 No writing and analysis technical report preparation 
  and interpretation  
 Individual job responsibility Capacity to form and innovate 
  in mixed groups  
 One-time learning of Life-long learning of different
 advanced competencies  advanced competencies  
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• Mathematical competency for understanding several procedures: dilutions, solu-
tion making, pH calculations, buffers, and other related procedures;
• Understanding what pH is and why it is crucial: for instance, knowing that an 
excursion from pH 7 to pH 9 could potentially kill the cells with which you are 
working;
• Understanding molarity and using it for solution making;
• Basic cellular biology;
• Basic molecular biology;
• Basic chemistry;
• Basic microbiology;
• Sterile technique.
advanced skills, too numerous to list, are expansions of the above, with specialized 
training provided either on the job by the employer for unique requirements, or by an 
institution of advanced learning that collaborates with companies to provide needed 
skills.
Mindset
attitudes to work alter from one generation to the next. The veteran generation—born 
between 90 and 94—are seen as mentors who understood their obligations to family 
and country. Baby boomers—born between 943 and 965—are now the older worker 
pioneers. Generation Xers—born between 966 and 979—are considered cautious and 
self-reliant skeptics. For this generation in the United States, international competition 
is noteworthy: issuance of 4 million college degrees is expected in the United States in 
00 (4% to women), and 6 million will be issued in China.
The Net generation—born between 980 and 995—is eager to innovate and change 
the world. They expect good wages, are nationalistic and have strong cultural values (e.g. 
Latinos are family-oriented), have high-tech skills which could widen the digital divide, 
they expect to have multiple jobs and careers, want a balanced life, do not consider baby 
boomers as role models, and they consider gender equality to be a given.
another factor worthy of consideration is the mindset of the current generation. an 
informative source on this subject is the Beloit College Mindset List® (http://www.beloit.
edu/~pubaff/mindset/), a gathering of ideas to prevent “hardening of the references,” 
according to authors tom McBride and ron Nief.
Summer 2005. In the coming weeks, millions of students will be entering college for 
the first time. On average, these members of the Class of 2009 will be 18 years old, 
which means they were born in 1987. Starbucks, souped-up car stereos, telephone 
voicemail systems, and Bill Gates have always been a part of their lives. 
Each August, as students start to arrive, Beloit College releases the Beloit College 
Mindset List, which offers a world view of today’s entering college students. It is the 
creation of Beloit’s Keefer Professor of the Humanities Tom McBride and Director of 
Public Affairs Ron Nief. 
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McBride, who directs Beloit’s First Year Initiatives (FYI) program for entering students, 
notes that “This year’s entering students have grown up in a country where the main 
business has become business, and where terrorism, from obscure beginnings, has 
built up slowly but surely to become the threat it is today. Cable channels have become 
as mainstream as the ‘Big 3’ used to be, formality in dress has become more quaint 
than ever, and Aretha Franklin, Kermit the Frog and Jimmy Carter have become old-
timers.”
The list is distributed to faculty on campus during the New Students Days orientation. 
According to McBride, “It is an important reminder, as faculty start to show signs of 
‘hardening of the references,’ that we think about the touchstones and benchmarks 
of a generation that has grown up with CNN, home computers, AIDS awareness, 
and digital cameras…these students missed out on the pleasures of being tossed in 
the back of a station wagon with a bunch of friends and told to keep the noise down, 
walking in the woods without fearing Lyme Disease, or setting out to try all of the 28 
ice cream flavors at Howard Johnson’s.” 
According to Nief, “This is not serious in-depth research. It is meant to be thought-pro-
voking and fun, yet accurate. It is as relevant as possible, given the broad social and 
geographic diversity of our students, who are drawn from every state and 50 countries. 
It is always open to challenge, which has an additional benefit in that it reminds us of 
students’ varied backgrounds.”
BELOIT COLLEGE’S MINDSET LIST®
Most students entering college in the fall of 2005 were born in 1987.
 1. Andy Warhol, Liberace, Jackie Gleason, and Lee Marvin have always been 
dead.
 2. They don’t remember when “cut and paste” involved scissors. 
 3. Heart-lung transplants have always been possible.
 4. Wayne Gretzky never played for Edmonton. 
 5. Boston has been working on the “The Big Dig” all their lives.
 6. With little need to practice, most of them do not know how to tie a tie.
 7. Pay-Per-View television has always been an option.
 8. They never had the fun of being thrown into the back of a station wagon with 
six others.
 9. Iran and Iraq have never been at war with each other.
 10. They are more familiar with Greg Gumbel than with Bryant Gumbel.
 11. Philip Morris has always owned Kraft Foods.
 12. Al-Qaida has always existed with Osama bin Laden at its head.
 13. They learned to count with Lotus 1-2-3. 
 14. Car stereos have always rivaled home component systems.
 15. Jimmy Swaggart and Jim Bakker have never preached on television.
 16. Voice mail has always been available. 
 17. “Whatever” is not part of a question but an expression of sullen rebuke or 
indifference.
 18. The federal budget has always been more than a trillion dollars.
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 19. Condoms have always been advertised on television.
 20. They may have fallen asleep playing with their Gameboys in the crib.
 21. They have always had the right to burn the flag. 
 22. For daily caffeine emergencies, Starbucks has always been around the cor-
ner. 
 23. Ferdinand Marcos has never been in charge of the Philippines.
 24. Money put in their savings account the year they were born earned almost 7% 
interest.
 25. Bill Gates has always been worth at least a billion dollars.
 26. Dirty dancing has always been acceptable.
 27. Southern fried chicken, prepared with a blend of 11 herbs and spices, has 
always been available in China.
 28. Michael Jackson has always been bad, and greed has always been good.
 29. The Starship Enterprise has always looked dated.
 30. Pixar has always existed.
 31. There has never been a “fairness doctrine” at the FCC.
 32. Judicial appointments routinely have been “Borked.”
 33. Aretha Franklin has always been in the Rock and Roll Hall of Fame.
 34. There have always been zebra mussels in the Great Lakes.
 35. Police have always been able to search garbage without a search warrant.
 36. It has always been possible to walk from England to mainland Europe on dry 
land.
 37. They have grown up in a single superpower world.
 38. They missed the oat bran diet craze.
 39. American Motors has never existed.
 40. Scientists have always been able to see supernovas.
 41. Les Miserables has always been on stage. 
 42. Halogen lights have always been available at home, with a warning. 
 43. “Baby M” may be a classmate, and contracts with surrogate mothers have 
always been legal.
 44. RU486 has always been on the market.
 45. There has always been a pyramid in front of the Louvre in Paris.
 46. British Airways has always been privately owned.
 47. Irradiated food has always been available but controversial.
 48. Snowboarding has always been a popular winter pastime.
 49. Libraries have always been the best centers for computer technology and ac-
cess to good software.
 50. Biosphere 2 has always been trying to create a revolution in the life sciences.
 51. The Hubble Telescope has always been focused on new frontiers.
 52. Researchers have always been looking for stem cells.
 53. They do not remember “a kinder and gentler nation.”
 54. They never saw the shuttle Challenger fly.
 55. The TV networks have always had cable partners.
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 56. Airports have always had upscale shops and restaurants.
 57. Black Americans have always been known as African-Americans.
 58. They never saw Pat Sajak or Arsenio Hall host a late night television show.
 59. Matt Groening has always had a Life in Hell.
 60. Salman Rushdie has always been watching over his shoulder.
 61. Digital cameras have always existed.
 62. Tom Landry never coached the Cowboys.
 63. Time Life and Warner Communications have always been joined.
 64. CNBC has always been on the air. 
65. The Field of Dreams has always been drawing people to Iowa. 
 66. They never saw a Howard Johnson’s with 28 ice cream flavors.
 67. Reindeer at Christmas have always distinguished between secular and reli-
gious decorations.
 68. Entertainment Weekly has always been on the newsstand.
 69. Lyme Disease has always been a ticking concern in the woods.
 70. Jimmy Carter has always been an elder statesman.
 71. Miss Piggy and Kermit have always dwelt in Disneyland.
 72. America’s Funniest Home Videos has always been on television.
 73. Their nervous new parents heard C. Everett Koop proclaim nicotine as addic-
tive as heroin.
 74. Lever has always been looking for 2000 parts to clean.
 75. They have always been challenged to distinguish between news and enter-
tainment on cable TV.”  (McBride and Nief, 2005)
One California Educational Institution’s Effort to Meet the 
Biotechnology Workforce Need
One of the most compelling issues about the workforce is its weight in corporate decisions 
and planning. In a 00 corporate survey, CEOs were asked to rank factors according to 
their importance in choosing a business site; availability of skilled labor ranked first, with 
cost of labor second. The same survey in 003 saw cost of labor again in second place, 
while availability of skilled labor came in third, at 89% (Gambale et al., 003). 
Biotechnology and nanotechnology—sets of skills and procedures already used in many 
businesses—will change how almost everything is manufactured, used, and recycled. 
Since these technologies are ubiquitous, estimating workforce need is a conundrum. a 
reasonable guess for the biotechnology industry cluster in California is that this workforce 
will, by 00, be in the range of 88,000, including pharmaceuticals, medical and dental 
labs, measuring and control devices, medical instruments, research and testing, engineer-
ing services and management and public relations. This is an increase of nearly 00,000 
workers from 000, i.e. about 0,000 per year. (Koehler and Koehler-Jones, 006)
The executive summary of an eighty-page report, California’s Biotechnology Workforce 
Training Needs for the 21st Century, (Koehler and Koehler-Jones, 006), outlines how to 
determine workforce needs and how to meet them. 
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As used in this report, Biotechnology refers to the application of scientific advances in 
the life sciences to create commercial products and services. The biotechnology industry 
cluster includes all of the support services and manufacturers of various instruments, 
reagents and other products that support the research, testing, and manufacturing of 
biotechnology products. Bioindustry firms can be organized into eight categories based 
on their end markets: therapeutics, diagnostics, agricultural, bioremediation, energy, 
materials including chemicals, bioindustry suppliers, and bioinformatics (each sector 
is defined in the report).
This study forecasts the biotechnology industry’s workforce skills training require-
ments anticipated over the next five years to ten years. The forecast is based on two 
studies: first, a literature review of anticipated California and global technological and 
industry developments and of workforce surveys and of training needs identified in 
various studies; and second, on a Time Structures survey of future training needs of 
California biotechnology firms. 
California Biotechnology Job Growth Means Many Training Opportunities
Today, US biotechnology firms employ between an estimated 146,000 to more than 
187,000 workers. By 2015, the industry may employ as many as 250,000 or more, 
particularly if the specialized research identified below takes off.  The job multiplier is 
about 1.9 for biotechnology, meaning that almost two additional jobs result from every 
biotechnology job created. US Dept of Labor projects that between 2002 and 2012, US 
employment in the Life Sciences will grow by18%.  Employment is predicted to grow 
by 19% for biological scientists, 19% for biological technicians, and 23% for workers 
in pharmaceutical and medicine manufacturing.
The top five occupations projected to grow in California by the Labor Market Information 
Division, California Employment Development Department, from 2000–2010 are: Bio-
informatics Specialist (99%), Scientific Programmer Analyst (59%), Animal Technician 
(44%), Microbiologist (41%), and Assay Analyst (35%). A total of 43,600 technicians 
with AA degrees are projected to be needed in 2010, an increase of 17 percent over 
2000.  An additional 8,100 technician level positions could open up due to separations 
and internal promotions. These estimates may be conservative given other industry 
size estimates by independent groups such as the California Health Care Institute, 
and by Henry Madrid, (a data analyst specialist examining trends).
Job opportunities requiring familiarity with biotechnology industry operations and pro-
cesses will develop as companies expand and as the supplier and specialized service 
provider networks grow.  These developments offer additional training opportunities 
for occupations like regulatory specialists, Intellectual Property attorneys, and clinical 
trials experts.
The report lists a large number of biotechnology industry and cluster related careers, 
including level of preparation required. Industry new hire skill preferences are identi-
fied. Examples of needed basic and intermediate occupational skills and of technical, 
laboratory, production, bioinformatics and other higher levels skills are provided. Sug-
gestions are made for training management to better retrain skilled workers.
California Biotechnology Industry Growth and Global Competition
Like all manufacturing today, biotechnology is global, involving extended research 
partnerships, specialized supplies chains, and logistics. Many other countries are 
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developing highly competitive niche research or manufacturing capabilities. Coun-
tries in Europe, Japan, China, Russia/Eastern Europe, Cuba, India, Brazil, Malaysia, 
Thailand, Korea, Singapore, Israel. Bahrain/Dubai/Middle, South Africa, Canada, 
and Australia/New Zealand have all established biotechnology clusters. The Asian 
biotechnology industry is growing rapidly. Global networks will compete with and link 
these activities to California. 
While Biotechnology is growing in the US, it appears to be growing more slowly than 
in the past and may not show a profit as an industry until 2010 or 2012. On the other 
hand, the pace of patent applications, and approval of California pharmaceuticals and 
medical devices has increased. At least 643 new drugs are in the pipeline today. The 
future issue is how many will actually be manufactured in California.
Mixed signals on manufacturing were detected in the literature review compared to 
the industry survey. The California Health Care Institute found that “…in 2003, 66% of 
the surveyed companies grew their manufacturing capacity in California, while 81% 
expanded manufacturing outside the borders of the California. Over the next two years, 
73% of the surveyed companies expect to grow their manufacturing within the state. 
However 88% anticipate expanding their manufacturing outside of the state.”
Biotechnology: Converging Technologies are Creating New Opportunities
A moment’s consideration of the biotechnology definition and sectors provided above 
shows that a convergence of diverse technologies—life sciences, materials sciences 
like Nanotechnology/MEMS (micro-electronic mechanical systems), and information 
technology—is taking place. This convergence will produce a unique materials and 
productivity advantage for California over the next ten to fifteen year. Biotechnology is 
one technology of a rapidly emerging group of technologies that are bringing together 
a number of previously separated science and production techniques in the state. From 
this broader perspective, life-science’s biologically based engineering represents a col-
lection of technologies that offer multiple life-sciences applications in essentially—by 
today’s way of thinking—non-biologically based industries. This convergence will cause 
biotechnology workforce training programs to evolve with them.
California Biotechnology Company’s Assessment of Future Technologies and 
Perceptions of Workforce Training Needs
Time Structures interviewed sixteen biotech business executives and seven spokesper-
sons from universities and industry associations. They were interviewed by telephone 
during autumn 2005, to obtain their perspectives on biotech trends and training needs 
for the 21st century.
Fastest Moving Technologies
When asked to evaluate the rate of market development for 19 biotechnologies: 1) 
fermentation, 2) bioprocessing, 3) biotransformation and 4) biomanufacturing were 
ranked as evolving the fastest. These market-related technologies are expected to 
experience significant change within the next one to three years.  
1) fermentation, 2) bioprocessing, 3) biotransformation and 
4) biomanufacturing were ranked as evolving the fastest.
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Five other market related technologies are expected to undergo similar but slower 
spurts of growth: 1) advanced drug delivery systems, 2) drug design, 3) culture and 
manipulation of cells, stem cells, tissues and embryos, 4) diagnostic tests, and 5) 
nanotechnology.
Protein extraction, purification and separation technologies were the most popular with 
business respondents. Significant market change—perhaps based on new product 
development—is expected within the next 1 to 5 years. Markets for cell receptors, 
cell signaling and signaling pheromone technologies are expected to experience the 
same rate of growth.
Market change for DNA recombination, DNA sequencing and DNA amplification tech-
nologies may be slower due to their maturity as a technology.
Three other technologies were given mixed reviews on their ability to influence mar-
ket change, partly because of maturity assessments and partly because of ambiguity 
about whether the question referred to research or application: Peptide and protein 
sequencing and synthesis; microbiology, virology and microbial ecology; and combi-
natorial chemistry, 3D molecular modeling, and structural biology all may experience 
significant long-term change within one to ten years.
While the market may be hot for some of these technologies, public policy issues are 
viewed as obstructions because of regulatory issues and problems with coordinating 
different levels of government.
The most requested “skills” are knowledge of biochemistry, 
molecular biology, cloning and cell culture.
Technical Workforce Skill Needs
Because the industry is rapidly changing in technology and applications, there is a con-
tinuing need for more training in the basics. The most requested “skills” are knowledge 
of biochemistry, molecular biology, cloning and cell culture. The second most requested 
skill has to do with the ability to perform basic research. Lab protocols and techniques 
are needed (such as aseptic techniques), and knowledge of instrumentation and data 
analysis. Most employers provide in-house training on procedures specific to their 
activities, but a foundation in practical laboratory procedures is necessary (more detail 
on skill occupational projections, skills, and business training needs are developed 
from other surveys and materials and are provided in the report).
Continuing Global Biotechnology Specialization and Diversity will Challenge the 
Biotechnology Initiative to be Flexible and Agile
Time Structures’ survey identified the need to strengthen existing skills consistent 
with basic research and manufacturing requirements. Businesses have also identi-
fied significant new and evolving technologies that will affect market position. The 
broader look at industry provided by the literature review indicates that a number of 
new enabling technologies are on the horizon and are expected to grow in influence. 
These converging technologies—nanotechnology, information technology, MEMS, 
and advanced manufacturing technologies—will revolutionize existing industries and 
produce new sectors and jobs in the next five to fifteen years. 
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The difficulty is that it is unclear how well California is actually positioned to take ad-
vantage of these developments even though many of these technologies are already 
highly developed in the state. “First move” advantage could be achieved by other 
developed nations in Europe or East Asia. “Niche” competition from smaller nations 
could winnow away individual sectors. This suggests a strong need for the Applied 
Biological Technologies Initiative to monitor promising convergent technology sectors 
and to firmly reach out to emerging industry sectors. 
Biotechnology Workforce Training Opportunities for California’s Community 
Colleges
California biotechnology businesses and association expressed a desire in the Time 
Structures survey to have the community colleges communicate and collaborate with 
them, to keep up with current trends through market and trend research, and to con-
tinuously update core programs.  Many used the survey opportunity to give accolades 
to the community colleges saying that the colleges should keep doing what they are 
already doing because it is being done well and meeting industry needs. Industry also 
is willing to serve as a resource for training both students and teachers by providing 
facilities. Many talked about developing internships. They expressed an interest in 
having trained students introduced to them. Some spoke to the issue of improving 
the Community Colleges’ course content by strengthening practical lab experience. 
Interviewees also expressed interest in improving their business’ customer service.
Research for the Biotechnology and other Economic and Workforce Development 
Programs indicates that it is important to resolve various Community College and 
system wide policy issues that limit Biotechnology’s and other initiative’s ability to hire 
instructors, to fund successful centers, and to disburse and/or integrate key programs 
amongst campuses. Specific options that could improve the Economic and Workforce 
Development Program’s operations include the following suggestions: 1) complete 
the removal of the statutory sunset clause from the California Community College’s 
Economic and Workforce Development Program’s enabling legislation; 2) that the 
Economic and Workforce Development Program create or facilitate a strategy that will 
satisfy the Community College system, making possible the rapid hiring of qualified 
part-time and full-time instructors for the Centers by examining limitations imposed 
by the “25%/75%” rule on program growth; and 3) that the Economic and Workforce 
Development Program investigate a strategy and develop options for a plan to facilitate 
movement of mature programs onto campus throughout the system without losing 
their essential capacity to generate new curricula in response to changing industry 
and workforce needs.” (Koehler and Koehler-Jones, 2006)
The only constant is change—learn to embrace it.
“the Only Constant Is Change—Learn to Embrace It”
—malcolm w. graham
We have an opportunity to embrace these changes. Global development affects workers 
and skills needed in the workplace, which in turn affect how well this and other nations 
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compete and thrive. The United States is no longer outpacing its competitors as it did 40 
to 50 years ago. Global competition is nipping at US heels. The Net generation expects 
good wages, which may be in jeopardy due to lower cost of living in other countries. 
Currently, many workers do not have the skills to meet the new needs in the workplace, 
and incoming workers often do not recognize the need for innovation as the driver for 
the US economy. They also may not realize that such innovation relies on workers hav-
ing scientific, mathematical and technical skills, alongside workplace competency skills. 
The California Community College Economic and Workforce Development Program 
(http://www.cccewd.net/) is one attempt in California to gather together these facts and 
apply them to meeting workforce needs for the biotechnology industry.
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DuPont’s agriculture and Nutrition Platform consists of three business units: Pioneer 
Hi-Bred International, DuPont Crop Protection Products, and Solae, an alliance between 
DuPont and Bunge Limited formed to develop and market nutritious soy-protein products. 
These businesses develop products for customers all along the agricultural value chain, 
from seed- and crop-protection chemical inputs for growers, to novel grain traits for food, 
feed and fuel processors, to more healthy and nutritious food products for consumers. The 
platform is supported by two r&D organizations. The focus here is on Crop Genetics 
r&D, aimed at the development of biotechnology traits.
Increased Demands on agriculture
Growing needs for biobased, renewable fuels and materials will place a greater demand on 
agricultural productivity leading to the adoption of more intensive agricultural practices. 
to be successful under such conditions, farmers will require a suite of traits that protects 
crops from abiotic and biotic stresses, especially if economic conditions benefit mono-
cropping practices. trait combinations will be needed that protect crops from disease and 
help minimize risk to growers, that enhance crop productivity and genetic gain and that 
increase the end-use value of the harvested grain. Expression of such traits will be required 
at appropriate stages of plant growth and development to maximize effectiveness.
Translating Discovery Research into 
Commercial Products
richard Broglie
DuPont
Wilmington, DE
Our pipeline includes Optimum GAT, which provides new weed-
control opportunities, the Herculex insect-control traits, increased 
nutrient-use efficiency, grain traits and drought tolerance.
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Figure  shows traits that will provide growers with new and better options for weed 
and insect control. Our pipeline is robust and contains second- and third-generation 
traits that will follow in the marketplace after initial trait concepts are commercialized. 
Some specific examples include Optimum Gat, a trait that provides new weed-control 
opportunities and the Herculex insect-control family of traits. Other longer-term traits 
include disease resistance from transgenic and native sources, traits that increase nutrient-
use efficiency, grain traits for food, feed and fuel uses and drought tolerance.
Complementary approaches to trait Development
Currently we employ two complementary technical paths to develop traits: a conventional 
transgenic plant approach and the use of marker-assisted breeding to identify and stack 
genetically complex, native-trait loci. We also use map-based cloning strategies to identify 
the genes and pathways involved in conditioning such complex traits. Often stacking 
both transgenic and native traits is required in order to achieve a product concept that 
meets customer needs. For example, to develop improved feed traits, we are exploiting 
natural variations for certain grain components—such as increased digestibility—and 
Figure . Intensive agricultural production will demand traits for 
increased agricultural productivity.
Successful product development demands that traits are bred into 
the most elite, high-yielding germplasm.
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combining these loci with transgenic approaches that achieve a more balanced amino acid 
composition in the grain. Successful product development also demands that traits are 
bred into the most elite, high-yielding germplasm, and the use of molecular markers and 
other technologies like double haploids can be used in conjunction with contra-seasonal 
seed production to accelerate trait integration and breeding timelines. 
robust Project Management
In addition to a strong discovery platform, product development requires a robust proj-
ect-management system to ensure that resources are allocated optimally to advance traits 
rapidly through the product-development timeline. at Pioneer, we use a process called 
Stages and Gateways to provide a framework for project-advancement decisions. It is 
a gated discovery process that provides defined technical and commercial criteria that 
must be achieved for projects to move toward commercial development. Projects that 
have achieved proof-of-concept, have a clear intellectual property protection strategy, and 
have confirmed phenotypes in field and greenhouse trials advance to Phase 3 or advanced 
Development where field and laboratory data are assembled and submitted for regulatory 
approval, and extensive field-efficacy and breeding trials are conducted. advancement to 
Phase 3 signals an organizational commitment to commercialize a product and requires a 
significant increase in dedicated resources. New products with novel end-use applications 
require extensive product testing to confirm their value in-use and to quantify specific 
customer benefits. Such early application testing also provides data to support commu-
nications about consumer benefits.
Figure . Pipeline of biotechnology traits.
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Product Pipeline
as we look at our trait pipeline (Figure ), we can see a shift from traits conditioned by 
single genes, such as insect or herbicide resistance, to traits where combinations of mul-
tiple genetic loci and/or several transgenes are required to achieve product specifications. 
In some cases, several genes are required to introduce new pathway branches to produce 
beneficial seed-oil compositions, such as in the production of long chain omega-3 fatty 
acids in soybeans. as more success is achieved in producing such products with clear 
consumer health benefits, more education will be required to achieve consumer accep-
tance of these products.
Production of health-promoting omega-3 fatty acids in soybeans 
represents a technical accomplishment achieved by introducing 
five to seven new biochemical steps.
Figure 3 shows our family of healthy oil products. On the market today is a non-trans-
genic, low-linolenic soybean oil product used in food-ingredient applications to reduce 
the amount of trans-fatty acids in the diet. This product will be followed in the market 
by a high oleic acid soybean product produced by reducing the amount of delta- de-
Figure 3. Soybean oil product pipeline.
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saturase in the seed and preventing the conversion of oleic acid to linoleic acid. High oleic 
soybean oil is extremely stable, eliminating the need for hydrogenation. Combinations 
of high oleic acid and high stearic acid traits provide novel, healthy oils for solid-fat food 
applications. Production of health-promoting omega-3 fatty acids in soybeans represents 
a technical accomplishment achieved by introducing five to seven new biochemical steps 
required for the production of long-chain omega-3 fatty acids. This trait has achieved 
the proof-of-concept milestone in our pipeline. The commercialization of such a com-
plex trait will require more investment of resources to ensure trait stability, agronomic 
performance and public acceptance than, for example, the introduction of second- and 
third-generation insect-resistance traits, where first-generation products already enjoy 
wide commercial acceptance.
In Conclusion
Several key components are required to translate discovery research into successful biotech-
nology-based products: a robust, technology-enhanced trait-discovery platform; a rigorous 
process for advancing products through the product-development process, increasing the 
probability of technical and commercial success at each step; a strong and experienced 
regulatory sciences program that provides high-quality data for agency approval; and a 
clear understanding of unmet customer needs.
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Broadly conceived, ethics is the study and review of whether any given practice is good 
or bad, right or wrong, justifiable or unjustifiable in a given set of circumstances. NaBC 
8 has explored a number of practices for linking scientific research with private enter-
prise. The fact that conferences are being held to explore ways to do this suggests that 
somebody thinks that this is a good thing to do. an ethical analysis of establishing closer 
ties between academic researchers and commercial technology providers needs to delve 
into those reasons and subject them to some critical discussion.
The current opinion and analysis on whether such partnerships are justifiable tends to 
make one of two framing assumptions. On one side, there is the view that society needs 
more efficient ways to deliver the benefits of publicly funded research to the public that 
funded it. Here, better (which usually means more extensive) linkages between academics 
and industry are promoted with the idea that for-profit firms are best able to make scientific 
discovery available for public use and consumption. This point of view led to the passage 
of the Bayh-Dole act (PL 96-57) in 980 and has been articulated explicitly as the basis 
for linking university research to state and national economic development.
On the other side is the view that science should be separated from profit-seeking tech-
nology development. Some people who hold this view prefer socialist political schemes and 
presume that pursuit of profit is intrinsically problematic. Others who make this criticism 
make one of two arguments to support the more subtle view that while capitalism is a 
legitimate form of society, some aspects of science should be isolated from capital. One 
argument stresses the public’s need for unbiased sources of information and expertise in 
order to bring about democratic governance, and interprets links between public-sector 
research and venture-capital investment as compromising the ability of university, gov-
ernment and non-profit scientific research to fill this need (Krimsky, 003). The other 
argument stresses the need for public disclosure and reproducibility within the research 
process itself. This view suggests that pressures to seek commercializable results and the 
secrecy that accompanies proprietary technology will ultimately lead to the weakening 
of science as a knowledge-seeking social institution (Busch et al., 99).
Technological Ethics in University-Industry 
Partnerships: The Best of Both Worlds? 
Paul B. thompson
Michigan State University
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While I am certainly willing to undertake the task of pursuing these assumptions to 
some degree, I want to suggest a somewhat different way to focus our deliberations. Let me 
begin with a bold conjecture, one for which I can offer no data and that will be contrary 
to the biases of many people: technological ethics are today better served in the private 
sector than in the universities. If my conjecture is correct, university/industry partnerships 
could have the result of improving the capacity for university-based science to address 
ethical issues, if they bring some of the norms and practices that are commonplace in 
the private sector into the university. Or they could have the result of transferring the 
relatively weak performance of university science to the private sector. While we can 
hope for the better outcome, my conjecture is that university/industry partnerships are 
likely to produce the worse one. But first I must say a bit more about what I mean by 
technological ethics.
What Is technological Ethics?
although there is no widespread consensus on what technological ethics involves, I am 
thinking about proposals made by the philosopher Hans Jonas in the 970s and 980s. 
Jonas began by making two very straightforward observations. First, he noted that the 
nature, rate and scope of technological innovation had been gradually increasing for at 
least 00 years. By the time that Jonas wrote his original German text some 30 years 
ago, it was no longer plausible to think that changes in technology could be treated as 
something like an act of God: relatively rare and beyond the ability of human beings 
to contemplate. Instead, Jonas argued that that technology had reached a point where 
humanity could and should engage in deliberate choices about the future direction that 
technical innovation should take (Jonas, 984).
Jonas was not suggesting that we have the ability to predict the future in detail, nor 
was he suggesting that we could determine the likely social or ecological impacts that 
would follow from discoveries in basic science. Instead, he was saying that cumulative 
experience with technical change and our increasing ability to model and forecast social 
and ecological trends establish a basis for social decision-making about which specific 
technologies to develop and implement, as well as how to regulate technological risk. I 
have often heard scientists object to this proposal by saying that it is just not possible to 
project the consequences of a scientific discovery. But Jonas was not claiming an ability 
to foresee the consequences of technological innovation that exceeds foresight commonly 
exercised by private firms and venture capitalists, who routinely do make decisions about 
which technologies to develop and implement. 
If there is anything truly controversial in Jonas’s observation, it is that there should be 
social decision-making about the ends-in-view that guide such choices. This is a point 
Technological ethics are today better served in the private sector 
than in the universities.
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that I will, of necessity, leave somewhat undeveloped in the balance of my remarks. I 
accept the validity of allowing capital markets to suffice for some forms of social decision-
making. Nevertheless, I also endorse the need for deliberative public and quasi-public 
forums in which constituencies excluded from capital markets can have a voice. Further 
specification of the means for social decision-making is one of the key problems in tech-
nological ethics. 
Jonas’s second observation concerns the nature of ethics. He claims that our current 
understanding of responsibility remains trapped in the village mentality of the eighteenth 
century. I believe that he has several related points in mind. Most importantly, we work 
with a conception of moral agency that presumes individually initiated actions having 
impacts that are limited to village-sized temporal and spatial scales. In fact, the acts that 
need to be brought under an ethic of responsibility are seldom initiated by a single indi-
vidual. They are the cumulative and corporate result of many people acting in organized 
fashion, often under the guidance of corporate decision-making structures. When I use 
the word “corporate” here, I do not necessarily mean multi-national or even business 
corporations. The point calls attention to organized, coordinated and at least partially 
controllable forms of collective action, as distinct from mob rule or the purely coincidental 
cumulative consequences of people acting in haphazard fashion (French, 984).
Modern technology development may not be orchestrated or bureaucratically governed 
in its details, but it is not haphazard. Practices of peer review in the applied sciences, tenure 
and promotion in universities, and grant-making by government and foundations join 
with somewhat bureaucratically controlled forms of r&D to generate a truly corporate 
form of action. Furthermore, these corporate acts involve the development and dissemina-
tion of new technology with spatial consequences that are global, affecting many people 
who are entirely unknown and even unknowable to the actors. as such, a conception of 
ethics that is grounded in personal loyalties based on face-to-face reciprocity established 
among neighbors and townsmen is increasingly inadequate. In addition, effects may be 
cumulative and latent, affecting people in the distant future. traditional ethics was keyed 
to forms of action where impacts would be felt by people known to one another within a 
time-frame that allowed one to link cause and effect in rather intuitive fashion.
Jonas’s point was that our working notion of ethical responsibility is simply out of sync 
with this new reality. While people of today may have the same desire to be ethically re-
sponsible as people in the past, the functional outcome of acting according to norms that 
emphasize personal loyalty and reciprocity is not the same as what it was in the past. 
On the one hand, technological ethics is the organized and thoughtful exercise of 
foresight and deliberative choice in selecting projects for applied science and technical 
innovation. This involves utilizing the limited but hardly inconsequential powers of fore-
sight we possess in an effort to innovate and validate new ethical understandings capable 
of guiding our technology. On the other hand, technological ethics is an effort in public 
scholarship aimed at understanding and addressing the conceptual, organizational and 
practical obstacles encountered in making such choices.
as an academic philosopher, I see myself working in this tradition of public scholarship. 
While predictive power is clearly one aspect of technological ethics, the philosophical 
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piece involves our understanding of fairly basic ideas such as “action,” “responsibility,” 
and “democracy,” as well as a more explicitly articulated vision of the future that we col-
lectively desire. Different conceptualizations of these basic elements can lead to striking 
differences in the way that one characterizes risk and risk-management. as such, there is 
always opportunity to discuss and debate how risks should be characterized in a given case, 
and such debates have been the main substance of technological ethics for agricultural 
biotechnology, (Thompson, 997, 003).
Ethics in Industry and University Settings
My bold conjecture is that scientists, engineers and business leaders working in the private 
sector have done a much better job of implementing technological ethics as a practical 
activity than have scientists, engineers and administrators in universities and public-sector 
laboratories. rather than pretending to have data that support this conjecture, I will make 
a brief conceptual argument to illustrate why I think this is the case. One element of this 
argument stresses the nature of private enterprise and the working environment created 
within for-profit firms, while the other describes the milieu and culture of university 
science and engineering departments.
The argument in favor of thinking that people in the private sector do in fact undertake 
the practical deliberations involved in technological ethics to some degree is fairly simple. 
First, they are human beings and as such are motivated by the same desires to act ethically 
and to be seen favorably as all human beings. Historically, people in business have aimed 
to market products and services that people want and need, and to encourage growth and 
prosperity in the communities in which they do business and reside. In short, they intend 
their business activities to have effects in these communities, and such intentions are a 
locus of moral responsibility. Second, the need to gain market acceptance for the goods 
and services that a business offers, and to have a reputation for quality and reliability, 
provides a reinforcing incentive for profit-seeking firms to act in an ethical manner. I see 
no reason to think that people engaged in business are particularly inclined to dismiss 
or belittle ethical responsibilities simply because they are in business, and every reason 
to think that they would like to conduct their business affairs, including and especially 
those involving technical innovations, in an ethically responsible manner. 
There are, of course, scam operations that are completely unethical, and they tarnish 
the very idea of business, but it is important to note that scams are not really business 
activities at all. Well known structural elements in innovation and profit-seeking enterprise 
can constrain the ability of legitimate businesses to fulfill ideals of technological ethics, as 
Scientists, engineers and business leaders working in the private 
sector have done a much better job of implementing technological 
ethics as a practical activity than have scientists, engineers and 
administrators in universities and public-sector laboratories.
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well. The most important structural tension for present purposes arises when a product 
or manufacturing process is seen to have unwanted health or environmental impacts 
well into the cycle of product development, sometimes long after products have been 
marketed and utilized by the public. In such situations, the economic incentive switches 
from being ethical to being secretive and avoiding losses. The chemical and pharmaceuti-
cal industries have been especially plagued by well-publicized incidents from thalidomide 
and Love Canal to Erin Brockovich and Vioxx®. Such incidents reinforce public cynicism 
about the private sector’s commitment to ethics, but they also reinforce the incentives for 
technological ethics early in the cycle of product development.
as such, I am content to leave my argument with the claim that for-profit enterprises 
have incentives to engage in technological ethics and that the people working in these 
firms are motivated to act ethically. I do believe that the private sector has not been as 
assiduous in utilizing or encouraging public scholarship in technological ethics as it 
should be, mainly because there is an attempt to rely on the kind of village ethics that 
Jonas critiques so ably. But that is a matter to which I will return later. The other point 
that I must make to establish my larger claim is that, quite contrary to those who see 
university-based science as contributing to democratic governance of science and technol-
ogy, university science departments have actually not been very good places to pursue 
technological ethics at all.
The conceptual argument for this claim is that the incentives in university science and 
engineering departments are organized around publications, grantsmanship and patents. 
While university scientists are human beings, they do not really intend that their research 
will have immediate impacts on the communities in which they work and reside, and it 
is very easy for them to assume that any ethical questions associated with their research 
will be dealt with by someone else at some other time. These basic incentives of univer-
sity research have been reinforced by a positivist philosophy of science which holds that 
statements about values or ethics cannot be subjected to the same standards of validity 
as statements reporting data or relationships among data, and, as such, have no place in 
the professional activities of the working scientist. While the hold that this philosophy 
has over working scientists has weakened significantly over the last 5 years, it continues 
to provide an obstacle to the practical discussions and deliberations characteristic of tech-
nological ethics within the environment of academic science departments, and especially 
within the training and education of scientists. 
Paul rabinow’s study of the biotechnology industry, Making PCR, shows that many 
molecular biologists in the 980s and 990s chose industry careers over academic careers 
precisely because they saw university science departments as incompatible with their values 
University scientists do not really intend that their research will 
have immediate impacts on the communities in which they 
work and reside.
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and resistant to change. The subjects interviewed for this study describe academic science 
as competitive and obsessed with egotistic gratification and career advancement. They 
chose industry because the work environment was more cooperative and was dedicated 
to science in pursuit of environmental and public-health values they held dear. rabinow’s 
informants also describe biotechnology companies as more accepting of women and 
minorities than were university science departments (rabinow, 996).
There are, of course, many exceptions to these generalizations among individual scien-
tists. I have personally found many molecular biologists and agricultural scientists working 
in academic settings to be deeply interested in my work on the ethics of agricultural bio-
technology, and I have learned a great deal from those individuals who have taken the time 
to read and criticize my work. Nevertheless, as robert Zimdahl’s new book, Agriculture’s 
Ethical Horizon, makes clear, positivist values are still quite prevalent in agricultural sci-
ence departments. Debate, discussion, teaching and thoughtful deliberation on the ethical 
dimensions of agricultural science and technology are still the exception to the rule in 
agricultural universities and government research laboratories (Zimdahl, 006).
as such, I reiterate my claim that technological ethics are better established in private 
industry than in academic science. This is not to say, however, that the mode of practice 
for technological ethics in the biotechnology industry is beyond criticism, nor to imply 
that university-based technological ethics is wholly inferior. In fact, there are interesting 
complementarities between the weaknesses in private-sector technological ethics and the 
strengths of academic approaches. respective weakness and strength in both cases relates 
to the role of scholarship in technological ethics, a practice that currently exists primarily 
in university ethics centers and social science departments, and that is poorly utilized by 
even industry decision makers who are well-motivated and have economic incentives to 
understand the likely impacts of and public receptivity to their technologies. 
toward Partnership in Ethics?
University-based scholarship in technological ethics has two important features not 
typically present in industry settings. One is simply the luxury of expertise. Scholars in 
technological ethics are professionally devoted to understanding the normative, social 
and theoretical issues involved in effectively anticipating and understanding the social, 
economic, cultural and ethical significance of innovation and technical change. They can 
bring a variety of empirical, comparative and analytic methods to this task. Ironically, the 
cultivation of expertise can have unfortunate consequences, as academic scholars come 
to rely on complex and jargon-ridden theoretical models that make it difficult for them 
to extend the fruits of their studies to an audience with more practical and immediate 
concerns in mind. In addition, scholars of technological ethics are always at least one 
step removed from actual decision-making in research and development settings. This 
distance can be the source of many errors and irrelevancies that make this work less useful 
to practical application than it might otherwise be. Nevertheless, I believe that those of 
us who conduct scholarship on technological ethics have learned a few things that would 
be of use in conducting practical ethical inquiries about which technologies to develop 
and what applications of science to pursue.
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One might argue that the findings of the scholarly community are available to industry 
on a consulting basis, and this is true. In point of fact, they are freely available as published 
materials, too, but consulting arrangements may be preferable to decision-makers who 
are already strapped for time. Here, however, the second limitation of industry-based 
technological ethics comes to the fore, and it is a limitation that lies at the very heart of 
the public/private divide. Scholarship on technological ethics is effective to the extent 
that it is public, meaning that it is freely available for peer commentary and critique, but 
also that it both is and is seen as a non-strategic activity aimed solely at disclosing the 
ethics researcher’s best guess at ethically correct standards for development, dissemination, 
adaptation and regulation of new technology. Public criticism and debate over this guess 
is essential to the method, and this criticism must also be motivated solely by the goal of 
agreement on the best and ideally operative standards. 
While private industry can conduct exercises in ethical deliberation under such idealized 
conditions as a practice intended to inform their internal decision-making, there are sound 
business reasons why public disclosure of this process will, on occasion, be constrained 
by considerations of legal and business strategy. Because everyone understands this, state-
ments and disclosures made by private industry are regarded quite properly as strategic, 
as intended to manipulate the reaction and posture of others, rather than as trying to 
articulate the values and reasoning of company decision makers. Only a public activity 
independent of practical decision-making can provide the environment for legitimate 
inquiry into technological ethics.
as such, broad public competence in technological ethics, including familiarity with 
the terms and problems of r&D policy and the socio-cultural significance of technology 
and technical change depends on the existence of a non-strategic body of scholarship. Such 
public competence is needed if we are to realize Jonas’s goal of social decision-making 
on technical means. Given currently existing social institutions, universities remain the 
most likely home for such idealized types of public inquiry, despite the fact that univer-
sity-based scholarship is vulnerable to the distorting influences I have already mentioned. 
More intimate and effective insight into ongoing industry problems and practices would 
clearly strengthen scholarly attempts to understand and respond to technical change. Better 
communication between scholars and practical decision-makers could improve decision-
making. and now it is possible to return at last to the main theme: university/industry 
partnerships, and the development of innovative institutional settings for scientific work 
that bridges commercial and academic cultures. 
We might hope that these new ventures would become laboratories 
for technological ethics, places where the complementary strengths 
of practical ethics as practiced within industry and scholarly ethics 
as practiced within universities might be joined.
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Given what I have said so far, we might hope that these new ventures would become 
laboratories for technological ethics, places where the complementary strengths of practical 
ethics as practiced within industry and scholarly ethics as practiced within universities 
might be joined, or at least might come close enough together for practitioners on both 
sides of the public/private divide to peer over the fence and derive mutual benefit. This 
would indeed be the best of both worlds for technological ethics in university/industry 
partnerships. It will not happen automatically, however, and will require careful thought 
and planning as to how the social science and humanities disciplines so critical to scholar-
ship on technological ethics might be integrated into partnership activities.
What is more likely, I fear, is the opposite result, something more like the worst of both 
worlds. The scientific culture of the academic world that places so little value on reflective 
deliberation into the ethics of science and technology will dominate the partnership. The 
imprimatur of university research will substitute for the exercise of technological ethics 
that currently exists in the private sector, and the industry culture of strategic thinking 
will pick up the ball after key ethical commitments have been thoughtlessly made. The 
result will be a series of technical innovations even less subjected to deliberative ethical 
review and foresight than those of the past. These technologies have the potential to move 
so quickly into development and regulatory review that no one will have any opportunity 
to debate their likely impact or acceptability. What is more, as the public becomes wise 
to the overriding strategic ambitions of these partnerships, the fears of critics who worry 
that industry links will undermine confidence in science will be realized. 
This pessimistic scenario is not the inevitable result of university/industry partnerships, 
and it may not even be the most likely one. What we will probably get is something more 
like the status quo, with university scientists acting more like businessmen, which in this 
case is a good thing because it means that there will be some exercise of ethical foresight. 
researchers such as me, however, will remain on the margins, or more literally back on the 
main campus, where we will spend most of our time talking to one another. While there 
are some more hopeful signs on the horizon—my invitation to speak at this conference 
being one of them—we will have to wait and see what the individuals who execute these 
partnering activities actually do. 
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Tony Shelton: We’ve covered a lot of ground today but we now have the opportunity to 
ask some penetrating questions of the speakers.
Peter Welters (Phytowelt): I have a question for Mike adang regarding your BtBooster. 
The beauty of the Bt toxin is that it’s very specific because it has a specific binding site 
in the gut of insect. By delivering binding sites with your BtBooster, will specificity be 
compromised? Will there be higher toxicity for non-target insects or even mammals?
Mike Adang (University of Georgia): The question is, essentially: does BtBooster affect insect 
host-range? Well, we haven’t seen a change of the BtBooster toxin binding to the insect 
mid-gut in specificity. The Bt toxin still kills the same set of insects and if you have a level 
of toxin that kills maybe 0% to 5% of the insects, it kills them more rapidly. It doesn’t 
make a caterpillar-active toxin kill a beetle or a mosquito. We haven’t looked yet at other 
lacewings for non-target effects. and we haven’t done any mammalian tests. They will be 
done, but I would be very surprised if it has any effect like that, because it doesn’t seem 
to be altering the basic toxin mode of action requiring receptors, things like that.
Ralph Hardy (National Agricultural Biotechnology Council): I want to look at this from 
the industry side. I have a couple questions. One: what does industry expect from the 
public-sector research—arS, CSrEES, university research? and two: when industry is 
presented technologies that come from within and from without, how do you make a 
decision on which to pursue? How do you manage that?
Bridging the Gap: 
From Laboratory to Commercial Product
Q&A
Moderator: anthony Shelton
Cornell University/New York State Agriculture Experiment Station
Ithaca/Geneva, NY
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Richard Broglie (DuPont): Your first question is, what do we expect from the public sector? 
Certainly, because of what I talked about in the investments and the costs associated with 
developing the products that we have in our pipeline now, there are plenty of opportunities 
to look for new products to come into that log jam. The log jam is a good thing if you’ve 
got lots of logs coming into that so you can make the right choices, and certainly we 
know that we can’t do everything internally so we are looking for partnerships. We have 
a number of partnerships with both small biotech companies as well as various academic 
institutions. The key thing is looking for new traits to come in at that early discovery stage. 
and your second question: we haven’t come across that in too many instances. If you have 
something internally it’s more efficient to build on that because you’ve already made the 
investment rather than bringing in something that would be duplicative, let’s say, if it 
was developed externally. But more often than not they are complementary technologies 
and they provide maybe a first or second-generation product. It’s like complementing 
what we already have in place, which would be probably a more favorable situation to 
looking at something that was developed externally. We don’t have the “not-invented-
here” syndrome anymore. We certainly need to continue bringing new things into our 
pipeline—the recent acquisition of Verdia, for example.
Wim Jongen (Wageningen Business Generator): May I go to the other side of the story? It 
seems now that universities also have the ambition to bring knowledge to the market, 
to make science work. We see that with the SBIr funding. One question comes to my 
mind is: when we talk of that part of the system do we do it coincidentally or do we try 
to structure it one way or the other or make these ambitions really a structural approach 
of our way of working?
Bill Goldner (USDA-Small Business Innovation Research Grants Program): I’m not sure that 
the question came across fully—
Mary Pat Huxley (California Community Colleges): The question is: do we put the structure 
in universities for ethics and entrepreneurship or let it happen by chance?
Broglie: Let me try to address the entrepreneurship part of that and I’ll turn over the 
ethics part. Something quite obvious, at least to me, is that lots of new ideas are being 
generated at universities and certainly an important link to making those turn into com-
mercial realities is connecting early on with industrial partners. Incubator facilities are 
important for providing the opportunity for an academic laboratory to move off into an 
isolated area to continue to develop a technology. Building links early on—so that it’s 
not just by chance that these things develop—with businesses that can pull technologies 
into the marketplace, is important.
We don’t have the “not-invented-here” syndrome anymore.
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Paul Thompson (Michigan State University): One of my colleagues at the University of 
Guelph, Dave Sparling, teaches a course on science entrepreneurship. He gets a lot of 
students from the sciences, most of whom conceal the fact that they are taking the course 
from their major professors. They have to do that. Many of them take it as an overload 
and don’t tell their professors that they are doing so. This reflects differences in the gen-
erations. They recognize the need to do this, whereas their major professors see it as time 
away from the main topic. and I see a little bit of that in ethics, but not quite as much. 
and let me also say that, in terms of what we are prepared to teach in ethics, it’s not like 
we have a curriculum that’s well developed and widely accepted. In fact—speaking of my 
own discipline—very few of the philosophy people who are interested in technology and 
technological ethics are at what are considered to be the leading philosophy departments. 
There is a certain sense in which philosophy is institutionalized such that it allows us 
to keep working on problems that are ,000 years old. and nobody expects philosophy 
departments to do much, but everybody thinks that you’ve got to have a good one in 
order to be a respectable university. So there is no reason for a philosophy department at 
a top university to do technological ethics. That’s not where the action is in my discipline. 
I don’t think that most of you would be able to ring up the philosophy department at 
your institution and necessarily get anything that would be worthwhile.
Milt Zaitlin (Cornell University): a question for Dr. adang. I used to sit on a committee 
here at Cornell where we dealt with conflict of interest questions that came up when a 
professor’s company invested in his lab and graduate students were doing research directed 
at the company’s interests. How do you address those kinds of issues?
Adang: During my talk I mentioned that the university has developed a document that 
addresses some of these issues. The university communicates any concerns to the profes-
sor—providing the document and then sitting in a group that reviews it with the professor. 
Then the professor makes it known to the graduate students and others in the lab where 
the lines are drawn between what is company-sponsored research versus other publicly 
funded research. as a policy, I have not had students work directly on company projects 
with the exception of one graduate student who is a co-inventor of BtBooster technology; 
he has continued working with this. I have updates with my dean in the college, along 
with Cliff Baile who is the executive of the company. We have open communication and 
disclosure of what’s going on, what’s sponsored by whom and who is doing what within 
the laboratory. I have no restriction on my people in terms of what they present, etc., to 
the public. Did I answer your question?
Zaitlin: (inaudible)
One of my colleagues at the University of Guelph, Dave Sparling, 
teaches a course on science entrepreneurship.
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Adang: You don’t allow the company to actually put projects in the laboratory?
Zaitlin: That’s right.
Adang: Yeah, different degrees of policy are in place. There’s no “blanket” across the US 
universities. I had this discussion a couple of weeks ago at a meeting with colleagues 
from Iowa State, University of Connecticut, University of Kentucky and a couple other 
places—you might call it an entrepreneurs’ club. We talked about the different policies 
universities have. Maybe there should be a standardized way of addressing this issue in 
ag colleges and universities.
Bruce McPheron (Pennsylvania State University): Can you look into your crystal ball and 
give us an assessment of where you think the kind of relationships we are talking about 
are going? We heard positive information about some federal funding sources within the 
last month. The Chronicle of Higher Education has reported that industry investment in 
university research has actually declined over the past 3 years. It’s taken its first dip in quite 
a while. What’s the trend line here? We talked in the last  days about the difficulties of 
getting venture capital for biotech projects, particularly in agriculture. What do you see 
the slope of the line of these kinds of relationships being over the next several years?
Thompson: This is not my area of research, but I know some people who do work on 
this. Not just in the biosciences—it’s even in the arts and humanities—university faculty 
are becoming overwhelmingly involved in various kinds of for-profit entrepreneurship 
activities. It’s grown dramatically over the last 0 years. Increasingly there is pressure 
from faculty at almost all institutions to facilitate this kind of thing. I’ve seen data from 
economists and others who study this and there’s no suggestion that this trend is abating. 
You guys talk about patents and in my line of work we talk about copyrights but, increas-
ingly, professors are doing things like copyrighting syllabi—trying to protect intellectual 
property in something as simple as a course syllabus.
Goldner: There’s a lot of room right now for speculation. You asked a very good ques-
tion. I was on the off campus faculty at rutgers before I came over to USDa—like what 
Mike was referring to, a lot depends on the culture of the university that you are working 
with—whether or not you are encouraged to develop technology, develop relationships. 
When I was at rutgers certainly that was strongly encouraged in the department that 
I was involved with to try to be relevant. I’m in the Cooperative State research Educa-
tion Extension Service and we have the National research Initiative, we have the SBIr 
Increasingly, professors are doing things like copyrighting syllabi—
trying to protect intellectual property in something as simple 
as a course syllabus.
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program, we have other grant agencies that support grant mechanisms that support all 
types of university research activities, and the internal discussion that we have is: how can 
we remain relevant? It’s the kind of question that we all need to ask ourselves, whether 
from the university perspective or the industry perspective. The industry perspective is 
sort of self-limiting in that if you aren’t relevant in industry you are gone. You can see 
from this meeting the synergies and needs to interact among the academic communi-
ties, the government in all its permutations and the private sector. That’s certainly very 
important and when we all start thinking like that we will move a little bit more easily 
towards that. That’s not to say that there isn’t a role for research in the university systems 
outside of industry. I think there is a very, very strong need for that. There is no question 
about it. a lot of funding goes into basic research, but mission-oriented research is also 
very important. 
Rick Brenner (USDA-Agricultural Research Service): The issues of commercial success and 
economic competitiveness are complicated. That has come out loud and clear over the last 
few days. These partnerships truly are critical if we are going to succeed in this, whether we 
are starting with a small operation in Geneva, NY, or any of the 50 university research 
parks across the nation or even in the federal laboratories. It is complicated, it’s complex, 
but it’s also essential that we find some solutions to that. I see our role in part is to help 
develop these public/private partnerships and that’s truly what this is about. None of us 
individually has all the right pieces. and that includes the funding issues. Some of that 
can come from the federal sector, but a lot of it isn’t going to come from the federal sector. 
The private sector may want to contribute to that funding, but who’s going to manage the 
risks? Who’s going to absorb some of that? That is another federal role. regulatory issues 
are also involved. How can we not make all of these a no-go just because the regulatory 
hurdles are far too high? We’ve begun talking about having workshops where we will pull 
all of the complementary aspects together that are needed to really be successful in this 
and that’s going to be the funding issues, the research issues, the regulatory aspects. and 
where we might have an opportunity to begin looking at that is in the current hot-topic 
items, is in the energy issues, because every one of us feels the need to be successful at 
coming up with innovative solutions to be less dependent. I can tell you that in arS 
we’ve been getting a lot more interest from private-sector companies talking about what 
our research capacities may be to help on some of these more basic research issues. and 
I’ll also tell you that we’ve had venture-fund people calling us and asking us. We have 
clients interested in this particular area: “What can you tell us about it?” So, there’s 
We’ve begun talking about having workshops where we will pull 
all of the complementary aspects together . . . the funding issues, 
the research issues, the regulatory aspects.
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enough interest. The question is, is there enough momentum to take this through? From 
the energy standpoint, that is going to depend on what the price of the barrel does. From 
my perspective we are going to move forward. We’re going to see more creative measures 
to bring all of these complementary assets together. One of my concerns is: how do we 
manage those conflicts of interest, especially in the public sector? There are ways to do it 
but it will involve networking and getting together and talking about these issues.
Huxley: There is something I want to share before we close. When a company chooses 
to relocate, the choice of location includes appraisal of whether a ready and well-trained 
workforce is available. also, depending on company size, seven to fifteen workers support 
upper management and/or upper scientific investigators. Of those seven to fifteen people 
who support each person on the higher level, about 30% are technical. The question 
then becomes: once the company has an idea, gets first funding, second funding, proof 
of concept, begins to commercialise, are the worker bees available? Generally speaking, 
the answer is “no.” I want to leave that with the group. It’s wonderful to have these ideas, 
tech transfer, etc., but is it possible to bring the product to market and for the company 
to grow with the right workforce? In many cases, probably not—not right now anyway. 
That needs to be looked at.
Are the worker bees available? Generally speaking, 
the answer is “no.”
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I will provide an overview of technology-transfer trends and what is working well and 
what could and should work better. I will discuss some of the shifts in the economy that 
translate into a new role for universities in terms of economic development and engage-
ment. “Engagement” is a wonderful term, used increasingly to define the role of land-grant 
colleges in the twenty-first century, which I will amplify. and I will make some suggestions 
on how an engaged university should interpret its role analogous to that of land-grants 
in the nineteenth century. Our role is very much the same today, taking knowledge and 
translating it into ways that benefit society, improve quality of life and improve well-be-
ing and wealth creation for the regions in which we operate. and finally, I want to talk 
briefly about what my professional group has done to extend this conversation into the 
area of engagement and public benefit.
Knowledge Transfer and Economic 
Development: The Role of the Engaged 
University in the Twenty-First Century
Mark Crowell
University of North Carolina
Chapel Hill, NC
In the academic setting, technology transfer is a global business.
aUtM
I’ve just spent a year as president of the association of University technology Managers, 
an international organization with about 3,500 members, % of whom are from outside 
of North america and 0% are from Canada. The non-North american group is growing 
at ½ times the rate of the US group. Clearly, in the academic setting, technology transfer 
is a global business, like many other aspects covered at this conference.
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Bayh-Dole
technology transfer as we know it in universities started in 980 with the passage of the 
Bayh-Dole act, which was the foundation upon which most of us launched our first activi-
ties in the tech-transfer arena. as a result of Bayh-Dole, universities can own intellectual 
property. Prior to it, we could not. In the past 5 years in particular, technology-licensing 
offices or technology-transfer offices—tLOs or ttOs—have begun to flourish, and not 
only at large research universities. They are increasingly present also at regional universities, 
at relatively small universities, at historically minority universities and in other countries 
throughout the world. Furthermore, they are dealing not only with patentable inventions 
but also with innovation and knowledge. It is important to realize that, in addition to 
transferring patents to industry, research discoveries and innovations made by our faculty 
and graduate students are being made available for the common good.
ttO Explosion
In the past 5 to 8 years, many countries have adopted similar policy infrastructures for 
technology transfer, both in large industrialized countries and emerging countries. In 005 
I made about fifteen trips around the world, including with Dr. “Vijay” Vijayaraghavan 
to India, where we helped launch an Indian Society of technology Managers.
The growth in emphasis of technology transfer, by every measure that we have, has 
exploded during this period of time. Clearly, it’s an activity that is being embraced. On 
many of our campuses, particularly younger faculty actually interview ttOs when they 
are looking at jobs, because they expect this asset to be available to help in their research 
and translational activities. There has been a large increase in the number of licenses 
granted and many universities are using their intellectual property to leverage research 
funding from industry. Such knowledge transfer impinges on industrial development 
nationally, regionally and locally.
recent years have seen a rapid increase in number of start-up companies resulting from 
university research. Interestingly, 75% of them locate near the university. Data show that 
their ability to sustain themselves is affected by the distance from the lab where the sci-
ence was done; the closer they locate to the university, the higher the chance of success. 
again, this speaks to economic development potential.
Impact on research
How is this phenomenon affecting how research is done at universities and how research 
agendas are set? Some studies are examining impact of technology transfer in terms of 
the research environment, academic issues, and graduate students’ progress toward their 
degrees. We don’t have to rely on inferences, suppositions or anecdotes to address these 
issues. Scholarly research has been done by anthropologists, sociologists and economists. 
Jerry and Marie Thursby at Emory University and Georgia tech, atlanta, tracked a 
number of laboratories that have increased the numbers of their inventions, in an effort 
to determine whether the portion of research the PIs are involved with that is classified 
as “basic” changes over time: as they disclose more inventions that are involved in licens-
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ing or start-ups do their research programs and students shift more to applied kinds of 
research activity? The study was rigorous, and the results, published in Science (Thursby 
and Thursby, 003), indicated no increase in the portion of research that was labeled 
“applied” over a period of time in which the level of patenting activity increased ten-fold 
in the laboratories under study—in short, good science is still being done for the sake 
of good science.
Emphasis on revenue?
But all is not rosy. One of the speakers commented that much of what we’ve done so far 
has been focused on driving up revenue. On the other hand, if that is true, then technol-
ogy transfer has been spectacularly unsuccessful. Comparison of the average university 
research budget with royalties indicates a % return on investment. However, I would 
argue that this is irrelevant. as an illustration: we just licensed a course for teaching 
conversational Spanish to healthcare workers in the State of North Carolina, a web-
administered course for addressing a tremendously under-served population in terms of 
their healthcare. We licensed this program to Yale University Press, who are now selling 
it all over the country. We will make a couple of hundred dollars a year, which will not 
show on the revenue meter. On the other hand, this is a highly successful technology-
transfer story and a good example of why we need to expand the conversation and talk 
about a lot more than money.
I am concerned that the model for tech transfer that has evolved resulted from early 
focus on pharmaceuticals and biotechnology and in pharma and biotech exclusive licens-
ing is the rule of the day. They will not invest in drug development if they don’t have an 
exclusive license. as a result, we have probably patented things that we should not; we 
were probably not as skilled as we are today in ensuring that, when we license a technology 
to a large pharmaceutical company, we reserve an academic or not-for-profit license to 
share with other academic laboratories. There are horror stories of important discoveries, 
e.g. research tools, becoming “locked up” and unavailable for use. We are developing 
new approaches to be more careful and better stewards of our intellectual property, so 
that as we seek new partnerships for licensing a property we do it in a way that helps to 
position our partner favorably in the marketplace, but also takes into account that these 
research tools are in large part paid for with tax dollars and should be available to other 
scientists who need them.
On a related issue, many of our technologies potentially have application and could 
impart great benefit to populations in less-developed countries. While maintaining our 
focus on traditional commercialization pathways in developed countries in our licensing 
We need to expand the conversation and talk about a lot 
more than money.
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practices, we have often failed to preserve avenues of knowledge transfer where it is needed 
most. However, many universities in aUtM are addressing that issue by partnering with 
all kinds of organizations and foundations and working very hard to develop new ap-
proaches, new standard license agreements that tend to reserve rights to do both types of 
licensing and technology transfer.
Land-Grant role
as university technology-transfer offices have increased in numbers since 980 with pres-
sure to form start-ups, offer licenses and generate research dollars, technology-transfer 
offices have evolved to be all things to all people. I tell my staff that no matter what we 
do, a counterforce always seems to be at work to suggest that something could have been 
done faster, better, cheaper, generating more money, etc. The fact is, we have many dif-
ferent competing aims and priorities for our intellectual property assets; it’s our job to 
be as successful as possible in meeting priorities across the spectrum. However, another 
component is being added to the tech transfer office. We are being asked to become ex-
perts in economic development, forcing us to broaden our horizons even further to help 
reposition land-grant universities in this field of engagement to continue to articulate a 
compelling role in the new century.
What’s driving this? The economy is shifting and our research programs and disciplines 
and academic boundaries are shifting similarly. From these new alignments, it does appear 
that the world really is flat. In a speech in September 005, I heard the prime minister of 
Singapore end a speech by saying, “remember: innovate or die.” Perhaps a little startling, 
but it speaks to the fact that the winners in this new economy—particularly in our society 
where competition is strong and where we can no longer compete on price—will be those 
who do great work, who produce great technology. The thing that we have always done 
well and that we have to continue to do well, is innovate, innovate, innovate. We must 
feed the research beast and stay ahead of the game, continuing to translate discoveries 
through technology transfer to help drive economic development.
Mary Walshok, an extension person at UC San Diego, is one of my favorite writers on 
this subject. In her book, Knowledge Without Boundaries (San Francisco: Jossey-Bass, 995), 
she was one of the first to talk about the universities’ role in the knowledge economy. as 
economic power shifted from possession of territories or natural resources into genera-
tors or possessors of knowledge, she stepped up even in the mid-90s to address where 
universities, particularly land-grants, are going to be asked to function. Whether we want 
it or not, we are involved in economic development. It’s time not only to acknowledge 
that, but to step up and embrace it.
We are being asked to become experts in economic development,
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the Engaged University
In my opinion, knowledge transfer, technology transfer, should be at the epicenter of an 
engaged university’s activities in this new economy and this new century. The Kellogg 
Commission defined engagement as the interface for connecting people and communities 
to supplies of knowledge and research residing in the university for connecting the univer-
sity with real community problems. By seeing engagement in these terms, and thinking 
about the assets and resources we have to make this happen it becomes clear how these 
activities converge and why I argue that knowledge transfer should be at the epicenter.
First of all, we must partner effectively and make sure that our training and our research 
programs are aligned to the extent appropriate and possible with clusters of industry 
excellence in our state and our region. and we must be sure that we are smoothing the 
interface between those two to ensure good communication, back and forth, and that 
our own planning for our research and training programs is informed by what they say 
their needs are and not by what we think their needs are.
technology-transfer offices need to develop. They need to be at the forefront of this 
activity as these plans are laid to ensure that the research programs connect with busi-
ness and industry needs. Particularly, we must focus on clusters of excellence within the 
economy, and try to connect them strategically and carefully with those appropriate sec-
tors in our states and our regions. We need to focus on developing a portal to lower the 
barriers and reduce the “black-box” factor. We hear often from our industry friends that 
they love to work with the university, they know we are doing great research, but they are 
unable to determine what we are doing and they find it all very mysterious. We’ve got to 
somehow remove the mystery and remove the black box and make it easy and transparent 
for them to see what’s going on, to know how to partner, to know how to navigate these 
strange structures called universities.
It is incumbent on universities to remember the global part of “global economy” and 
“globalization.” We cannot do it in isolation and, in fact, I would argue that by focusing 
on global partnerships and our knowledge-transfer and economic-development activities, 
we are also helping the companies and partners in our regions and states and beyond to 
cope better with the effects of globalization. an economic historian at UNC has written 
a wonderful paper, Driving Down Highway 52, in which he talks about leaving the ivory 
tower and the lovely surrounding of Chapel Hill and riding through one of the most 
economically depressed parts of the state, seeing textile mills and manufacturing plants 
shuttered. He figures that if he stopped and talked about how wonderful the global 
economy is with those people they would probably run him out of town. as we seek to 
pursue the engagement initiatives that I talked about, we have an obligation to do so 
Knowledge transfer, technology transfer, should be at the epicenter 
of an engaged university’s activities in this new economy.
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also in a global sense and to use that knowledge and those partnerships and that synergy 
to leverage additional information and assistance to help such companies cope better, to 
get access to innovation, to retool what they are doing, to understand markets and look 
beyond the landscapes in which they have traditionally operated.
Partnership is fundamentally important with whoever is working in this space, in state 
and federal agencies, not-for profit organizations, and educational institutions. Partnering 
is the key because there is too much to be done and too many resources are required for 
any university to be effective alone.
a Better World
aUtM is beginning to address this conversation and to position the profession of tech 
transfer to be more credible and to have more of a voice and more of an impact in this 
discussion; it’s what we call our Better World Project. For 0 years, aUtM has published 
an annual survey that counts all the things we shouldn’t count: licenses and patents and 
revenue, what everyone always wants to know, but which don’t speak to public impact. 
The Better World Project is an attempt by aUtM to do just that. The Better World Report 
is a series of twenty-five in-depth stories of university innovation that has been translated 
into products that have been the bases for starting companies, that somehow changed an 
economic circumstance, a human-health circumstance, an environmental circumstance, 
with significant impact regardless of financial implications. a companion piece, Reports 
from the Field, contains a hundred shorter versions in vignette form. The objective is to 
educate our members and also to educate other interested parties who don’t quite un-
derstand why universities are involved in this. The stories are contained in a searchable 
database and more will be added over the next few years from the United States, Canada 
and around the world. We are sending these reports to all members of Congress and 
to most of the agencies in Washington that lobby for research dollars and technology-
transfer dollars. We are stepping up to this conversation in a major way to try to have a 
more positive impact on how the conversation about the universities’ role in knowledge 
transfer and economic development is going, and what impact it should have and what 
should we be looking at in the future.
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Q&a
Tony Shelton (Cornell University): Can you give an example of one of those stories?
Crowell: I’ll give you one from my university. a professor in chemistry, winner of the 
Presidential Green Chemist award, has done a lot of work in environmentally friendly 
manufacturing processes. He has an invention that uses super-critical CO as an environ-
mentally friendly cleaning agent that was first commercialized through Hangars cleaners, 
which is a franchise dry-cleaning chain that uses this patented process and does not use 
perchloroethylene. It hasn’t been a terribly successful business model, it’s not a venture-
capital play and it hasn’t created lots of jobs. But it is getting an environmentally friendly 
process out there. another great example is from East Carolina University, a smaller 
regional university in our state with a good family-medicine-oriented medical school. 
Professors in speech pathology developed a novel anti-stuttering device that was featured 
on the Today show. This device is amazing in its ability to reduce stuttering in people for 
whom nothing else has worked. This invention hasn’t generated a lot of money for East 
Carolina but it has had tremendous impact on the lives of a large number of people.
I encourage you to go to aUtM.net. You can order copies or you can search the database 
online. It will grow over time and I think it will be a helpful tool for many of you.
Steve Pueppke (Michigan State University): I agree with you that the major criterion of 
success shouldn’t always be dollars, but how do you argue that this isn’t the best measure 
of tech-transfer success?
Crowell: You keep telling stories such as those in the Better World Report. and you look at 
places that are up-and-comers in tech transfer—such as UK universities that are turning 
out more companies and more products. What are they doing differently? Their tech-
transfer offices are funded by the government. The problem with our model is that many 
of us have set our offices up with the expectation that they become self-supporting, which 
places us in a vicious cycle. My office gets 0% of what we make. My chancellor says he 
agrees that it’s not about money, but when I ask for more positions for my office he asks 
what were our revenues last year. So, it’s a tough one. I don’t have any magic solutions 
but people are working on it. Stay tuned.
Milt Zaitlin (Cornell University): One of my observations is that tech-transfer offices often 
don’t have the expertise that they need and are not willing to go out and get it.
Crowell: I agree. The level of expertise and agility varies widely as you would imagine. 
I would not agree that it’s true across the board, but it is true in many cases. Many of 
us—even those who have good understanding of what’s patentable and what should be 
patented—probably have patented more than we should have. Fear that we are going 
to miss something drives a lot of that. again, what should the mission statement for 
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your tech-transfer office be? Is it there to generate money and make sure that you don’t 
miss one? Or is it there to enhance the research environment to get knowledge assets 
out to help people and adopt a philosophy that you only patent when that is the best 
way to achieve that objective? In the pharmaceutical world you would never not patent 
something that is fundamentally important, whereas in the IP world it’s quite common 
to find pathways to the market that don’t require patents. and as I said earlier, many of 
us adopted or developed our practices around the pharma model. But we are trying to 
address these issues. a speaker today said that we’ve got to stop maintaining patents that 
didn’t go anywhere and that’s also very true.
Audience Member: Do you have any idea of how much the technology transfer coming 
out of universities is going to the state and to companies?
Crowell: I can give you a couple, but they are not great numbers. There haven’t been 
longitudinal studies on that. When I was at NC State we did one of the most entrepre-
neurial things I’ve ever seen any university do. We took $0 million out of the university’s 
endowment over 3 years, and created a venture fund. We used that fund to invest in fifteen 
companies and over a 4-year period those fifteen attracted almost $00 million in follow-on 
funding, created about 400 jobs and twelve of the fifteen located on NC State’s research 
campus. So, irrespective of the eventual return on investment, the economic development 
success spoke volumes about the value of this type of activity. Furthermore, we tracked 
how many of those jobs went to NC State graduates of 5 years or less duration; we were 
looking at brain drain. So we had some wonderful research going on. The VC people, at 
the end of the day, want to know what’s the financial return and that story is not out yet. 
It’s going to come in soon. The fund was from 998 to 000. Some of the companies 
are starting to cash out, so I hear they are going to actually make some money on it to 
boot. There’s not a lot of good numbers longitudinally. at UNC Chapel Hill we’ve done 
thirty-four start-ups in the past 5 years. We have a research budget of almost $600 million 
a year. I think some of that was pent-up demand, some of it was just a new sort of can-do 
approach and a new “lets get the deals done and out of here,” and a new mandate from 
me to the staff saying, “I don’t care if you leave a dollar on the table—I want you to do a 
good deal but I’d rather have deals get done then get hung up on squeezing every dollar, 
every share of stock.” Somebody might come in and criticize the economic portion of 
our deals, but I think they would at least be impressed with the deal-flow.
Audience member: Do offices such as yours administer in terms of whether something 
will be patented or not? Do you become gatekeepers to what research should be done? 
If research is not going to be patentable, is advice given to drop it although it may have 
tremendous potential for public good?
Crowell: We try to make sure that more is discussed than patentability. Our assumption 
is that anything that is disclosed to our office is patentable. We presume that our faculty 
are so good at what they do and are so out front in their fields that if they come forward 
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and say, “I’ve got this invention I think is patentable,” we generally agree that it probably 
is. The question is: “Should it be patented?” and that’s where we try to look at business 
and market and application and issues of the type you are alluding to, and try to make a 
decision that has no implications in terms of the quality of the science. We simply look at 
our patent budget as a venture capitalist would. My university spends $.5 million a year 
filing patents. It’s unbelievable how expensive this is, and my view is we ought to be just 
as picky as venture capitalists who turn down at least ten to twenty projects for every one 
they take. I don’t know if that answers your question, but we try not to play that gatekeeper 
role. We try to make sure that it’s at least done objectively and not subjectively. We may 
find something in the patent literature that kills it and which then sends a company away 
that otherwise would have funded the research, but that’s going to happen anyway. That’s 
good due diligence and good in the long-term for our partners.
My university spends $2.5 million a year filing patents. 
It’s unbelievable how expensive this is.
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In 998 the pharmaceutical/agricultural biotechnology firm Novartis (which has since 
created the agricultural biotechnology company Syngenta) signed an agreement with the 
Department of Plant and Microbial Biology of the University of California at Berkeley. 
Novartis provided $5 million over 5 years to the department to fund research into 
plant genomics and offered UCB scientists access to Novartis’s proprietary technology 
and molecular databases. In turn, Novartis gained representation on the department’s 
research committee and obtained rights of first refusal to negotiate exclusive licenses for 
up to a third of discoveries made in the department by faculty members who signed the 
agreement. The agreement created a controversy on the UCB campus. Some faculty 
spoke against the agreement while other faculty and many administrators supported it. 
Press and Washburn (000) reported that a survey of faculty of the College of Natural 
resources found deep divisions over the benefits of the agreement (Busch et al., 004). 
an external review of the “Novartis-Berkeley deal” recommended, among other things, 
that UCB should avoid industry funding arrangements that involve large numbers of 
faculty with academic units; and to ensure that such deals do not impinge on regulatory 
relevant research such as risk assessment (see Busch et al., 004).
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One result of the agreement was that civil society groups critical of agricultural bio-
technologies have become more focused on the relationship between the biotechnology 
industry and university scientists’ research agendas. This is also a controversial topic on 
many campuses, especially those of land-grant universities. Land-grant universities have 
long maintained close ties with various sectors within the agricultural industry, but they 
are also publicly supported institutions with a mission to serve the public good. a host 
of scholars debate the ability of a public institution to serve public interests while also 
serving specific private organizations (Lacy, 00; Krimsky, 003; Busch et al., 004).
appropriate Links
Three related developments lie at the center of the debates concerning the appropriate 
links between universities and private firms:
• legislation such as the 980 Bayh-Dole act;
• the decrease in state and federal support for agricultural research relative to pri-
vate sector investment; and
• the increasing emphasis on university biotechnology research as an engine of in-
novation that will lead to regional and national economic development through 
the commercialization of technologies by industry from university discoveries 
(Slaughter and Leslie, 997; Busch et al., 004).
Bayh-Dole enables universities to patent the results of federally funded research in 
order to provide incentives, through royalties, for universities to link with industry to 
commercialize technologies and scientific knowledge. Meanwhile, as public money for 
agricultural research declines, private-sector firms become more attractive to university 
scientists and administrators as sources of operating funds, research facilities and propri-
etary knowledge and technology. and with the protection of patents and the potential for 
licenses, including exclusive licenses, university-based science becomes more commercially 
attractive to firms. These changes are couched within an evolving view of universities as 
critical centers of knowledge and talent that can generate economic growth if the right 
public policy and institutional capacities are in place (Etzkowitz, 00). In many cases, 
remaining public funds—especially state funds—are contingent on university scientists 
identifying industry partners and a potential economic development outcome, such as 
increases in jobs through the creation of private companies “spun-off” from university 
research efforts.
regarding university-agricultural biotechnology industry relations, these types of 
changes have resulted not only in increased scrutiny of university-industry relationships 
(UIrs) by civil society organizations and the scientific and popular press (e.g., Press and 
Washburn, 000; Nature, 00), but also in shifts in rewards structures and scientific 
cultures within academic departments. University scientists are more often evaluated 
according to private-sector criteria, such as developing a self-sustaining or profitable 
laboratory through patent activity, licensing revenues and external funding (Kleinman 
and Vallas, 00; Kleinman, 003).
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analytical Frameworks
researchers who analyze UIrs often examine the broader institutional consequences of 
the relationships. They assume that the industry and the university play overlapping but 
different roles in society, and question whether those roles might be compromised when 
the individuals from these two organizations increase their interaction in particular ways. 
For example, Hackett (00) found that society increasingly sends an ambivalent message 
to universities. That is, universities should perform their traditional (less business-oriented) 
role while also responding to national economic imperatives.
In this vein, Slaughter and rhoades (996; 004) and Slaughter and Leslie (997) 
provided an informative framework for understanding the changing societal role of 
universities. They argued that we are witnessing the emergence of an “academic capital-
ism.” academic capitalism refers to the role universities have adopted as the knowledge 
economy has emerged over the past three decades. The knowledge economy refers to the 
set of intellectual property policies and practices that convert advanced knowledge into 
the raw material for commercialized products and services. Because much of the advanced 
knowledge in the United States is contained in research universities, a central compo-
nent of the construction of the knowledge economy has been to integrate the research 
university into the intellectual property process [see also Kenney (986) and Busch et al. 
(99)]. Global economic restructuring, whereby states find it increasingly difficult to 
raise revenue from mobile firms, drives this change. In addition, the end of the Cold War 
removed the dominant rationale for state funding of universities and state sponsoring of 
university-industry links: national defense. These authors document a bipartisan political 
shift toward a “competitiveness agenda” and away from a Cold War or defense agenda. 
The competitiveness agenda entails the focus on universities as engines of innovation and 
potential growth, and an emphasis on competitive grants for allocating federal funds [see 
also Croissant and restivo (00)].
In addition, Slaughter and Leslie (997) asserted that, as a professional class, academics 
have shielded themselves from the vagaries of labor markets by maintaining a monopoly 
control over specific kinds of knowledge in exchange for a tacit social contract: do research 
to benefit society, not to maximize private gain. However the policy changes to overcome 
the economic crises of the 970s and 980s have led universities and professors to adopt 
market-like behavior, using goods, services and labor to pursue profit. Slaughter (990) 
has also noticed the rise of a new “institutional class” comprised of university presidents 
and industry CEOs. They claim they need unlimited authority and resources to produce 
this common good. They define that common good as funding universities to promote 
entrepreneurialism among faculty and the commercialization of scientific knowledge 
to inspire economic growth [see also Croissant and restive (00), Etkowtiz (00), 
Slaughter and Leslie (00), Krimsky (003) and Busch et al. (004)]. 
Owen-Smith and Powell (00) found that some scientists tended toward an “old 
school” orientation, skeptical of increasing ties between universities and private-sector 
firms. Other university scientists embraced the blurring of traditional lines between the 
university and the for-profit sector. and still other scientists fell somewhere in the middle 
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between the two extremes. That is, some “old schoolers” felt compelled to move into com-
mercial science in order to develop a research program and to retain cutting-edge faculty. 
Meanwhile some entrepreneurs recognized that the breakthroughs generated from new 
arrangements threaten important aspects of the university.
Data and Methods
We are building on this study, and others, by developing and analyzing three comple-
mentary databases:
• in-depth interviews with eighty-four scientists and sixty-six research administra-
tors at five major land-grant universities (LGUs), supplemented by interviews 
from two private universities, a small LGU, and one public non-LGU;
• interviews with sixty-three scientists and managers at thirty agricultural biotech-
nology companies; and
• a national survey of academic bioscientists.
The interviews generated qualitative information regarding the motivations, constraints, 
advantages, and limitations of UIrs. Insights from the case studies informed our behav-
ioral model and the design and enumeration of the national survey as well as fostered our 
understanding of the survey results.
Our national survey is the first random sample of US academic scientists conducting 
research with implications for biotechnologies in agriculture, forestry, and aquaculture. 
a response rate of approximately 60% (859 of 44) was achieved. Contrasting the 
respondents who received industry support with those who did not, permitted inference 
about UIr effects on academic research programs. Econometric methods were used to 
estimate the marginal effects of industry support while controlling for such other influ-
ences as the scientists’ human capital, research field, and views about the proper role of 
public science.
Results
turning to the interview data, we found that university scientists seek out industry partners 
to access a number of important resources. These include:
• Funding
• Equipment
• Knowledge
Our national survey is the first random sample of US 
academic scientists conducting research with implications for 
biotechnologies in agriculture, forestry, and aquaculture.
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• Materials
• Expertise
• access to databases
• technology
• Opportunities to place graduate students
• Institutional legitimacy
In their turn, industry personnel establish working relationships with universities to gain 
access to the following items:
• University scientists
• Graduate students/future employees
• Increased credibility/legitimacy
• Enhanced regulatory success
• Strengthening marketing possibilities
• Leveraging resources and structural linkages (extension)
• Increased research efficiency
• Lower infrastructure costs
• Decreased labor costs
In addition, we asked university scientists and administrators, as well as industry 
partners, to rate the perceived advantages and disadvantages of UIrs. all three groups 
were complimentary of UIrs. However, administrators were the most optimistic group, 
industry second and university scientists were the least positive. In general, industry 
viewed UIrs as vehicles for:
• Leveraging research money
• taking advantage of a natural division of labor: basic/applied research
• Facilitating regulatory approval of new technologies.
The most insistent concern on the part of industry was that the division of labor between 
public/private sector is fading. For example, one industry informant argued:
What we typically find though is that basic research, less and less of it is being 
done, and we find we’re competing against university labs for the same tech-
nologies, so it’s like funding your competitor. And Bayh-Dole has caused some 
changes in the way that universities protect IP, and some of them are very, very 
aggressive, so you’ve got to be careful (emphasis added).
Administrators viewed university-industry relationships (UIRs) as 
essential, bringing with them a number of advantages.
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administrators viewed UIrs as essential, bringing with them a number of advantages. 
These include:
• accelerating product development which leads to economic growth
• Leveraging additional scientists through wider networks
• Provision of additional research funds
and administrators saw a focus on biotechnology and ties with industry as partially driven 
by public policy and state funding of the land-grant system:
Another thing that helps is…for example,…the fact that the state recognizes 
biotechnology as an important component of their economic growth also helps 
identify biotechnology as a university priority area because it meshes well with 
the state vision for itself….We always use leveraging as part of our case to the 
state…
The main concern raised by administrators was that UIrs could create haves and have-
nots among their faculty, leading to problems with morale and collegiality. For example, 
one administrator argued that:
. . . in some instances you run the risk of faculty becoming too jaded by the money 
that industry might throw at them, by the prestige they might get by working in 
the industry . . .
While university scientists were the least favorably disposed toward UIrs, they tended 
to see more positives than negatives. Positives included:
• Leveraging research money
• Wider scientist network
• Financial support for graduate students and post-docs
But scientists also had concerns about communication and publication restrictions and 
the manner in which universities often handle IP issues:
…there may be more constraints than what a university scientist is used to; we’re 
used to open access, discussing your research results at meetings, publishing, 
talking with others about it...[depending on the research] a company can tell you, 
No, you can’t go to this meeting, you can’t disclose any of this information….
The university wants to patent, big time. It has almost become more impor-
tant…than publications. …it’s status for the university… I think more and more 
universities are being judged on how many patents they [produce].
turning to the survey of university bioscientists, our intent was to address one central 
question and two guiding questions. 
While university scientists were the least favorably disposed 
toward UIRs, they tended to see more positives than negatives.
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• Central question—Does industry support lead to more applied and excludable 
research, diminishing basic and publicly accessible knowledge about ag biotech-
nology? 
• Guiding questions—What factors affect the “basicness” of scientists’ research and 
the “excludability” of their discoveries?
We measured “basicness” by having the scientists estimate the percentage of their re-
search identified as basic (vs applied). We measured “excludability” by having the scientists 
estimate the percentage of discoveries that may be withheld from public use through 
proprietary tools and strategies such as patenting. 
Basicness
Using National Science Foundation (NSF) funding as a base, sources that led to more 
applied research were, in order:
• Industry 
• State
• USDa
• Other federal and miscellaneous
• Non-profit foundation
In addition, important factors that influenced the basicness of scientists’ research agendas 
were the values of the scientists themselves. In general, the more importance a scientist 
attributed to making theoretical contributions as part of his or her research program, the 
more basic the scientist’s research. also, if a scientist develops a research agenda in part for 
its potential to publish scholarly articles the research agenda is more basic. Contrariwise, 
if a scientist thinks it important to patent research results, the research program tends 
to be more applied.
Excludability
again, using NSF funding as a base, sources that led to more excludable research were, 
in order of importance:
• Industry
• NIH
• State
Scientists’ values continued to be important determinants of the profile of scientists’ 
research programs. regarding excludability, the more importance scientists attributed to 
providing nonexcludable benefits through their research, the less excludable the program. 
also, if scientists believed that it was important to make significant theoretical contribu-
tions, their research program was less excludable or proprietary in nature. and if scientists 
believed that it was important to patent discoveries, their research programs had a more 
proprietary or excludable character to them.
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Conclusions
In general, industry funding brings modestly less basic and more excludable (e.g. patent-
able) research than does NSF or NIH funding. Industry is wary of the decline in the 
level of basic research at universities, but contributes to this decline through its funding 
relationships. This finding points to the importance to a number of parties of continuing 
to publicly fund basic research at universities. This argument also holds true for public-
versus-private biotech research. Industry funding tends to lead to more excludable or 
proprietary agendas as designated by the scientists themselves. to generate a broad array 
of biotech interventions, e.g. minor and major crops and traits (Welsh and Glenna, 006), 
diverse sources of support appear to be important. 
In addition, professional values exert stronger effects on research basicness and accessibil-
ity than do funding sources. This final finding points to the importance of “selection” of 
academic scientists by schools and departments in order to maintain a distinction from the 
private sector and to provide balance in the research portfolios of university scientists. 
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Q&a
Audience member: What is the status of the survey?
Welsh: We’ve finished collecting the data and are starting to publish the results. We have 
publications coming out in Sociological Quarterly and Social Studies of Science. We were 
unsuccessful at Science, but are having some success getting it out elsewhere. We are just 
scratching the surface in terms of analyzing the data.
Steve Slack (Ohio State University): Please make a point of drawing NaBC’s attention to 
the resulting publications.
Welsh: I’ll put you on the list. Our grant rationale included outreach and education, which 
is one reason I am here. I’ll definitely get those to you.
Bruce McPheron (Pennsylvania State University): This is an observation rather than a ques-
tion. Several of us attending this meeting are experiment station directors in the land-grant 
system and tomorrow our 5-year plan of work is due. It’s a new system that USDa has 
developed to allow us to build our plans to direct our experiment station expenditures 
from 007. Under that system, they built in sections under each of the programs that we 
propose, to list what we assume will be the outputs and outcomes of that federally funded 
research and extension. and they put in only one metric: number of patents. So, what’s 
the message that coming to the administrators of these organizations? They couldn’t think 
of anything else across the system that they wanted to ask us about in advance, only how 
many patents will come out of each of these programs.
Welsh: That helps explain and adds some substance to our findings—what is considered 
most important.
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Steve Slack: The panel members will provide brief self-introductions to provide context 
in terms of their responsibilities in the system; each has or has had important roles in 
land-grant institutions. Then they will share some thoughts emerging from rick Welsh’s 
presentation in particular and the meeting in general, and I will then ask rick to join the 
panel for questions from the audience.
Steve Pueppke: I’m a research administrator at Michigan State University as of a couple 
of months ago, having spent 8 years at the University of Illinois doing the same thing at 
the ag experiment station.
Part of my job has been in building research relationships with companies. In my ex-
perience, this generally plays out as somebody like me contacts somebody with a similar 
position in a company, saying, “Your people and our people ought to get together to 
discuss common interests.” Behind this—if you are a university person—is the vision of 
obtaining funding, which is a powerful driver. at the university, we make a few phone 
calls and ask people to think about projects of possible interest to our industrial friends. 
We get on a bus or a plane and get together and have an interesting, thought-provoking 
half-day discussion—throwing out ideas that we think might interest our friends in in-
dustry—and return home. and we get busy. and at some point we realize, “Gee, haven’t 
seen any checks.” We call up the colleague who says, “They were really interesting ideas, 
but we are not really sure that we’re ready to fund them. But we are genuinely interested 
in the interaction, so why don’t we get together again?” With one company, we went 
through this cycle five times. Eventually, my industrial colleague obtained a new job and 
I had to make a new connection. Then I got a new job!
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as an administrator, one does need to manage expectations in building relationships 
that go though administrative channels. It’s different from building on scientists who have 
common interests. Sometimes I think that we administrators would serve ourselves well 
by listening more to the faculty and coming in behind them more.
at Michigan State, when I contacted my first company—actually they contacted me—to 
start this process, at the end of the conversation the gentleman asked, “Michigan State, 
what do you want out of this? How do you want to proceed?” I responded: “I don’t want 
to talk about money, and we don’t want any money from you. at least, not now.” and he 
said, “Thanks. Let’s proceed and try to build a relationship.” I have thought a lot about 
what is a nice standard—at least for us administrators—for building relationships with 
companies that are not driven primarily on the notion of a money flow. There’s a lot that 
we administrators don’t know, a lot of commonality that can be found, things that can 
emerge from conversations. Sometimes such things emerge and are shared more readily 
when no money, project or proposal is on the table.
Molly Jahn: I’ve been a plant breeder at Cornell for 5 years and, as of august , 006, I 
will move to the University of Wisconsin College of agriculture as dean. I have partici-
pated in relationships with industry for a number of years. I have also been the object of 
study in this regard: social scientists—sociologists and economists—have evaluated the 
impact of our work.
University scientists have not lost any ambition to have impact. Idealism is alive and 
well. However, I agree with a point Paul Thompson made: many university scientists, 
including those with strong desire for relevance and impact, are woefully, even shock-
ingly, ignorant of how that actually happens, despite the best efforts of administrators 
and technology-transfer offices and, sometimes, of our commercial partners. Something 
I have thought a lot about is the extent to which some of the traditional functional divi-
sions—those legs on a stool—can actively obscure potentially beneficial connections. 
Some of the success that my program has had results from my not knowing about the 
legs of the stool, as someone who came to Cornell from outside the land-grant system. I 
did my own extension. also, at Cornell we have the benefit of strong relationships with 
companies from the era when things were freely distributed, when packets of seeds went 
out the door without a backwards glance. My career spans the transition; now for every-
thing that leaves—even in a project with organic farmers—material transfer agreements 
(Mtas) have to be signed.
What is a nice standard for building relationships with 
companies that are not driven primarily on the notion 
of a money flow?
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again, it’s important to realize the degree to which desiring to have impact is different 
from knowing how to achieve it. Some do know how to achieve it and making connec-
tions with them is important. also, as a university scientist I would argue that my ability 
to contribute to economic and workforce development—both of which are difficult to 
measure—is affected by our credibility as a public institution and the perception that we 
offer objectivity. One of the things that the institutions I work for think a lot about is 
not avoiding conflict of interest, but acknowledging that engagement generates conflict of 
interest and conflicts of commitment, and that, as institutions, our job is to manage them 
as opposed to avoiding them. There are many ways in which this is done, one important 
way in which we can contribute to this—and this is something we have experimented 
with in my research program for the past decade—is, as public-sector scientists engaged 
heavily with multiple facets of the private sector, we declare our principles ahead of time. 
and, as public-sector scientists—and this speaks to a point that rick Welsh made about 
public-sector activity being, in some respects, fundamentally different from proprietary 
activity—our principles are different from those that guide proprietary activity. We are 
not fundamentally a profit-making enterprise, and I have never made decisions—either 
individually or on behalf of my institution—based on the financial aspect of a relation-
ship. However, in my experience, successful relationships that generate value for both 
sides generate money for the public sector. We just passed the $00,000 mark in gifts 
to a consortium I am part of; each year we are offered royalties—considered “research 
assessments,” resulting from less-formal relationships—of at least $50,000, which is 
very helpful to a public-sector research program, although our fundamental motivation 
is impact and distribution of benefit as opposed to profit. as economic and workforce 
development are hard to measure, so are objectivity and credibility. Patents are a poor 
indicator of impact. Licences are better, but still present issues. Evidence of engagement 
is less difficult to at least describe.
In an era of declining public-sector support for all types of research, I concur with 
rick Welsh that we are in a stronger position with respect to credibility and objectivity 
if we are working from diverse funding portfolios, which has been a feature of how we 
have done business, allowing us the independence to declare some of those principles as 
we intersect with sources of funds.
Milt Zaitlin: I am a professor emeritus of plant pathology at Cornell. I was once the direc-
tor of Cornell’s biotechnology program and I co-teach a class in plant biotechnology.
I want to deal with an aspect that has emerged from the meeting: I am concerned about 
the poor climate for the introduction of genetically engineered crops, particularly in the 
food arena, whether from the public or private sector.
Successful relationships that generate value for both sides generate 
money for the public sector.
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I don’t need to tell this audience that genetically engineered foods have been demonized 
by a number of interest groups, and the public remains sceptical, as shown by surveys. In 
particular in Europe, but also in this country, when asked, most people are opposed to 
it. They don’t know a lot about it, but have been told that it’s bad. I was struck by what 
richard Broglie said about the new oils that DuPont has in the pipeline. What will the 
opponents do when these come onto the market? There have been objections to canola 
oil and cotton fibers from genetically engineered plants, even though they contain no 
genetically engineered component. They are said to contain an “essence” of genetically 
engineering, which is troublesome.
My area is plant virology, and towards the end of my career we developed a technology 
for making virus-resistant plants by transformation with the viral replicase gene. Cornell 
patented this technology and licensed it to Monsanto, which had established a potato 
company in Idaho, NatureMark, where they were bulking up to produce russet Burbank 
potatoes resistant to the Colorado potato beetle (via Bt) and to the potato leaf roll virus 
(via the replicase gene). Lo and behold, the fast-food industry—the principal market for 
russet Burbank—refused them because of fear of being picketed. The NatureMark opera-
tion closed down despite the fact that it was a good product that would have benefited 
the farmers who were embracing the technology.
It’s distressing that a number of excellent technologies in the pipeline may not see 
commercialization. My expertise relates to disease resistance and many virus resistances 
have great potential utility, yet companies, at least in this country, are unwilling to com-
mit to this approach because of these objections and costs of the regulatory process. We 
can only hope that things will change in the near future. They cannot cry wolf forever. 
Warnings of how dangerous these products are will eventually be tempered by the fact 
that consumers are not getting sick.
Slack: The forum is open to general discussion.
Audience member: GM technology is not transparent enough. Some consumer concerns 
may be valid. Is there an institution where the pros and cons could be set out clearly, for 
particular use by policymakers?
Rick Welsh (Clarkson University): a large part of the public perspective on agbiotech has 
been driven by lack of comfort with certain agrichemical companies that have dominated 
the market. If a broader diversity of firms were involved, it would be harder to mount 
campaigns and they would be less successful. There is movement to provide greater 
transparency, which may have a profound effect.
It’s distressing that a number of excellent technologies in the 
pipeline may not see commercialization.
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Jahn: Many of us at universities have failed to understand the extent to which we think we 
are doing God’s work, whereas the public sees us as corporate tools. We fail to recognize, 
often, the extent to which many issues—particularly the corporate control of food—are 
confounded. We want to have a conversation about safety, which is the essence of the 
discussion, but the picture is more complicated and we are unprepared to disentangle 
the issues, and neither is our counterpart. So, we have the same conversations year after 
year. I didn’t understand the extent to which this college—Cornell—was perceived that 
way until I began working with the “organic” community. to balance that, we ended up 
with some products that that community wanted, so we developed dialogue and at one 
point the only thing I had to offer was a transgenic product. I asked them how they would 
feel about it—a silencing technology, not “frankenfood”—and they answered, “I don’t 
know.” I considered this a significant victory, because it finally presented the opportunity 
to discuss the product rather than who is running the supermarket, etc.
Slack: Milt, you mentioned being in charge of the biotech program here at Cornell. 
When that was set up there was funding from the state, with certain expectations about 
economic development tied in. Largely it was operated as a grants program that, in part, 
matched up with industry. So, you had a mix of public and private funds. How did the 
blending of funding sources affect the nature of research that was done?
Zaitlin: We let the faculty decide what they want to do. We never told anyone, “Work on 
this project and you’ll get money.” The program has changed. The money for economic 
development comes from New York State with the objective of fostering development 
of small businesses. So, the program has actually supported research faculty by giving 
them some of that money. The way it works now, matching funds are provided to faculty 
members who go out and get outside money.
Slack: Has that changed the dynamic of the kinds of research done?
Zaitlin: Oh, yes. When we started, we funded a lot of basic research, whereas now we 
fund essentially none. It’s driven by the ability to attract matching industry funds.
Tony Shelton (Cornell University): Milt, when you were running the biotech program, how 
many businesses were spun off from those relationships, and how many continue?
Zaitlin: I haven’t been associated with the program for a couple of years, but they claim 
that they have generated thirty spin-offs. and a few have done fairly well.
Allan Eaglesham (National Agricultural Biotechnology Council): Molly, although your 
progress with the people in the organic-farming community was modest, do you see op-
portunities for meaningful dialogue at some point in the future and what can we do on 
our side of the fence to foster that?
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Jahn: I see many opportunities. I agree with Milt that the argument that you will grow 
a second head can last only for so long, especially given the predominance of foods that 
contain the “essence” of genetic engineering. One of the issues has been the nature of the 
first, perhaps also the second, generation of genetically engineered traits being offered, 
which continue to confound in terms of corporate control of food versus safety of the 
technology. I have tried to listen carefully for that mixture and to take it apart, not to 
disregard the emotion over the structure of our food supply, but to separate that from the 
conversation that we are, in theory, really having. as we worked with that community, 
we established credibility, and we are now a resource that that community looks to. We 
were not similarly viewed even 5 years ago—and I believe we are rare among public-sector 
scientists. That is the basis for the conversation. If there were more engagement of the 
public sector with that community there would be commensurately more opportunity for 
meaningful exchanges, which do not develop from adversarial stances. Modest, yes, but a 
significant victory for me in that it was a genuine interaction focussed on communication 
over a real question—not us peddling a product that they didn’t want—a real question 
that the community had and potential technical solutions. and that is really what the 
public sector was introduced to do about 50 years ago.
Welsh: Molly, you worked with them over time and they trusted you. They trusted your 
perspective on an issue they knew that you know more about than they did. That’s the 
way it works. They will listen to that from you but not from someone else. You had proven 
yourself, in a way. Can that be extrapolated, somehow?—that is the question.
Jahn: Let me emphasize that that relationship started out with us listening and asking, as 
opposed to showing up and telling and selling.
Bruce McPheron (Pennsylvania State University): I have a question for rick, but first I’ll 
follow up on that last exchange. I talk to many extension audiences and stakeholder audi-
ences, and I try to tell them that the thing that differentiates the land-grant system from 
a Google search is that we have done the filtering of the results. When we give advice, it’s 
science-based and we hold our credibility very dear. Molly, that may be one of the values 
that you would put at the forefront.
rick, do I recall correctly that one of your outcome slides from discussions with the 
industry people in the survey was a perception that we are doing less basic research?
Welsh: Yes, essentially echoing what Milt just said, that industry funding tends to be 
linked to the availability of public funds. We found that industry funding tended to 
draw research programs toward more-applied outcomes, and even though industry was 
That relationship started out with us listening and asking, as 
opposed to showing up and telling and selling.
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part of that dynamic, they felt it had either gone too far or wasn’t a positive outcome 
because basicness was what they thought universities should be focussing on. They argued 
that there was a comparative advantage there because of the public-sector nature of the 
university. also it’s not the university’s role to compete with industry, and they felt that 
they were in competition, which is not what they wanted.
McPheron: That’s an interesting perspective. I would say that the flip-side is that the ag-
production stakeholders with whom we interact—and, in fact many of the more vocal 
members of our college—would argue just the opposite, that all we do is basic research. 
So, there’s an interesting perception that’s based upon your starting point, that I think 
we need to be aware of, at least, as we plan our research agendas.
Ralph Hardy (National Agricultural Biotechnology Council): In the twentieth century, 
agricultural research was marvellously successful in terms of food productivity and as-
sociated aspects. In the twenty-first century, agriculture—probably better than any other 
single entity out there—has the potential to address an array of societal problems. How 
do you see we are going to communicate that potential, and structure and fund it to 
make it a reality?
Slack: That sounds like a “dean” question. Molly?
Jahn: I would argue that we will communicate more effectively if we have the qualities 
that I highlighted: maintenance of credibility and objectivity as already perceived by 
many in the public. On the other hand, many in the public don’t perceive that, and to the 
extent that those dynamics are in play, we don’t communicate effectively. GMOs provide 
the classic illustration: we’ve been out there answering questions for decades and are still 
unable to deliver the technology. On my mind is the extent to which public institutions 
are becoming an extension of capitalism, then there is nothing to distinguish us from the 
private sector. also, as administrators, we need to watch out for the perception that our 
scientists are engaged in conflicts of interest, with resultant loss of credibility.
With regard to big-picture issues—energy, global warming, economic viability of rural 
communities—I would argue that the capacities of the land-grant colleges are perfectly 
crafted to address them, albeit possibly with new approaches. Frequently we perceive 
competition when, in fact—particularly with declining resources—we should be thinking 
With regard to big-picture issues—energy, global warming, 
economic viability of rural communities—the capacities of the 
land-grant colleges are perfectly crafted to address them, albeit 
possibly with new approaches.
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about partnerships, university-industry being an important one. We’ve had great success 
partnering with non-profit organizations, which was an important vehicle into the “or-
ganic” community in the absence of an extension apparatus. But we had a message and 
we knew that we needed to learn. Our ability to react to current and future problems will 
depend on the extent to which we can craft common-sense, comprehensive approaches 
as opposed to, “Here is research, here’s teaching and here’s extension.”
Pueppke: We’ve made progress already. In my academic career I’ve seen movement away 
from heavy emphasis on production agriculture. We haven’t turned our back on any of 
that, but we’ve moved on and expanded our view and captured the food system in our 
thoughts, and we’ve become good at obtaining funding and building relationships with 
a variety of funding agencies. I see it as a logical extension of this. We have to keep on 
that pathway.
Jahn: I didn’t touch on funding. The federal agencies are important. Madison and Cornell 
rely heavily on NIH and USaID through USDa. State money is also important as are 
industry relationships of many sorts. Other avenues of public support exist; our non-
profit relationship has been a phenomenal advantage for us in terms of connecting with 
a community with whom we could not otherwise have communicated.
Slack: rick, it’s clear that your research touches on a very important dialogue and that 
there are strong feelings on it in our leadership. We look forward to your information as 
you release it, and further interesting discussions in due course.
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